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Using the GSL3 transgenic mouse model, we have provided evidence that
muscle glycogen concentration, per se, does not affect post-exercise insulin action
in vivo or in muscle using an in situ preparation. Transgenic gastrocnemius
muscle had significantly greater (7-fold) muscle glycogen concentration
compared to wildtype. Glycogen concentration was unchanged 24 h following
exhaustive exercise. In vivo insulin action during an intraperitoneal glucose
tolerance test was improved 24 h following exercise regardless of the muscle
glycogen concentration. Resting insulin-stimulated muscle glucose uptake was
30% lower in non-exercised transgenic versus wildtype muscle. Insulin-
stimulated muscle glucose uptake was improved 24 h following exercise in
vi
transgenic (84%) only. PI3-kinase and PKB/Akt activation was similar in non-
and post-exercise wildtype and transgenic muscle. However, insulin-stimulated
muscle glucose uptake and PKB/Akt activation were reduced in wildtype muscle
with elevated muscle glycogen levels. Thirty minutes of contraction via in situ
electrical stimulation of the sciatic nerve significantly reduced gastrocnemius
muscle glycogen concentration in wildtype (49%) and transgenic (27%) mice
although transgenic mice retained significantly more glycogen than wildtype
mice. Muscle of transgenic and wildtype mice demonstrated similar pre- and post-
contraction insulin-stimulated glucose uptakes. However, the percentage of [14C]
glucose incorporated into glycogen was greater in non-contracted (151%) and
contracted transgenic muscle (157%) versus muscle of wildtype mice. PKB/Akt
Ser473 phosphorylation was greater in transgenic mice as compared to wildtype
mice post-contraction. Taken together, these results demonstrate that glycogen
concentration appears to influence post-exercise muscle insulin signaling and
insulin-stimulated glucose uptake in wildtype muscle when elevated above
normal. However, the insulin signaling results indicate that the normal inverse
relationship between muscle glycogen concentration and insulin-stimulated
glucose uptake is absent in GSL3 transgenic muscle. Therefore, there may be
additional mechanisms influencing the rate of insulin-stimulated muscle glucose
uptake.
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1CHAPTER I: INTRODUCTION
It has long been established that skeletal muscle glycogen is an important
energy source during intense aerobic exercise (Ahlborg et al., 1967; Bergström et
al., 1967; Hermansen et al., 1967; Hultman, 1967). Following exercise, muscle
glycogen resynthesis occurs as a bi-phasic response with the first phase being
insulin-independent and the second phase being insulin-dependent (Ivy, 1977;
Mæhlum et al., 1977; Price et al., 1994).
Glycogen synthesis is very rapid during the insulin-independent phase but
lasts only 30 to 60 minutes (Price et al., 1994). Glucose transport remains elevated
immediately following cessation of exercise (Fell et al., 1982; Holloszy and
Narahara, 1965; Ivy and Holloszy, 1981; Richter et al., 1982) because of an
increased number of glucose transporters on the plasma membrane (Goodyear et
al., 1990). The combination of a rapid glucose transport, but low glycolytic flux
results in an initial elevation of glucose-6-phosphate (G-6-P) (Bloch et al., 1994).
The increase in G-6-P stimulates glycogen synthase, the rate-limiting enzyme in
the glycogen synthesis pathway (Bloch et al., 1994). As the residual effects of
muscle contraction subside, the membrane bound GLUT4 returns to an
intracellular site (Derave et al., 1999; Etgen et al., 1996; Goodyear et al., 1990)
and glucose transport declines (Goodyear et al., 1990; Hespel and Richter, 1990;
Holloszy and Narahara, 1965; Wallberg-Henriksson and Holloszy, 1984).
2While the acute, insulin-independent effect on glucose transport rapidly
declines, it is replaced by a marked increase in the sensitivity of muscle glucose
transport to insulin (Cartee et al., 1989; Garetto et al., 1984; Price et al., 1994;
Richter et al., 1982). This enhanced insulin action persists until the muscle
glycogen level is increased to above normal (Cartee et al., 1989; Derave et al.,
2000; Fell et al., 1982; Jensen et al., 1997, Kawanaka et al., 2000; Richter et al.,
1984). The mechanisms responsible for the attenuation of exercise-induced
insulin action are not entirely clear. However, a decline in glucose transport
during post-exercise recovery appears to be inversely related to the muscle
glycogen content (Cartee and Holloszy, 1990; Cartee et al., 1989; Hespel and
Richter, 1990; Richter et al., 1984). Thus, it has been suggested that muscle
glycogen concentration may have some control over the number of glucose
transporters that can be actively associated with the plasma membrane. Recent
studies utilizing the ATB-BMPA cell surface GLUT4 labeling technique have
demonstrated an inverse relationship between muscle glycogen content and
GLUT4 protein associated with the plasma membrane following insulin
stimulation (Derave et al., 2000; Etgen et al., 1996; Kawanaka et al., 1999).
Increased muscle glycogen content also lowers the activity of PKB/Akt (Derave
et al., 2000; Kawanaka et al., 2000), a key insulin signaling protein involved in
stimulation of GLUT4 translocation (Cheatham and Kahn, 1995). There is also an
inverse relationship between glycogen concentration and the activity of glycogen
synthase, the rate-limiting enzyme for glycogen synthesis (Danforth, 1965;
Laurent et al., 2000).
3The binding of insulin to its receptor initiates a cascade of intracellular
events that ultimately results in an increase in glucose transport and metabolism
(Illustration 1). Once insulin is bound to its receptor, the tyrosine kinase activity
of the insulin receptor ß-subunit is activated and the insulin receptor substrate
(IRS) isoforms are phosphorylated. In skeletal muscle, the predominant insulin-
mediated IRS isoforms are IRS-1 and IRS-2. When phosphorylated, they act as
docking proteins for downstream signaling molecules containing Src homology 2
domains including PI3-kinase (Cheatham and Kahn, 1995; Ruderman et al.,
1995). PI3-kinase has been implicated in the insulin-mediated activation of
PKB/Akt (Alessi et al., 1996; Cross et al., 1995) and subsequent GLUT4
translocation (Hajduch et al., 1998; Kohn et al., 1996; Tanti et al., 1997). The
association between PKB/Akt activity and GLUT4 protein translocation,
however, has not always been observed (Kitamura et al., 1998; Song et al., 1999).
Recent research suggests that insulin activates muscle glycogen synthase in part
by decreasing the activity of GSK-3 (Cross et al., 1997; Ueki et al., 1998). In
skeletal muscle, this GSK-3 inactivation may be mediated by insulin-stimulated
PKB/Akt activity (Cross et al., 1995). GSK-3, in turn, has been implicated in
feedback inhibition of IRS-1 facilitated PI3-kinase activity (Eldar-Finkelman and
Krebs, 1997; Summers et al., 1999). Thus, PKB/Akt may play a pivotal role in
both insulin regulation of glucose transport and glycogen synthase activity.
4Illustration 1: Signaling proteins involved in regulation of glycogen synthase.
During post-exercise muscle glycogen resynthesis, insulin-stimulated
glucose transport (Richter et al., 1984; Cartee et al., 1989) and activation of
PKB/Akt by insulin (Derave et al., 2000; Kawanaka et al., 2000) remains elevated
until muscle glycogen concentration is increased to above normal levels.
Subsequently, PKB/Akt-mediated cell-surface GLUT4 protein (Derave et al.,
2000) and glycogen synthase activity (Laurent et al., 2000; Wojitaszewski et al.,
2000) are elevated until muscle glycogen levels are elevated above normal. As
glycogen is supercompensated, however, the ability of insulin to activate glucose
transport (Cartee et al., 1989; Derave et al., 2000; Fell et al., 1982; Jensen et al.,
1997; Kawanaka et al., 2000; Richter et al., 1984), glycogen synthase (Danforth,
1965; Laurent et al., 2000) and PKB/Akt (Derave et al., 2000; Kawanaka et al.,
52000) is significantly depressed. This inhibition might occur directly via the
glycogen macromolecule itself or indirectly through glycogen-mediated inhibition
of PKB/Akt. Furthermore, inhibition of PKB/Akt with glycogen
supercompensation could lead to reduced insulin sensitivity of IRS via
disinhibition of GSK-3 (Eldar-Finkelman and Krebs, 1997; Summers et al., 1999).
Manchester et al. (1996) recently observed that glycogen concentration
was markedly elevated (5-fold) in muscles of transgenic mice (GSL3)
overexpressing a constitutively active form of glycogen synthase (10-fold).
Azpiazu et al. (2000) extended these findings by demonstrating that glycogen
synthase overexpression was associated with an increased rate of insulin-
stimulated glycogen accumulation. However, in vitro basal and insulin-stimulated
glucose uptake, as assessed by isolated muscle incubation, was not significantly
different between GSL3 transgenic and wildtype mice (Azpiazu et al., 2000).
These findings suggest that overexpression of glycogen synthase is sufficient to
promote glycogen accumulation without reducing insulin action on muscle
glucose uptake. Since the transgenic muscle did not demonstrate the classic
insulin resistance typically associated with an elevated muscle glycogen level, this
raises the question of whether or not insulin-stimulated glucose uptake is
influenced by muscle glycogen content in this animal model.
To date, no study has assessed the importance of increased glycogen
synthase activity on glycogen synthesis following exercise independent of muscle
glycogen concentration. By utilizing the GSL3 transgenic mouse, which
overexpresses glycogen synthase, we have investigated the effects of glycogen
6synthase on post-exercise muscle glucose metabolism independent of muscle
glycogen concentration. In Study 1, we determined the effects of exercise on
whole body glucose tolerance and insulin-stimulated skeletal muscle glucose
uptake and insulin signaling pre- and post-exercise independent of muscle
glycogen concentration. Study 2 investigated the effects of elevated glycogen
synthase activity on insulin-stimulated muscle glucose uptake and glycogen
synthesis immediately following a lowering of initial glycogen levels by in situ
electrical stimulation of muscle. It was hypothesized that transgenic muscle would
exhibit a greater post-exercise insulin-stimulated muscle glucose uptake
independent of muscle glycogen level. In other words, because of the increased
activity of glycogen synthase in the muscle of these mice, enhanced post-exercise
insulin action will be maintained regardless of glycogen concentration.
7CHAPTER II: STATEMENT OF PURPOSE AND
EXPERIMENTAL DESIGN
Statement of Purpose
STUDY 1
The purpose of Study 1 was to assess the effects of prior exercise on
whole body glucose tolerance and insulin-stimulated skeletal muscle glucose
uptake independent of muscle glycogen concentration. This study was designed to
determine if overexpression of glycogen synthase affects: 1) whole body glucose
and insulin responses to a carbohydrate challenge; 2) in situ skeletal muscle
insulin-stimulated glucose uptake; and 3) insulin sensitivity and/or responsiveness
before and after exercise independent of muscle glycogen concentration.
An acute bout of exercise has an insulin-like effect on muscle glucose
transport, which rapidly reverses after exercise is stopped (Holloszy and
Narahara, 1965; Wallberg-Henriksson and Holloszy, 1984). As the direct effect of
muscle contraction on glucose transport is lost, it is replaced by a marked increase
in the action of insulin on glucose transport and stimulation of glycogen synthase
(Cartee et al., 1989; Price et al., 1994). This increase in muscle insulin action
following an acute bout of exercise persists until muscle glycogen is restored to
above normal levels or “supercompensates” (Richter et al., 1984; Cartee et al.,
1989). The muscle glycogen levels of wildtype mice are restored and the
enhanced post-exercise insulin action lost within 24 h following exhaustive
8exercise (pilot data). Therefore, Study 1 was also designed to determine if
overexpression of glycogen synthase: 1) affects whole body blood glucose and
insulin responses to a carbohydrate challenge 24 h after exhaustive exercise
independent of muscle glycogen concentration; 2) affects in situ skeletal muscle
insulin-stimulated glucose uptake 24 h after exhaustive exercise independent of
muscle glycogen concentration; and 3) affects insulin sensitivity and/or
responsiveness 24 h after exhaustive exercise independent of muscle glycogen
concentration.
STUDY 2
The purpose of Study 2 was to determine the effects of glycogen synthase
overexpression on the post-contraction, insulin-independent phase of glycogen
resynthesis. Insulin-stimulated skeletal muscle glucose uptake and glucose
incorporation into glycogen were assessed under conditions in which glycogen
levels were lowered by in situ electrical stimulation. This study was designed to
determine if overexpression of glycogen synthase affects in situ glucose uptake
and glycogen synthesis, in the absence and presence of insulin, when muscle
glycogen levels are lowered by muscle contraction.
9Specific Aims
STUDY 1
1) To determine whether overexpression of muscle glycogen synthase
affects whole body glucose and insulin responses to a carbohydrate
challenge.
2) To investigate whether overexpression of muscle glycogen synthase
affects in situ skeletal muscle insulin-stimulated glucose uptake.
3) To determine whether overexpression of muscle glycogen synthase
affects muscle insulin sensitivity and/or responsiveness.
4) To determine whether prior exercise affects whole body glucose and
insulin responses to a carbohydrate challenge independent of muscle
glycogen levels.
5) To investigate whether prior exercise affects in situ skeletal muscle
insulin-stimulated glucose uptake independent of muscle glycogen
levels.
6) To determine whether prior exercise affects muscle insulin sensitivity
and/or responsiveness independent of muscle glycogen levels.
7) To determine whether maximizing muscle glycogen levels in wildtype
mice 24 h after exhaustive exercise will result in whole body glucose
and insulin responses to a carbohydrate challenge similar to those of
transgenic mice.
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8) To investigate whether maximizing muscle glycogen levels in
wildtype mice 24 h after exhaustive exercise will result in in situ
insulin-stimulated muscle glucose uptake similar to that of transgenic
mice.
9) To determine whether maximizing muscle glycogen levels in wildtype
mice 24 h after exercise will result in muscle insulin sensitivity and/or
responsiveness similar to that of transgenic mice.
STUDY 2
1) To investigate whether overexpression of glycogen synthase affects in
situ insulin-stimulated glucose uptake when muscle glycogen levels of
transgenic and wildtype mice have been reduced by in situ  electrical
stimulation of muscle.
2) To assess the effects of glycogen synthase overexpression on insulin-
stimulated [14C] glucose incorporation into muscle glycogen following
reduction of muscle glycogen by electrical stimulation of muscle.
3) To assess peak twitch tension, peak tetanic tension, and fatigability in
muscles of transgenic and wildtype mice during in situ electrical
stimulation of muscle.
11
Significance of Studies
Skeletal muscle is the primary tissue responsible for clearing glucose from
the blood following a meal (DeFronzo et al., 1981; Baron et al., 1988). When
skeletal muscle cannot remove excess glucose from the blood quickly enough to
equal the glucose appearing from the gut or liver, blood glucose concentrations
will rise. Muscle glycogen is the predominant storage form of glucose in the
body. Insulin activates both glucose transport into the cell and the enzyme
glycogen synthase, thereby affecting the initial as well as the final step in the
pathway leading from extracellular glucose to muscle glycogen (Lawrence and
Roach, 1997). Thus, regulation of insulin-stimulated glycogen synthesis in
skeletal muscle is of particular relevance to blood glucose homeostasis. Impaired
insulin-stimulated glucose uptake is associated with decreased glycogen
formation and impaired glycogen synthase activity in type 2 diabetes (DeFronzo
et al., 1992). In addition, glycogen synthase activity is also reduced in non-
diabetic subjects with a strong family history of type 2 diabetes (DeFronzo et al.,
1992).
Exercise training is beneficial in the prevention and treatment of insulin
resistance (for review see Ivy et al. 1999). The actual mechanisms involved have
not been completely identified but occur at the systemic, tissue, and cellular
levels. Cellular adaptations responsible for the residual effects of exercise include
increased skeletal muscle insulin action. The benefits of exercise on insulin
action, however, start to subside rapidly once exercise ceases and are completely
12
lost in days. Therefore, repeated bouts of exercise of sufficient intensity and
duration to lower muscle glycogen stores may benefit insulin resistant individuals.
Exercise can have both an acute and chronic effect on insulin action. With
regard to the acute effect, a single bout of exercise has an insulin-like effect on
muscle glucose transport, which reverses rapidly after exercise ceases (Holloszy
and Narahara, 1965; Wallberg-Henriksson and Holloszy, 1984). As the direct
effect on transport is lost, it is replaced by a marked increase in the action of
insulin on muscle glucose transport and glycogen synthesis (Cartee et al., 1986;
Garetto et al., 1984). This increase in insulin action following an acute bout of
exercise persists until the muscle glycogen is restored to above normal levels or
“supercompensated” (Cartee et al., 1986). Regulation of the insulin-dependent
phase of post-exercise glycogen recovery is not well understood.
The relative importance of glucose transport and glycogen synthase in
controlling the rate of insulin-stimulated muscle glucose uptake has been debated
for years. Most evidence suggests that glucose transport is rate limiting under
most conditions (Hansen et al., 1995; Ren et al., 1993; Rossetti et al., 1997; Tsao
et al., 1996). However, no study has been able to demonstrate the contribution of
glycogen synthase activity to glucose uptake independent of glucose transport and
muscle glycogen concentration. Furthermore, the contribution of glycogen
synthase independent of muscle glycogen content during the post-exercise period
of enhanced insulin action has not been assessed. The transgenic mouse model
used in this study has allowed investigation into the roles of increased skeletal
muscle glycogen synthase activity and muscle glycogen concentration in whole
13
body glucose tolerance and insulin-stimulated muscle glucose uptake and
glycogen synthesis. In addition, the assessment of increased glycogen synthase
activity was independent of muscle glycogen and differences in glucose
transporters between transgenic and wildtype mice. This novel transgenic model
allowed investigation of research questions that we are unable to ascertain from
rat or human experiments. This dissertation provides valuable insight into the
regulation of post-exercise insulin-stimulated glucose uptake and glycogen
synthesis, which, in turn, is vital in the understanding of muscle insulin resistance
and type 2 diabetes mellitus.
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CHAPTER III: STUDY 1
EFFECTS OF MUSCLE GLYCOGEN ON GLUCOSE
TOLERANCE AND INSULIN-STIMULATED MUSCLE
GLUCOSE UPTAKE PRE AND POST-EXERCISE IN
TRANSGENIC MICE OVEREXPRESSING GLYCOGEN
SYNTHASE
15
Abstract
Using a unique mouse model that overexpresses glycogen synthase, we
have re-investigated the effects of muscle glycogen concentration on glucose
tolerance and insulin-stimulated glucose uptake pre- and post-exercise. GSL3
transgenic (TG) mice, wildtype (WT) and glycogen supercompensated wildtype
(SUPER) mice were studied using an intraperitoneal glucose tolerance test and
hindlimb perfusion technique at rest or following two successive days of
exhaustive exercise with carbohydrate restriction. TG gastrocnemius muscle had
7-fold greater muscle glycogen concentration compared to WT. Glycogen
concentration was unchanged from pre-exercise values 24 h following the
exercise/dietary manipulation in WT and TG. In vivo insulin action was improved
following exercise regardless of the muscle glycogen concentration. Resting
insulin-stimulated muscle glucose uptake was 30% lower in non-exercised TG
versus WT muscle. Post-exercise insulin-stimulated glucose uptake was improved
in TG (84%) but not WT. PI3-kinase and PKB/Akt activation was similar in non-
and post-exercise WT and TG muscle. However, insulin-stimulated glucose
uptake and activation of PKB/Akt were reduced in SUPER muscle. Using the
GSL3 transgenic mouse model, we have provided evidence that muscle glycogen
concentration, per se, does not affect post-exercise insulin action in vivo or in
muscle using an in situ preparation.
16
Introduction
Prior exercise results in insulin-independent and insulin-dependent effects
on glucose uptake in skeletal muscle. With regard to the insulin-independent
effect, post-exercise muscle glucose transport is enhanced (Fell et al., 1982;
Holloszy and Narahara, 1965; Ivy and Holloszy, 1981; Richter et al., 1982) due to
an increased number of GLUT4 glucose transporters on the plasma membrane
(Goodyear et al., 1990). As the residual effects of muscle contraction subside, the
membrane-bound GLUT4 returns to an intracellular site (Derave et al., 1999;
Etgen et al., 1996; Goodyear et al., 1990) and glucose transport declines
(Goodyear et al., 1990; Hespel and Richter, 1990; Holloszy and Narahara, 1965;
Wallberg-Henriksson and Holloszy, 1984).
While the acute, insulin-independent exercise-mediated effect on glucose
transport rapidly declines, it is replaced by a marked increase in the sensitivity of
muscle glucose transport to insulin (Cartee et al., 1989; Garetto et al., 1984; Price
et al., 1994; Richter et al., 1982). This enhanced insulin action persists until the
muscle glycogen level is increased to above normal (Cartee et al., 1989; Derave et
al., 2000; Fell et al., 1982; Jensen et al., 1997, Kawanaka et al., 2000; Richter et
al., 1984). The mechanisms responsible for the reversal of exercise-induced
insulin action are not entirely clear. However, the decline in glucose transport
during post-exercise recovery appears to be inversely related to the muscle
glycogen content (Cartee and Holloszy, 1990; Cartee et al., 1989; Hespel and
Richter, 1990; Richter et al., 1984). Thus, it has been suggested that glycogen
17
may have some control over the number of glucose transporters that can be
actively associated with the plasma membrane. Recent studies utilizing the ATB-
BMPA cell surface GLUT4 labeling technique have demonstrated an inverse
relationship between muscle glycogen content and GLUT4 protein associated
with the plasma membrane following insulin stimulation (Derave et al., 2000;
Etgen et al., 1996; Kawanaka et al., 1999). Increased muscle glycogen content
also lowers the activity of PKB/Akt (Derave et al., 2000; Kawanaka et al., 2000),
a key insulin signaling protein involved in stimulation of GLUT4 translocation
(Cheatham and Kahn, 1995). There is also an inverse relationship between
glycogen concentration and the activity of glycogen synthase, the rate-limiting
enzyme for glycogen synthesis (Danforth, 1965; Laurent et al., 2000).
Manchester et al. (1996) recently observed that glycogen concentration
was markedly elevated (5-fold) in muscles of transgenic mice (GSL3)
overexpressing a constitutively active form of glycogen synthase (10-fold).
Azpiazu et al. (2000) extended these findings by demonstrating that glycogen
synthase overexpression was associated with an increased rate of insulin-
stimulated glycogen accumulation. However, in vitro basal and insulin-stimulated
glucose uptake, as assessed by isolated muscle incubation, was not significantly
different between GSL3 transgenic and wildtype mice. These findings suggest
that overexpression of glycogen synthase is sufficient to promote glycogen
accumulation without reducing insulin action on muscle glucose uptake. Since the
transgenic muscle did not demonstrate the classic insulin resistance typically
associated with an elevated muscle glycogen level, this raises the question of
18
whether or not insulin-stimulated glucose uptake is influenced by muscle
glycogen content in this animal model. Using the GSL3 transgenic model, we
have investigated the effects of muscle glycogen on glucose tolerance and insulin-
stimulated muscle glucose uptake pre- and post-exercise. Our results suggest that
the normal regulatory effect of glycogen on glucose metabolism is absent in
GSL3 transgenic mice.
Methods
Experimental animals. Transgenic (GSL3 line) and non-transgenic
wildtype littermates [(C57BL6 X CBA)F1] were donated by Dr. John Lawrence,
University of Virginia, Charlottesville, VA. GSL3 transgenic mice overexpress
glycogen synthase [GS(2,3a)], a rabbit skeletal muscle glycogen synthase having
Ser to Ala mutations at sites 2 and 3a. The generation of the transgenic line is
described by Manchester et al. (1996). Transgenic expression of the constitutively
active glycogen synthase is 10 times higher compared to wildtype muscle, with 5
times greater expression in fast twitch versus slow twitch muscle (Manchester et
al., 1996). Upon receiving the mice, they were individually housed at The
University of Texas Animal Resource Center on a 12:12 h light-dark cycle.
Laboratory chow and water were provided ad libitum throughout the experiments
except where noted below. The animal room temperature was maintained at 21ºC.
Animals were transferred to the laboratory at least 24 h prior to the first
experimental procedures following the same light cycle. The University of Texas
Animal Care and Use Committee approved all procedures for this study.
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Experimental procedure. GSL3 transgenic and wildtype mice (n=60)
weighing 20-35 g were assigned to either non-exercised or exercised treatment
groups. An additional group of wildtype mice (designated SUPER, n=12) was
assigned to a glycogen supercompensation group. All mice underwent an
intraperitoneal glucose tolerance test (IPGTT) followed approximately 1-2 weeks
later by the hindlimb perfusion procedure. Wildtype and transgenic non-exercised
groups (designated WT and TG, respectively) were allowed free access to
laboratory chow and water and were otherwise restricted to normal cage activities.
The wildtype and transgenic exercised groups (designated WTX and TGX,
respectively) underwent two days of glycogen depleting exercise on a motorized
treadmill (3 h • d-1, 26 m • min-1) with carbohydrate restriction between runs to
limit glycogen restoration. Following the first run, mice were given 1 g of
laboratory chow with lard provided ad libitum. Following the second run mice
had free access to lard but did not receive chow. This glycogen depleting
exercise/diet protocol was performed prior to both the IPGTT and the hindlimb
perfusion procedure allowing glycogen restoration but not supercompensation 24
h following exercise. The wildtype SUPER mice underwent a protocol to raise
muscle glycogen levels to above-normal levels. These mice performed an
exhaustive run (3 h • d -1, 26 m • min-1) followed by 24 h of a high carbohydrate
chow/table syrup mix and 15% carbohydrate (sucrose in water) solution ad
libitum. This supercompensation procedure was performed prior to both the
IPGTT and the hindlimb perfusion. Mice from all groups were fasted 6 h prior to
both the IPGTT and the hindlimb perfusion.
20
Intraperitoneal glucose tolerance test. Mice were placed in a restrainer
placed on a heating pad to maximize tail blood flow. The mice were given 1 mg •
g-1 body weight of a 10% sterile dextrose solution by intraperitoneal injection.
Blood glucose was assessed on a single drop of whole blood from the tail prior to
and 30, 60, 120, and 150 min following glucose administration. In addition,
approximately 0.15 ml of blood was taken prior to, 30 and 60 min following
glucose administration and added to tubes containing 24 mg • ml-1 EDTA.
Following a 10 min centrifugation in a benchtop centrifuge (3,000 g), the plasma
was stored at -80ºC until analysis for insulin. Blood glucose was determined with
the ONE TOUCH BASIC blood glucose monitoring system from Johnson &
Johnson (Milpitas, CA). Validity of this blood glucose monitoring system was
tested against a YSI blood glucose analyzer (Yellow Springs Instrument
Company, Yellow Springs, OH). Plasma insulin was determined by
radioimmunoassay (cat #: HI-11K, Linco Research, St. Charles, MO), utilizing
the double antibody procedure of Morgan and Lazarow (1963).
Determination of muscle glycogen. Muscle glycogen concentration was
determined by complete enzymatic degradation with amyloglucosidase
(Boehringer Mannheim, Indianapolis, IN) by a modified method of Passonneau
and Lauderdale (1974). A 100 µl aliquot of neutralized homogenate prepared for
glucose uptake measurements was added to 250 µl of 0.3 M sodium acetate, pH
4.8 and vortexed. Then 250 µl of 0.3 M sodium acetate, pH 4.8, containing 10 mg
• ml-1 amyloglucosidase was added and vortexed. Following an overnight
incubation, 25 µl of 1 N NaOH was added and vortexed. Liberated glucose was
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measured using a spectrophotometric Trinder reaction (Cat. #: 315-100, Sigma
Diagnostics, Inc., St. Louis, MO). Duplicate 150 µl aliquots were placed in test
tubes containing 0, 50, 100, and 200 mg • 100 ml-1 glucose. One milliliter of
Trinder reagent was added to each tube, mixed gently and incubated for 18 min at
room temperature and then read on a Beckman DU 6 spectrophotometer
(Fullerton, CA) at an absorbance of 505 nm. A linear interpolation against the
standard was used to determine the concentration of glucose units in the original
sample. The muscle glycogen concentration was expressed as µmole glucose • g-1
muscle.
Measurement of glycogen synthase activity.  Glycogen synthase was
measured by direct incorporation of [U-14C] UDP-1-glucose (ICN Biochemicals,
Costa Mesa, CA) into glycogen with several concentrations of G-6-P (0.01, 0.5,
1.5, and 25 mM) as previously described (Sherman et al., 1988). Total activity
was defined as that measured in the presence of 25 mM G-6-P. Fractional
velocities of submaximal (0.5 and 1.5 mM G-6-P) to that of maximal (25 mM) G-
6-P glycogen synthase activity (expressed as percentages) as well as -/+ G-6-P
activity ratios were also calculated. The activity ratio was calculated as the
enzyme activity measured in the presence of 0.01 mM G-6-P divided by the total
activity.
Hindlimb perfusion. Mice were anesthetized with an intraperitoneal
injection of pentobarbital sodium (6.5 mg • 100 g-1 body weight) following a 6 h
fast and kept warm by performing the surgery on a heating pad. The surgical
technique was similar to that described previously (Brozinick et al., 1996; Ivy et
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al., 1983). Major vessels branching from the abdominal aorta and vena cava
except the common iliac artery and iliac vein were ligated. Heparin (100 U) was
injected into the inferior vena cava just inferior to the diaphragm. Following the
heparin injection, the descending aorta and inferior vena cava were cannulated as
previously described (Ivy et al., 1983). Catheters were placed in line with the non-
circulating hindlimb perfusion apparatus providing a 37ºC, continuously gassed
(95% O2/5% CO2) perfusate flow of 1.8 ml • min-1. Both hindlimbs were perfused
during the equilibrium (10 min) and tracer (20 min) periods. Perfusates consisted
of 6% bovine serum albumin (BSA) in Krebs-Henseleit buffer (KHB, pH 7.4)
with 0.2 mM pyruvate. During the tracer period, the perfusate contained 6 mM
[1,2-3H] 2-deoxyglucose (7.5 µCi • mmol-1; ICN Biochemicals), 2 mM [U-14C]
mannitol (60 µCi • mmol -1; ICN Biochemicals) and the appropriate insulin
(Humulin R-100, Eli Lilly, Indianapolis, IN) concentration (0.2 mU • ml-1 or 10
mU • ml-1). Immediately following the perfusion period, both gastrocnemii were
dissected from the hindlimbs, frozen with Wollenberg tongs cooled in liquid N2
and stored frozen (-80ºC) until further analysis.
Determination of 2-Deoxyglucose Uptake. Freeze-clamped gastrocnemius
muscle from the perfused hindlimbs were sectioned and weighed frozen. A 60-
100 mg piece of mixed-fiber muscle was dissolved in 1 ml 1 N KOH by
incubating for 15 min at 65ºC, mixed, and incubated an additional 5 min at 65ºC.
An equal volume of 1 N HCl was added to the digested samples, mixed, and
aliquots of the neutralized samples counted for [3H] and [14C] DPM (Beckman LS
6000SC). Muscle 2-deoxyglucose uptake was calculated from the specific activity
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of the original perfusate after subtracting out the appropriate volume for
extracellular space as determined from radiolabelled mannitol in the muscle
sample. Mixed gastrocnemius was used because it has been shown to exhibit a
high transgene expression but contains similar GLUT4 content in GSL3
transgenic and non-transgenic littermates (Manchester et al., 1996).
GLUT4 protein concentration. Frozen muscle was homogenized (1:20
wt:vol) in HES buffer containing 20 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid buffer, 1 mM EDTA, and 250 mM sucrose (HEPES, pH 7.4).
Samples were homogenized at 15,000 g for 20 min at 4°C and protein
determinations were performed on each homogenate using the method of
Bradford (1976). A 75 µg protein aliquot of each supernatant sample and a mouse
heart standard were subjected to SDS-PAGE on a 12.5% polyacrylamide
resolving gel. A mouse heart supernatant standard (16 µl) was run on each gel. A
Miniprotean II dual slab cell (BioRad, Richmond, CA) was used to perform the
electrophoresis. Samples were transferred from the resolving gel onto
polyvinylidene diflouride (PVDF) sheets (BioRad). The transferred PVDF
membranes were blocked for 1 h by incubation in 5% nonfat dry milk (Carnation,
Los Angeles, CA) in TTBS (0.06% Tween-20, 20 mM Tris, 500 mM NaCl, pH
7.5) at room temperature. Following a rinse using TTBS, the membranes were
incubated with GLUT4 rabbit anti-rat antibody (donated by Dr. Samuel Cushman,
NIH, Bethesda, MD). After two additional 5 min rinses in TTBS, the membranes
were incubated with horseradish peroxidase-conjugated donkey anti-rabbit
antibody (Amersham, Arlington Heights, IL) for one hour. The membranes were
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then washed in sacosyl buffer (50 mM Tris Base, 1 M NaCl, O.4% w/v N-
laurylsarcosine, 5 mM EDTA, pH 7.5) three times to decrease non-specific
binding. After the blotting procedure, antibody-bound protein was visualized
using an ECL Western blot detection kit (Amersham) according to the
manufacturer’s instructions. GLUT4 concentration was expressed as percent heart
standard.
Hexokinase activity. For assessment of hexokinase activity, HES
homogenates were centrifuged in a benchtop centrifuge at 3,000 g for 15 min.
Hexokinase activity was measured on the supernatant using the
spectrophotometric determination of glucose-6-phosphate as described by Uyeda
and Racker (1965).
Insulin Signaling Proteins. Insulin-stimulated muscle samples were
prepared as described by Kawanaka et al. (2000). Muscle pieces (30 mg) were
homogenized in ice-cold buffer containing 50 mM HEPES (pH 7.4), 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1.0 mM EDTA, 10 mM
Na4P2O7, 100 mM NaF, 2.0 mM Na3VO4, aprotinin (10 µg • ml-1), leupeptin (10
µg • ml-1), pepstatin (0.5 µg • ml -1), 1% Igepal and 2 mM phenylmethylsulfonyl
fluoride. Homogentates for IRS-1-associated PI3-kinase activity were incubated
with end-over-end rotation at 4ºC for 60 min and then centrifuged at 200,000 g for
50 min at 4ºC. IRS-1-associtated PI3-kinase was immunoprecipitated using a 2 µg
• µl-1 protein sample as previously described (Christ et al., 2001) using an anti-
IRS-1 antibody (2 µg, Upstate Biotechnology Inc., Lake Placid, NY) for 2 h at
4ºC, followed by an overnight protein A-Sepharose (Sigma) incubation (4ºC). The
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immunoprecipitates were successively washed prior to in vitro phosphorylation of
phosphatidylinositol. Sonicated phosphatidylinositol (Avanti Polar Lipids,
Pelman, AL) was added to each sample and the PI3-kinase reaction started by
addition of 10 µl of 50 mM MgCl2, 250 µM [ γ-32P]-ATP (0.5 µCi • ml-1,
Amersham) in a buffer consisting of 20 mM HEPES (pH 7.4), 0.4 mM EGTA,
and 0.4 mM Na2PO4 and stopped by addition of 6 M HCl. Lipids were extracted
by chloroform-methanol (1:1) and applied to a thin layer chromatography plate
(Silica gel 60, Whatman, Hillsboro, OR). The plates were developed (60 min) in
running solvent (CHCl3:MeOH:H2O:NH4OH, 60:47:11.3:2). Radioactivity of
TLC spots for standards and samples was quantified via scintillation counting for
32P (Beckman LS 6000SC).
For quantification of phosphorylated PKB/Akt-1α, aliquots of the 200,000
g supernatant were treated with 2x Laemmli sample buffer containing 100 mM
dithiothreitol and boiled for 5 min. Samples (80 µg protein) were subjected to
SDS-PAGE (10% resolving gel) and transferred to nitrocellulose membranes. An
insulin-stimulated mouse gastrocnemius muscle standard (80 µg) was run on each
gel. The membranes were blocked in 5% nonfat dry milk in TBS containing 0.1%
Tween 10 (pH 7.5) for 1 h. Following a rinse in 0.1% Tween 10, the membranes
were incubated with sheep antiphospho-PKB/Akt-1 (Ser473) antibody (Upstate
Biotechnology Inc.) for 4 h. Three isoforms of PKB/Akt have been identified. The
primary insulin-stimulated isoform in rodent muscle is PKB/Akt-1α (Turinsky
and Damrau-Abney, 1999; Walker et al., 1998). In addition, insulin-stimulated
PKB/Akt-1α activity was inversely related to skeletal muscle glycogen content 18
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h post-exercise in the study by Derave et al. (2000). Therefore, PKB/Akt-1α is
was the isoform assessed in the present study. Membranes were rinsed in 0.1%
Tween 10 and incubated with horseradish peroxidase-conjugated rabbit anti-sheep
IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) for 60 min.
Antibody-bound protein was visualized using an ECL Western blot detection kit
(Amersham) according to the manufacturer’s instructions. Phosphorylated
PKB/Akt-1α of samples was expressed relative to the insulin-stimulated mouse
standard.
Total PKB/Akt-1α protein content was assessed on nitrocellulose
membranes used for phosphorylated PKB/Akt-1α. Membranes were stripped of
antibodies by incubation with stripping buffer containing 100 mM 2-
mercaptoethanol, 2% sodium dodecyl sulfate, 62.5 mM Tris HCl (pH 6.7) for 30
min. Membranes were then washed three times for 15 min in TTBS buffer.
Membranes were blocked overnight, washed three more times for 15 min in
TTBS, and incubated with sheep anti-Akt/PKB-1α (1:1000 vol/vol) (Upstate
Biotechnology Inc.) for 4 h with gentle agitation. Following three more TTBS
washes, antibody-bound protein was visualized using ECL (Amersham) and total
PKB/Akt-1α was expressed relative to the insulin-stimulated mouse standard.
Statistics. One-way analysis of variance was performed on muscle
glycogen, glycogen synthase, GLUT4, hexokinase, and total PKB/Akt. Repeated
measures analyzing treatment versus time was performed for IPGTT blood
glucose and plasma insulin responses. An additional one-way analysis of variance
comparing groups was performed for individual IPGTT time points. For glucose
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uptake, IRS-1-associated PI3-kinase activity and phosphorylated PKB/Akt-1α,
one-way analysis of variance was performed for experimental groups within low
and high insulin levels. Post hoc tests were performed using Fishers’s Protected
LSD and differences were considered statistically significant if P ≤ 0.05.
Results
IPGTT responses. During an intraperitoneal glucose tolerance test, blood
glucose responses were not different between TG and WT mice (Figure 3.1).
Resting blood glucose concentrations for TGX and WTX mice were
approximately 50% of those observed in the non-exercised groups. Prior exercise
resulted in a lower blood glucose response in WTX compared to WT. This
exercise effect was not observed in transgenic mice. In addition, the blood glucose
response in TGX was significantly higher than WTX. This was due to TGX blood
glucose concentrations that were 20-25% greater than the WTX at 30 and 60 min
following the glucose injection. Glycogen supercompensation did not result in
altered glucose tolerance, as SUPER and WTX blood glucose responses were
similar.
Plasma insulin responses to the carbohydrate challenge were similar in TG
and WT mice (Figure 3.2). Prior exercise resulted in a significantly lower plasma
insulin response as responses in TGX, WTX and SUPER mice were significantly
lower than the non-exercised groups prior to, 30 and 60 min following the glucose
injection. However, exercise elicited a greater effect in WTX compared to TGX
as plasma insulin was significantly higher in TGX versus WTX mice at 30 min.
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Muscle glycogen. Gastrocnemius glycogen concentration was 7-fold
greater in TG compared to WT (Figure 3.3). Following 2 days of exercise and
dietary manipulation, WTX and TGX gastrocnemius glycogen concentrations
were similar to pre-exercise values. Subjecting wildtype mice to a 24 h glycogen
supercompensation protocol following exhaustive exercise (SUPER) increased
muscle glycogen 3.6-fold compared to WT and WTX. However, SUPER muscle
glycogen levels remained markedly lower than the transgenic groups.
Glycogen synthase activity. Glycogen synthase fractional velocities at 1.5
and 0.5 mM G-6-P and -/+ G-6-P activity ratios were similar in all groups (Table
3.1). However, there were considerable differences in terms of absolute glycogen
synthase activity, expressed in nmol • g-1 wet weight • min-1, is presented in Figure
3.4. Total activity of glycogen synthase as well as allosteric activation at
submaximal G-6-P concentrations (1.5 and 0.5 mM) were significantly greater in
TG and TGX compared to WT, WTX, and SUPER (Figure 3.4). This was true for
either perfusion insulin concentration. In TG, TGX, and WTX, glycogen synthase
total activity was approximately 120% greater following high insulin perfusion
compared to the low insulin perfusion. Allosteric activation by submaximal G-6-P
concentrations (1.5 and 0.5 mM) following perfusion with high insulin was
greater in TG compared to WT and SUPER. Prior exercise did not significantly
affect insulin-stimulated total glycogen synthase activity in either transgenic or
wildtype muscle. SUPER glycogen synthase total activity was not different from
WT or WTX following perfusion with either insulin concentration.
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2-Deoxyglucose uptake. Muscle glucose uptake was 30-36% lower in TG
versus WT muscle at both perfusion insulin concentrations (Figure 3.5). However,
there were no differences in glucose uptake between WTX and TGX at either
insulin concentration. During perfusion with low insulin, glucose uptake remained
similar for WT and WTX but glucose uptake of TGX was significantly higher
than TG. A similar response was found during perfusion with the high insulin
concentration. Glucose uptake in TGX was approximately 84% higher than TG
during both low and high insulin perfusions. SUPER muscle glucose uptake was
45% lower than WT during the low insulin perfusion. This trend was also
observed during the high insulin perfusion although the difference (15%) was not
statistically significant. SUPER muscle glucose uptake was 51% of WTX during
the low insulin perfusion and 73% of WTX during perfusion with a high insulin
concentration.
GLUT4 protein concentration and hexokinase activity. Gastrocnemius
muscle GLUT4 protein concentrations were similar in WT, WTX and TG (Figure
3.6). However, gastrocnemius GLUT4 concentrations of TGX and SUPER were
significantly higher than WT. Hexokinase activity was similar between WT,
WTX, TGX, and SUPER (Figure 3.7). TG hexokinase activity was significantly
greater than WTX and SUPER.
Insulin signaling proteins. IRS-1-associated PI3-kinase activities in
muscles from WT and TG groups were not significantly different although
activity in transgenic muscle tended to be higher (Figure 3.8). During perfusion
with the low insulin concentration, exercise did not affect PI3-kinase activity in
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either genotype. However, following the high insulin perfusion, prior exercise
was associated with a significantly greater insulin-stimulated activation of PI3-
kinase in wildtype. This was not the case in transgenic muscle as TG and TGX
PI3-kinase activities were similar following the high insulin perfusion. SUPER
PI3-kinase activity was only assessed following the high insulin perfusion.
SUPER PI3-kinase activity was lower but not significantly different from WT.
However, PI3-kinase activity was significantly lower in SUPER compared to
WTX.
Total PKB/Akt protein concentration was similar in wildtype and
transgenic muscle (Figure 3.9). Exercise, per se, had no effect on total PKB/Akt
protein (i.e. WTX similar to WT and TGX similar to TG). Total PKB/Akt protein
of SUPER, however, was significantly higher than that found for WT, WTX, and
TGX groups. Perfusion insulin concentration did not affect total PKB/Akt protein
concentration (data not shown).
Insulin-stimulated PKB/Akt (Ser473) phosphorylation was similar between
WT and TG as well as between WTX and TGX for both perfusion insulin
concentrations (Figure 3.10). Previous exercise increased PKB/Akt
phosphorylation in both genotypes following the low insulin perfusion (103% in
wildtype and 50% in transgenic). The slight increase in PKB/Akt phosphorylation
following the high insulin perfusion was not significantly different in either
genotype. Phosphorylated PKB/Akt in SUPER muscle was significantly lower
than WTX following the low insulin perfusion as well as the high insulin
perfusion. In addition, SUPER muscle phosphorylated PKB/Akt was significantly
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lower than WT following the high insulin perfusion and although this trend was
also observed during the low insulin perfusion, it was not statistically significant.
Discussion
Acute exercise is associated with a marked increase in the sensitivity of
muscle glucose transport and glycogen synthesis to insulin during the insulin-
dependent phase of post-exercise glycogen recovery (Cartee et al., 1989; Garetto
et al., 1984; Holloszy and Narahara, 1965; Price et al., 1994; Ren et al., 1994;
Richter et al., 1984). Attenuation of improved insulin action during post-exercise
recovery appears to be related to muscle glycogen levels (Cartee and Holloszy,
1990; Cartee et al., 1989; Hespel and Richter, 1990; Richter et al., 1984). The
mechanisms responsible for the reversal of exercise-induced insulin action are not
entirely clear. However, elevated muscle glycogen concentrations are associated
with decreased insulin-stimulated cell surface GLUT4 transporter protein (Derave
et al., 2000; Etgen et al., 1996; Kawanaka et al., 1999) and PKB/Akt activity
(Derave et al., 2000; Kawanaka et al., 2000), a key insulin signaling protein
involved in stimulation of GLUT4 translocation (Cheatham and Kahn, 1995).
Using the GSL3 transgenic mouse model, we have re-examined the effects of
muscle glycogen concentration on glucose tolerance and insulin-stimulated
muscle glucose uptake pre- and post-exercise. We have provided evidence that
muscle glycogen concentration, per se, may not affect post-exercise insulin action
in vivo or in muscle using an in situ preparation.
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In the present study, IPGTT glucose responses were similar in non-
exercised wildtype and GSL3 transgenic mice suggesting that muscle glycogen
concentration does not affect glucose tolerance. In addition, glucose tolerance was
improved in exercised wildtype although muscle glycogen concentrations of
exercised and non-exercised wildtype were similar. In contrast, post-exercise
glucose tolerance was not improved in mice with above normal muscle glycogen
concentrations (i.e., GSL3 transgenic and glycogen supercompensated wildtype).
Prior exercise, however, resulted in a much lower plasma insulin response
regardless of muscle glycogen concentration. A lower insulin response despite a
normal or improved glucose response is indicative of enhanced insulin action in
tissues responsible for glucose disposal. Thus, unlike glucose tolerance, post-
exercise in vivo insulin action was improved regardless of the muscle glycogen
concentration. This suggests that the effect of acute exercise on in vivo insulin
action is independent of the muscle glycogen concentration.
Azpiazu et al. (2000) demonstrated that glycogen synthase overexpression
was associated with an increased rate of insulin-stimulated glycogen
accumulation while basal and insulin-stimulated glucose uptake remained similar
to wildtype mice. These in vitro findings suggest that overexpression of glycogen
synthase is sufficient to promote glycogen accumulation but does not improve
insulin action on glucose uptake in muscle. In the present study, insulin-
stimulated muscle glucose uptake was lower in non-exercised GSL3 transgenic
versus wildtype muscle. This finding is in contrast with those of Azpiazu et al.
(2000) but agrees with several studies demonstrating an inverse relationship
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between muscle glycogen concentration and insulin-stimulated muscle glucose
uptake (Fell et al., 1982; Hespel and Richter, 1990; Jensen et al., 1997). Further
support for this inverse relationship is evident when comparing our post-exercise
insulin-stimulated muscle glucose uptake results from exercised wildtype and
glycogen supercompensated wildtype. When glycogen levels had recovered
following exercise in wildtype muscle, insulin-stimulated glucose uptake was
normal. However, when muscle glycogen is elevated to above normal levels,
glucose uptake is significantly reduced compared to non- and post-exercised
wildtype treatments.
The inverse relationship between muscle glycogen concentration and
insulin-stimulated muscle glucose uptake was not observed in post-exercise GSL3
transgenic muscle. The effect of glycogen on post-exercise, insulin-stimulated
glucose uptake was not consistent with that observed in wildtype mice. GSL3
transgenic muscle demonstrated an increase in post-exercise insulin-stimulated
glucose uptake independent of muscle glycogen concentration. Thus, muscle
glycogen does not appear to be a regulator of insulin-stimulated muscle glucose
uptake in GSL3 transgenic mice post-exercise. Therefore, the post-exercise
insulin resistance normally associated with above normal muscle glycogen levels
is eliminated in this model. Why post-exercise insulin action is maintained in
GSL3 transgenic muscle is not immediately clear. In the present study, we have
assessed several key sites of insulin action to address this question.
The binding of insulin to its receptor initiates a cascade of intracellular
events that ultimately results in an increase in glucose transport and metabolism.
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Once insulin is bound to its receptor, the tyrosine kinase activity of the insulin
receptor ß-subunit is activated and the insulin receptor substrate (IRS) isoforms
are phosphorylated. In skeletal muscle, the predominant insulin-mediated IRS
isoforms are IRS-1 and IRS-2. When phosphorylated, they act as docking proteins
for downstream signaling molecules containing Src homology 2 domains
including PI3-kinase (Cheatham and Kahn, 1995; Ruderman et al., 1995). PI3-
kinase has been implicated in the insulin-mediated activation of PKB/Akt (Alessi
et al., 1996; Cross et al., 1995) and subsequent GLUT4 translocation (Hajduch et
al., 1998; Kohn et al., 1996; Tanti et al., 1997). The association between PKB/Akt
activity and GLUT4 protein translocation, however, has not always been observed
(Kitamura et al., 1998; Song et al., 1999). Recent research suggests that insulin
activates muscle glycogen synthase in part by decreasing the activity of GSK-3
(Cross et al., 1997; Ueki et al., 1998). In skeletal muscle, this GSK-3 inactivation
may be mediated by insulin-stimulated PKB/Akt activity (Cross et al., 1995).
GSK-3, in turn, has been implicated in feedback inhibition of IRS-1 facilitated
PI3-kinase activity (Eldar-Finkelman and Krebs, 1997; Summers et al., 1999).
Thus, PKB/Akt may play a pivotal role in both insulin regulation of glucose
transport and glycogen synthase activity.
During post-exercise muscle glycogen resynthesis, insulin-stimulated
glucose transport (Richter et al., 1984; Cartee et al., 1989) and activation of
PKB/Akt by insulin (Derave et al., 2000; Kawanaka et al., 2000) remains elevated
until muscle glycogen concentration is increased to above normal levels.
Subsequently, PKB/Akt-mediated cell-surface GLUT4 protein (Derave et al.,
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2000) and glycogen synthase activity (Laurent et al., 2000; Wojitaszewski et al.,
2000) are elevated until muscle glycogen levels are elevated above normal. As
glycogen is supercompensated, however, the ability of insulin to activate glucose
transport (Cartee et al., 1989; Derave et al., 2000; Fell et al., 1982; Jensen et al.,
1997; Kawanaka et al., 2000; Richter et al., 1984), glycogen synthase (Danforth,
1965; Laurent et al., 2000) and PKB/Akt (Derave et al., 2000; Kawanaka et al.,
2000) is significantly depressed. This inhibition might occur directly via the
glycogen macromolecule itself or indirectly through glycogen-mediated inhibition
of PKB/Akt. Furthermore, inhibition of PKB/Akt with glycogen
supercompensation could lead to reduced insulin sensitivity of IRS via
disinhibition of GSK-3 (Eldar-Finkelman and Krebs, 1997; Summers et al., 1999).
In the present study, prior exercise was associated with a significantly
greater maximal insulin-stimulated IRS-1-associated PI3-kinase activity in
wildtype muscle. This finding is in agreement with a recent study by Chibalin et
al. (2000) in which insulin-stimulated IRS-1-associated PI3-kinase activity was
increased 2.6-fold in rat muscle 16 h following acute exercise. An increase in
insulin-stimulated PI3-kinase activity was also observed with submaximal insulin
although this increase did not reach statistical significance. The post-exercise
activation of PKB/Akt with insulin followed a similar pattern as that observed
with PI3-kinase activity. In wildtype muscle, submaximal insulin-stimulated
PKB/Akt phosphorylation was doubled and maximal insulin-stimulated PKB/Akt
phosphorylation was increased slightly (29%), but not significantly, following
exercise. However, despite increased insulin activation of PI3-kinase and
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PKB/Akt, post-exercise insulin-stimulated glucose uptake was not improved at
either perfusion insulin concentration. Taken together, these results demonstrate a
disassociation between insulin signaling and glucose uptake following exercise in
wildtype mice when muscle glycogen levels have recovered.
When wildtype muscle glycogen concentration was elevated above normal
levels (i.e., supercompensated), the exercise effect of increased maximal insulin-
stimulated IRS-1-associated PI3-kinase activity was abolished. This finding is in
contrast to recent evidence suggesting that muscle glycogen content does not
affect the insulin-mediated activation of this kinase (Derave et al., 2000;
Kawanaka et al., 2000). In addition, phosphorylated PKB/Akt in glycogen
supercompensated muscle was significantly lower than exercised wildtype
following both perfusion insulin concentrations. The decrease in IRS-1-associated
PI3-kinase activity and corresponding reduction in the phosphorylation of
PKB/Akt were associated with impaired insulin-stimulated glucose uptake in
glycogen supercompensated muscle. The impairment of insulin-stimulated
glucose uptake that was observed in glycogen supercompensated wildtype was
not due to a lower total GLUT4 protein content or hexokinase activity. On the
contrary, total GLUT4 protein was significantly elevated in glycogen
supercompensated muscle. Taken together, these results suggest that glycogen
appears to influence post-exercise muscle insulin signaling and insulin-stimulated
glucose uptake but only when elevated to above normal levels in wildtype mice.
The normal suppression of insulin signaling associated with an elevated
muscle glycogen concentration was disrupted in muscle overexpressing a
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constitutively active glycogen synthase. In non-exercised GSL3 transgenic
muscle, insulin-stimulated glucose uptake was lower than that observed in non-
exercised wildtype despite slightly higher PI3-kinase activity and PKB/Akt
phosphorylation in the transgenic muscle. The differences in insulin-stimulated
glucose uptake observed between non-exercised wildtype and GSL3 transgenic
could not be accounted for by differences in GLUT4 protein or hexokinase
activity. This finding suggests that an alternative mechanism, other than reduced
PKB/Akt activity, may exist for a reduced insulin-stimulated glucose uptake
during conditions of elevated muscle glycogen.
Following exercise, insulin-stimulated muscle glucose uptake was higher
in exercised GSL3 transgenic compared to exercised wildtype and glycogen
supercompensated treatments. This post-exercise increase in GSL3 transgenic
insulin-stimulated glucose uptake occurred despite markedly elevated muscle
glycogen. Although a significant increase in IRS-1-associated PI3-kinase activity
was not observed in GSL3 transgenic muscle as in wildtype, IRS-1-associated
PI3-kinase activity was greater in GSL3 transgenic muscle compared to glycogen
supercompensated wildtype. PKB/Akt activation (phosphorylated to total
PKB/Akt ratio) was similar in exercised GSL3 transgenic and exercised wildtype.
Again, exercised GSL3 transgenic PKB/Akt activation was higher than glycogen
supercompensated wildtype muscle. Our GSL3 transgenic findings contrast the
inhibition of insulin signaling and glucose uptake observed in the glycogen
supercompensated wildtype treatment. Furthermore, the GSL3 transgenic results
differ from previous studies (Derave et al., 2000; Kawanaka et al., 2000)
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demonstrating an inverse relationship between muscle glycogen concentration and
PKB/Akt phosphorylation. The finding that insulin-stimulated muscle glucose
uptake was higher in GSL3 transgenic versus glycogen supercompensated
wildtype suggest that the putative association between glycogen levels and
glucose uptake is absent in the transgenic model. Why resting and post-exercise
PKB/Akt phosphorylation remains highly active in GSL3 transgenic muscle
despite elevated muscle glycogen remains unclear. However, this may be related
to the constitutively active glycogen synthase. Furthermore, the influence of
glycogen on PKB/Akt may be due to the ability of glycogen to depress glycogen
synthase activity. This may represent a putative, yet unknown, association
between the activation states of glycogen synthase and PKB/Akt, both of which
are normally inhibited when muscle glycogen has been elevated above normal.
Recently, it was demonstrated that immediately following exhaustive
exercise, skeletal muscle GLUT4 mRNA is elevated (Kuo et al. 1999a; Ren et al.,
1994). However, once carbohydrate is consumed, the GLUT4 mRNA
concentration declines while total GLUT4 protein is increased (Kuo et al. 1999b).
Kuo et al. (1999b) suggested that there is an increased GLUT4 mRNA translation
efficiency with carbohydrate supplementation following exercise. Our finding that
GLUT4 protein was significantly higher in glycogen supercompensated muscle
than exercised wildtype or transgenic mice further support this theory. The
glycogen supercompensated mice were provided a high carbohydrate diet
immediately following exercise while carbohydrate was restricted in the exercised
wildtype and transgenic treatments. In addition total PKB/Akt protein in glycogen
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supercompensated muscle was significantly higher than in exercised wildtype and
GSL3 transgenic suggesting that control of PKB/Akt protein expression is similar
to that of GLUT4.
In summary, we have determined the effects of glycogen synthase over
expression on post-exercise muscle glucose metabolism independent of muscle
glycogen concentration. Using the GSL3 transgenic mouse model, we have
provided evidence that muscle glycogen concentration, per se, does not affect
post-exercise insulin action in vivo or in muscle using an in situ preparation.
Following exercise, GSL3 transgenic muscle exhibits greater insulin action and
insulin-stimulated muscle glucose uptake independent of muscle glycogen content
relative to wildtype muscle. The increase in insulin-stimulated muscle glucose
uptake following exercise in GSL3 transgenic muscle could not be accounted for
by increases in GLUT4 protein or hexokinase activity. Glycogen concentration
appears to influence post-exercise muscle insulin signaling and insulin-stimulated
glucose uptake in wildtype muscle when elevated above normal. However, our
insulin signaling results support the possibility that the normal mechanisms
responsible for the inverse relationship between muscle glycogen concentration
and glucose uptake may be absent in GSL3 transgenic muscle. This may represent
a putative, yet unknown, association between the activation states of glycogen
synthase and PKB/Akt, both of which are normally inhibited when muscle
glycogen has been elevated above normal. In addition, overexpression of
glycogen synthase may facilitate a repartitioning of intracellular glucose
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intermediates towards glycogen synthesis as opposed to the glycolytic,
hexosamine, and oxidative pathways.
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Table 3.1 Gastrocnemius muscle fractional velocity at 1.5 mM and 0.5 mM G-
6-P; and -/+ G-6-P activity ratio following hindlimb perfusion with
either low (0.2 mU • ml-1) or high (10 mU • ml-1) insulin
concentration. Fractional velocities are expressed as percentages.
Groups are wildtype (WT, N=4), transgenic (TG, N=4), exercised
wildtype (WTX, N=4), exercised transgenic (TGX, N=5), and
wildtype exercised/supercompensated (SUPER, N=5).
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Figure 3.1. Blood glucose response to a 1 mg • g BW-1 intraperitoneal glucose
tolerance test. Groups are wildtype (WT, N=10), transgenic (TG,
N=12), exercised wildtype (WTX, N=12), exercised transgenic
(TGX, N=13), and wildtype exercised/supercompensated (SUPER,
N=8). Group means ± SEM presented. †P < 0.05, non-exercised vs.
exercised within each genotype; ‡P < 0.05, TG vs. WTX; *P < 0.05,
WT vs. TGX, #P < 0.05, WTX vs. SUPER; §P < 0.05, TGX vs.
SUPER; %P < 0.05, TG vs. SUPER; @P < 0.05, WTX vs. TGX.
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Figure 3.2. Plasma insulin response to a 1 mg • g BW-1 intraperitoneal glucose
tolerance test. Groups are wildtype (WT, N=10), transgenic (TG,
N=12), exercised wildtype (WTX, N=12), exercised transgenic
(TGX, N=13), and wildtype exercised/supercompensated (SUPER,
N=8). Group means ± SEM presented. †P < 0.05, non-exercised vs.
exercised within each genotype; ‡P < 0.05, non-exercised groups vs.
SUPER; *P < 0.05, WTX vs. TGX.
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Figure 3.3. Muscle glycogen content in mixed gastrocnemius muscle from
GSL3 transgenic and wildtype mice. Groups are wildtype (WT,
N=13), transgenic (TG, N=14), exercised wildtype (WTX, N=13),
exercised transgenic (TGX, N=15), and wildtype
exercised/supercompensated (SUPER, N=12). Group means ± SEM
presented. *P < 0.05, vs. WT; †P < 0.05, vs. WTX; ‡P < 0.05,
SUPER vs. TG; §P < 0.05 SUPER vs. TGX.
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Figure 3.4. Muscle glycogen synthase activity following hindlimb perfusion
with either (A) low (0.2 mU • ml-1) or (B) high (10 mU • ml-1)
insulin. Groups are wildtype (WT, N=4), transgenic (TG, N=4),
exercised wildtype (WTX, N=4), exercised transgenic (TGX, N=5),
and wildtype exercised/supercompensated (SUPER, N=5). Group
means ± SEM presented. †P < 0.05, TGX vs. WT, WTX, and
SUPER; *P < 0.05, TG vs. WT, WTX, and SUPER.
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Figure 3.5. Mixed gastrocnemius muscle 2-deoxyglucose uptake following
hindlimb perfusion procedure at two insulin concentrations (0.2 mU
• ml-1 and 10 mU • ml-1). Groups are wildtype (WT, N=6-7),
transgenic (TG, N=7), exercised wildtype (WTX, N=6-7), exercised
transgenic (TGX, N=6-9), and wildtype exercised/supercompensated
(SUPER, N=6). Group means ± SEM presented. †P < 0.05, vs. TG
within respective insulin concentration; ‡P < 0.05 vs. SUPER within
respective insulin concentration; *P < 0.05, vs. WT within respective
insulin concentration.
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Figure 3.6. GLUT4 protein content in mixed gastrocnemius muscle. Values are
expressed as percent of an insulin-stimulated rat heart standard run
on all gels. Groups are wildtype (WT, N=10), transgenic (TG,
N=12), exercised wildtype (WTX, N=10), exercised transgenic
(TGX, N=10), and wildtype exercised/supercompensated (SUPER,
N=7). Group means ± SEM presented. †P < 0.05, vs. WT.
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Figure 3.7. Hexokinase activity in mixed gastrocnemius muscle. Values are
expressed as µmol • g -1 • min-1. Groups are wildtype (WT, N=10),
transgenic (TG, N=12), exercised wildtype (WTX, N=10), exercised
transgenic (TGX, N=10), and wildtype exercised/supercompensated
(SUPER, N=7). Group means ± SEM presented. †P < 0.05, vs.
WTX; #P < 0.05, vs. SUPER.
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Figure 3.8. Mixed gastrocnemius IRS-1-associated PI3-kinase activity assessed
following hindlimb perfusion. Values are expressed as percent of
insulin-stimulated mouse standard. Groups are wildtype (WT, N=5),
transgenic (TG, N=5-6), exercised wildtype (WTX, N=5), exercised
transgenic (TGX, N=6), and wildtype exercised/supercompensated
(SUPER, N=5). Group means ± SEM presented. †P < 0.05, vs. WT
within respective insulin concentration; ‡P < 0.05, vs. SUPER.
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Figure 3.9. Mixed gastrocnemius total PKB/Akt protein as assessed following
hindlimb perfusion. Values are expressed as percent of insulin-
stimulated mouse standard run on all gels. Groups are wildtype (WT,
N=6), transgenic (TG, N=7-8), exercised wildtype (WTX, N=8),
exercised transgenic (TGX, N=7-9), and wildtype
exercised/supercompensated (SUPER, N=5-6). Group means ± SEM
presented. ‡P < 0.05, vs. WT. †P < 0.05 vs. WTX. *P < 0.05 vs.
TGX.
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Figure 3.10. Mixed gastrocnemius phosphorylated (Ser473) PKB/Akt as assessed
following hindlimb perfusion. Values are expressed as percent of
insulin-stimulated mouse standard run on all gels. Groups are
wildtype (WT, N=6), transgenic (TG, N=7-8), exercised wildtype
(WTX, N=8), exercised transgenic (TGX, N=7-9), and wildtype
exercised/supercompensated (SUPER, N=5-6). Group means ± SEM
presented. ‡P < 0.05, vs. WT within respective insulin
concentration; *P < 0.05, vs. TG within respective insulin
concentration; †P < 0.05, vs. SUPER within respective insulin
concentration.
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CHAPTER IV: STUDY 2
EFFECTS OF GLYCOGEN SYNTHASE OVEREXPRESSION
ON THE INSULIN-INDEPENDENT PHASE OF POST-
EXERCISE GLYCOGEN RESYNTHESIS
59
Abstract
We have determined the effects of glycogen synthase overexpression on
muscle glucose metabolism following a lowering of muscle glycogen levels by in
situ electrical stimulation of the sciatic nerve. Right gastrocnemii from GSL3
transgenic and wildtype mice were subjected to 30 min of stimulation followed by
hindlimb perfusion of both hindlimbs. Thirty minutes of contraction significantly
reduced muscle glycogen concentration in wildtype (49%) and transgenic (27%)
mice although transgenic mice retained 168.8 ± 20.5 µmol • g -1 glycogen as
compared to 17.7 ± 2.57 µmol • g -1 glycogen for wildtype mice. Muscle of
transgenic and wildtype mice demonstrated similar pre- (3.6 ± 0.28 µmol • g-1 • h-1
and 3.9 ± 0.59 µmol • g-1 • h-1, for transgenic and wildtype, respectively) and post-
contraction (7.9 ± 0.34 µmol • g -1 • h-1 and 7.0 ± 0.38 µmol • g -1 • h-1, for
transgenic and wildtype, respectively) insulin-stimulated glucose uptakes.
However, the percentage of [14C] glucose incorporated into glycogen was greater
in non-contracted (151%) and contracted transgenic muscle (157%) versus muscle
of wildtype mice. Also, insulin-stimulated glycogen synthase responsiveness and
G-6-P sensitivity, as well as PKB/Akt Ser473 phosphorylation were greater in
transgenic mice as compared to wildtype mice post-contraction. Contractions
increased insulin-stimulated PKB/Akt phosphorylation in muscle of wildtype but
not in muscle of transgenic mice. These results indicate that the normal inverse
relationship between muscle glycogen concentration and insulin-stimulated
glucose uptake is absent in GSL3 transgenic mice. Furthermore, they suggest that
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a constitutively active glycogen synthase prevented an elevated glycogen
concentration from compromising post-contraction insulin-stimulated muscle
glucose uptake and glycogen synthesis.
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Introduction
Insulin-stimulated glucose transport during post-exercise recovery appears
to be inversely related to the muscle glycogen content (Cartee and Holloszy,
1990; Cartee et al., 1989; Fell et al., 1982; Hespel and Richter, 1990; Richter et
al., 1984). In this regard, it has been suggested that glycogen content may
influence the number of glucose transporters that can be actively associated with
the plasma membrane. Recent studies utilizing a cell surface GLUT4 protein
labeling technique have demonstrated an inverse relationship between muscle
glycogen content and GLUT4 transporters associated with the plasma membrane
following insulin stimulation (Derave et al., 2000; Etgen et al., 1996; Kawanaka
et al., 1999). Increased muscle glycogen content is also associated with decreased
activity of PKB/Akt (Derave et al., 2000; Kawanaka et al., 2000), a key insulin
signaling protein involved in stimulation of GLUT4 protein translocation
(Cheatham and Kahn, 1995; Hajduch et al., 1998; Kohn et al., 1996; Tanti et al.,
1997). In addition, an inverse relationship between glycogen concentration and
the activity of glycogen synthase, the rate-limiting enzyme for glycogen synthesis,
also exists (Danforth, 1965; Laurent et al., 2000).
Evidence from recent research utilizing the GSL3 transgenic mouse model
challenges the normal inverse relationship between muscle glycogen levels and
insulin-stimulated glucose transport. GSL3 transgenic mice overexpress a
constitutively active form of glycogen synthase (10-fold) which is associated with
a markedly elevated (5-fold) muscle glycogen concentration (Manchester et al.,
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1996). Using this model, Azpiazu et al. (2000) demonstrated that overexpression
of glycogen synthase is sufficient to promote glycogen accumulation without
reducing insulin action on muscle glucose uptake. Since GSL3 transgenic muscle
did not demonstrate the classic insulin resistance typically associated with an
elevated muscle glycogen level, this raises the question of whether or not insulin-
stimulated glucose uptake is influenced by muscle glycogen. We have previously
assessed in situ insulin-stimulated muscle glucose uptake in GSL3 transgenic
muscle following exhaustive running exercise combined with carbohydrate
restriction (Unpublished data). However, we were unable to lower muscle
glycogen concentrations of GSL3 mice using this experimental protocol. Thus, we
could not investigate the effects of glycogen on insulin-stimulated muscle glucose
uptake post-exercise. In an effort to assess the influence of muscle glycogen on
insulin action following muscular contractions, we electrically stimulated muscle
of wildtype and GSL3 transgenic mice in situ via the sciatic nerve. Our results
suggest that insulin action immediately following muscular contraction is
improved independent of muscle glycogen concentration.
Methods
Animals and Experimental Design. GSL3 transgenic and wildtype
littermates [(C57BL6 X CBA)F1] weighing 20-35 g (n=25) were used in these
experiments. The GSL3 transgenic mice overexpress a constitutively active form
of glycogen synthase [GS(2,3a)], a rabbit skeletal muscle glycogen synthase
having Ser to Ala mutations at sites 2 and 3a (donated by Dr. John Lawrence,
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University of Virginia, Charlottesville, VA). The generation of the transgenic line
is described by Manchester et al. (1996). Transgenic expression of the
constitutively active glycogen synthase is 10 times higher compared to wildtype
muscle, with 5 times greater expression in fast twitch versus slow twitch muscle
(Manchester et al., 1996). Upon receiving the mice, they were individually housed
at The University of Texas Animal Resource Center on a 12:12 h light-dark cycle.
Laboratory chow and water were provided ad libitum and the animal room
temperature was maintained at 21ºC. Animals were transferred to the laboratory at
least 24 h prior to the first experimental procedures following the same light
cycle. The University of Texas Animal Care and Use Committee approved all
procedures for this study.
Muscle Contraction Procedure. Following a 6 h fast, GSL3 transgenic
(n=13) and wildtype (n=12) mice were anesthetized with pentobarbitol sodium
(6.5 mg • 100 g-1 body weight). The skin from the right hindlimb was reflected
and a section of the calcaneous, with the Achilles tendon still attached, clipped
from the foot. The triceps surae muscle group was retracted from the tibia and the
distal tendon (detached from the bony insertion) of the muscle group was attached
to an isometric force transducer. However, the distal insertions of the plantaris
and soleus muscles were sectioned and teased away from the gastrocnemius so,
upon stimulation of the sciatic nerve, only the gastrocnemius was producing an
isometric contraction. The sciatic nerve was isolated and placed in-line, via hook
electrode, with a Grass Stimulator (Grass Instruments, Quincy, MA). Both the
non-stimulated left hindlimb and the mouse torso were immobilized in a specially
64
designed cradle and gastrocnemius length adjusted to achieve peak twitch tension
(Pt). Pt and peak tetanic tension (Po) were assessed (Series 300 B Lever System,
Aurora Scientific Inc., Ontario, Canada) with supramaximal stimulation strength
at the optimal length for the muscle contracting at 90º to the knee joint.
The goal of this stimulation procedure was to reduce muscle glycogen
prior to the assessment of 2-deoxyglucose uptake. Therefore, a modified version
of the protocol described by Johannsson et al. (1996a & 1996b) and Roy et al.
(1997) was employed. The gastrocnemius was stimulated for 30 min using
supramaximal (8 V) trains composed of 1 ms square-wave pulses firing at 100 Hz.
Trains of 200 ms were delivered at a rate of 30 per min (1 per 2 sec). Tetanic
tension was assessed throughout the stimulation period. Gastrocnemius muscle
cross sectional area was estimated by dividing wet weight by the measured
optimal muscle length (cm) multiplied by the fiber to muscle length ratio for
rodent gastrocnemius (0.4) multiplied by mammalian muscle specific gravity
(1.06 g/cm3). Specific force (N/cm2) was then estimated by dividing muscle Po,
expressed in newtons (N), by the estimated cross-sectional area (cm2) (Brooks and
Faulkner, 1988). Following the stimulation period, the mice were prepared for in
situ hindlimb perfusion to measure insulin-stimulated [3H] 2-deoxyglucose uptake
or to determine [14C] glucose incorporation into glycogen using a submaximal
insulin concentration (0.2 mU • ml-1).
Hindlimb perfusion. The perfusion surgical technique was similar to that
described previously (Brozinick et al., 1996; Ivy et al., 1983). Major vessels
branching from the abdominal aorta and vena cava except the common iliac artery
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and iliac vein were ligated. Heparin (100 U) was injected into the inferior vena
cava just inferior to the diaphragm. Following the heparin injection, the
descending aorta and inferior vena cava were cannulated as previously described
(Ivy et al., 1983). Catheters were placed in line with the non-circulating hindlimb
perfusion apparatus providing a 37ºC, continuously gassed (95% O2/5% CO2)
perfusate flow of 1.8 ml • min-1. Both hindlimbs were perfused during the
equilibrium (10 min) and tracer (20 min) periods. Perfusates consisted of 6%
bovine serum albumin (BSA) in Krebs-Henseleit buffer (KHB, pH 7.4) with 0.2
mM pyruvate. Tracer perfusion periods varied between assessment of glucose
uptake and glucose incorporation and are described below. Immediately following
the perfusion period, the gastrocnemius from both hindlimbs were excised, frozen
with Wollenberg tongs cooled in liquid N2 and stored frozen (-80ºC) until further
analysis.
Determination of 2-Deoxyglucose Uptake. During the perfusion tracer
period, the perfusate contained 6 mM [1,2-3H] 2-deoxyglucose (7.5 µCi • mmol -1;
ICN Biochemicals, Costa Mesa, CA), 2 mM [U-14C] mannitol (60 µCi • mmol-1;
ICN Biochemicals) and 0.2 mU • ml-1 insulin (Humulin R-100, Eli Lilly,
Indianapolis, IN). Freeze-clamped gastrocnemius muscles from the perfused
wildtype (n = 6) and transgenic (n = 6) hindlimbs were sectioned and weighed
frozen. A 60-100 mg piece of mixed-fiber muscle was dissolved in 1 ml 1 N KOH
by incubating for 15 min at 65ºC, mixed, and incubated an additional 5 min at
65ºC. An equal volume of 1 N HCl was added to the digested samples, mixed,
and aliquots of the neutralized samples counted for [3H] and [14C] DPM (Beckman
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LS 6000SC, Fullerton, CA). Muscle 2-deoxyglucose uptake was calculated from
the specific activity of the original perfusate after subtracting out the appropriate
volume for extracellular space as determined from radiolabelled mannitol in the
muscle sample. The mixed gastrocnemius was used because it exhibits a high
transgene expression but contains similar GLUT4 content in wildtype and GSL3
transgenic mice (Manchester et al., 1996).
[14C] Glucose incorporation into glycogen. [14C] Glucose incorporation
into glycogen was assessed in a different group of wildtype (n = 7) and transgenic
(n = 5) hindlimbs as previously described (Willems et al., 1991). The perfusion
surgery and preparation was essentially the same as described for 2-deoxyglucose
uptake during the pre-tracer perfusion period. During the 20 min tracer perfusion
period both hindlimbs were perfused with 6 mM glucose (0.15 µCi • ml-1 D-
[14C(U)] glucose) (ICN Biochemicals) with a submaximal insulin concentration
(0.2 mU • ml-1). Following the perfusion period, both gastrocnemii were excised,
weighed frozen and placed in screw-top test tubes containing 1 ml of 30% KOH
saturated with Na2SO4. Samples were digested by incubating the tubes for 30 min
at 100ºC. After the incubation, the tubes were cooled to room temperature and the
glycogen precipitated overnight at 4ºC after the addition of 1:2 volumes of 95%
ethanol. The glycogen was pelleted by centrifugation and resuspended in distilled
H2O. An aliquot of this resuspension was used for determination of muscle
glycogen concentration as per Lo et al. (1970). A second aliquot was transferred
to a scintillation vial containing 5 ml of scintillation fluid and the rate of [14C]
glucose incorporation into glycogen determined.
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Measurement of glycogen synthase activity.  Glycogen synthase was
measured by direct incorporation of [U-14C] UDP-1-glucose (ICN Biochemicals)
into glycogen with several concentrations of G-6-P (0.01, 0.5, 1.5, and 25 mM) as
previously described (Sherman et al., 1988). Glycogen synthase total activity was
determined in the presence of 25 mM G-6-P. The fractional velocities of glycogen
synthase were determined by dividing the enzyme activity of 0.5 and 1.5 mM G-
6-P by that of maximal (25 mM) G-6-P glycogen synthase activity and are
expressed as percentages. In addition, the G-6-P +/- activity ratio was calculated
by dividing the glycogen synthase activity measured in the presence of 0.01 mM
G-6-P divided by the total activity.
Total and Phosphorylated PKB/Akt-1α. Three isoforms of PKB/Akt have
been identified. The primary insulin-stimulated isoform in rodent muscle is
PKB/Akt-1α (Turinsky and Damrau-Abney, 1999; Walker et al., 1998). In
addition, post-exercise insulin-stimulated PKB/Akt-1α activity was inversely
related to skeletal muscle glycogen content in the study by Derave et al. (2000).
Therefore, PKB/Akt-1α is was the isoform assessed in the present study. Frozen
muscle samples were prepared as described by Kawanaka et al. (2000). Muscle
pieces (30 mg) were homogenized in ice-cold buffer containing 50 mM HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer, 1 mM EDTA, and
250 mM sucrose, pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5
mM MgCl2, 1.0 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 2.0 mM Na3VO4,
aprotinin (10 µg • ml-1), leupeptin (10 µg • ml-1), pepstatin (0.5 µg • ml-1), 1%
Igepal and 2 mM phenylmethylsulfonyl fluoride. For quantification of
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phosphorylated PKB/Akt-1α, aliquots of the 200,000 g supernatant were treated
with 2x Laemmli sample buffer containing 100 mM dithiothreitol and boiled for 5
min. Samples (80 µg protein) were subjected to SDS-PAGE (10% resolving gel)
and transferred to nitrocellulose membranes. An insulin-stimulated mouse
gastrocnemius muscle standard (80 µg) was run on each gel. The membranes
were blocked in 5% nonfat dry milk in TBS containing 0.1% Tween 10 (pH 7.5)
for 1 h. Following a rinse in 0.1% Tween 10, the membranes were incubated with
sheep antiphospho-PKB/Akt-1α (Ser473) antibody (Upstate Biotechnology Inc.)
for 4 h. Membranes were rinsed in 0.1% Tween 10 and incubated with
horseradish peroxidase-conjugated rabbit anti-sheep IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA) for 60 min. Antibody-bound
protein was visualized using an ECL Western blot detection kit (Amersham)
according to the manufacturer’s instructions. Phosphorylated PKB/Akt of samples
was expressed relative to the insulin-stimulated mouse standard.
Total PKB/Akt-1α protein content was assessed on the nitrocellulose
membranes used for phosphorylated PKB/Akt-1α. Membranes were stripped of
antibodies by incubation with stripping buffer containing 100 mM 2-
mercaptoethanol, 2% sodium dodecyl sulfate, 62.5 mM Tris HCl (pH 6.7) for 30
min. Membranes were then washed three times for 15 min in TTBS buffer.
Membranes were blocked overnight, washed three more times for 15 min in
TTBS, and incubated with sheep anti-Akt/PKB-1α (1:1000 vol/vol) (Upstate
Biotechnology Inc.) for 4 h with gentle agitation. Following three more TTBS
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washes, antibody-bound protein was visualized using ECL (Amersham) and total
PKB/Akt-1α was expressed relative to the insulin-stimulated mouse standard.
Statistics. One-way analysis of variance was performed on in situ
electrical stimulation performance data. Two-way analysis of variance was
performed on all tissue analyses. Post hoc tests were performed using Fishers’s
Protected LSD with differences considered statistically significant if P ≤ 0.05.
Results
Muscle contractile performance. Gastrocnemius Pt, optimal muscle
length, muscle wet weight and estimated muscle cross-sectional area were not
significantly different between wildtype and GSL3 transgenic mice (Table 4.1).
Transgenic muscle Po was 14% lower than wildtype (Table 4.1). This difference
was significant at the P < 0.06 level. Specific force was significantly lower in
GSL3 transgenic muscle (16.1 ± 0.88 N/cm2) compared to wildtype muscle (21.4
± 1.5 N/cm2) (Table 4.1). Gastrocnemius tetanic tension production declined to
48% of Po for wildtype mice and 61% of Po in GSL3 transgenic mice by 5 min of
stimulation (Figure 4.1). Tetanic tension production remained essentially
unchanged from 5 min throughout the 30 min stimulation period. Wildtype
muscle contractile performance was similar to those found by Johannson et al.
(1996a), using a similar stimulation protocol in the rat.
Muscle glycogen concentration. There was a significant genotype and
treatment effect with respect to muscle glycogen concentration. Glycogen
concentration of gastrocnemius from transgenic mice was approximately 7-fold
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greater than that of wildtype mice (Figure 4.2). Muscle contraction significantly
lowered muscle glycogen in both genotypes. The reduction in muscle glycogen
was 49% in wildtype gastrocnemius and 27% in transgenic gastrocnemius.
However, in absolute terms, 30 min of contraction reduced glycogen by 63 µmol •
g-1 wet weight in transgenic muscle and 17 µmol • g-1 wet weight in wildtype
muscle. Quadriceps muscle glycogen content was unchanged by stimulation in
either genotype (data not shown) demonstrating that the decline in gastrocnemius
muscle glycogen was specific to the muscle stimulated by the sciatic nerve.
Glycogen synthase. A significant genotype effect was evident for glycogen
synthase fractional velocities at 1.5 and 0.5 mM G-6-P, as well as -/+ G-6-P
activity ratio. These measures were markedly lower in GSL3 transgenic muscle
compared to wildtype and unchanged by treatment in either genotype (Table 4.2).
However the total activity of glycogen synthase (25 mM G-6-P), expressed in
nmol • g-1 • min-1, was significantly greater in non-contracted (1197%) and
contracted (1761%) transgenic compared to muscle from the respective wildtype
treatment. In addition, allosteric activation of glycogen synthase was greater at G-
6-P concentrations of 1.5 (361%) and 0.5 mM (142%) in non-contracted
transgenic muscle compared to muscle from wildtype mice. Following 30 min of
contractions, glycogen synthase allosteric activation was greater (1062% and
291% for 1.5 and 0.5 mM, respectively) in transgenic muscle compared to
wildtype muscle. Contraction of muscle of transgenic mice resulted in greater
total glycogen synthase activity (110%) and allosteric activation of glycogen
synthase at G-6-P concentrations of 1.5 (131%) and 0.5 mM (62%) compared to
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non-contracted transgenic muscle. No differences were observed between any
group during exposure to 0.01 mM G-6-P.
2-Deoxyglucose uptake. Genotype had no effect on insulin-stimulated
glucose uptake of the gastrocnemius muscle. There was, however, a significant
treatment effect as 30 min of contraction resulted in a 2-fold increase in insulin-
stimulated glucose uptake (Figure 4.4). This 2-fold increase occurred in both
transgenic and wildtype muscle.
[14C] Glucose incorporation into glycogen. Significant genotype and
treatment effects were observed with respect to insulin-stimulated glucose
incorporation into glycogen. Glucose incorporation into glycogen in transgenic
muscle was significantly higher prior to (151%) and following (157%) contraction
than in the corresponding wildtype muscle (Figure 4.5). However, contraction
resulted in a 1.9-fold increase in insulin-stimulated incorporation of glucose in
muscle of both genotypes.
Total and Phosphorylated PKB/Akt. Total PKB/Akt protein was similar in
wildtype and GSL3 transgenic muscle and was not altered by 30 min of
contraction (Figure 4.6). Significant genotype, treatment, and interaction effects
were evident with respect to insulin-stimulated PKB/Akt Ser473 phosphorylation.
Insulin-stimulated PKB/Akt Ser473 phosphorylation was significantly higher in
muscle of transgenic mice as compared to muscle of wildtype mice (Figure 4.7).
This difference was significant prior to (212%) and following (52%) muscle
contraction. Contraction significantly increased insulin-stimulated PKB/Akt
phosphorylation, but only in wildtype muscle (131%).
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Discussion
Insulin-stimulated glucose uptake during post-exercise recovery appears to
be inversely related to the muscle glycogen concentration (Cartee and Holloszy,
1990; Cartee et al., 1989; Fell et al., 1982; Hespel and Richter, 1990; Richter et
al., 1984). However, evidence from recent research utilizing the GSL3 transgenic
mouse model challenges this relationship (Azpiazu et al., 2000) In an effort to
assess the influence of muscle glycogen on insulin action following muscular
contractions, we electrically stimulated muscle of GSL3 transgenic and wildtype
mice in situ via the sciatic nerve. Our results suggest that insulin action
immediately following muscular contraction is improved independent of muscle
glycogen concentration.
Insulin-stimulated muscle glucose uptake was similar in transgenic and
wildtype mice prior to and following muscle contraction. However, this occurred
in the face of a markedly greater transgenic muscle glycogen concentration. These
findings suggest that the normal inverse relationship between elevated muscle
glycogen levels and insulin action on glucose uptake is absent in GSL3 transgenic
mice.
When muscle glycogen is elevated above normal levels, the ability of
insulin to activate glucose transport (Cartee et al., 1989; Derave et al., 2000; Fell
et al., 1982; Jensen et al., 1997; Kawanaka et al., 2000; Richter et al., 1984) is
significantly depressed. Thus, it has been suggested that glycogen may have some
control over the number of glucose transporters that can be actively associated
with the plasma membrane. Recent studies utilizing the ATB-BMPA cell surface
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GLUT4 labeling technique have demonstrated an inverse relationship between
muscle glycogen content and GLUT4 protein associated with the plasma
membrane following insulin stimulation (Derave et al., 2000; Etgen et al., 1996;
Kawanaka et al., 1999). The inhibition of GLUT4 translocation by elevated
muscle glycogen might occur directly via the glycogen macromolecule itself or
indirectly through glycogen-mediated inhibition of PKB/Akt (Derave et al., 2000;
Kawanaka et al., 2000). PKB/Akt is a key insulin signaling protein involved in
stimulation of GLUT4 translocation (Cheatham and Kahn, 1995; Hajduch et al.,
1998; Kohn et al., 1996; Tanti et al., 1997). An inverse relationship between
glycogen concentration and the activity of glycogen synthase, the rate-limiting
enzyme for glycogen synthesis (Danforth, 1965; Laurent et al., 2000) also exists.
In addition to a putative role in GLUT4 translocation to the cell surface,
PKB/Akt may catalyze the phosphorylation and inactivation of GSK-3 in skeletal
muscle (Cross et al., 1995). GSK-3, in turn, has been implicated in inhibition of
glycogen synthase (Cross et al., 1997; Ueki et al., 1998) as well as feedback
inhibition of IRS-1 facilitated PI3-kinase activity (Eldar-Finkelman and Krebs,
1997; Summers et al., 1999). Thus, PKB/Akt may play a pivotal role in both
insulin regulation of glucose transport and glycogen synthase activity.
Insulin-stimulated glucose uptake was normal while PKB/Akt
phosphorylation was significantly higher in transgenic muscle compared to
wildtype. These findings are in stark contrast to the inverse relationship normally
observed between muscle glycogen concentration and insulin-stimulated glucose
uptake and PKB/Akt phosphorylation. Thus, the normal suppression of insulin
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signaling and glucose uptake associated with elevated muscle glycogen
concentrations is disrupted in transgenic muscle.
Why resting and post-exercise insulin-stimulated PKB/Akt
phosphorylation remains highly active in GSL3 transgenic muscle despite
elevated muscle glycogen concentrations (>200 µmol • g-1) remains unclear.
Derave et al. (2000) and Kawanaka et al. (2000) both demonstrated that elevated
muscle glycogen concentration (~60-130 µmol • g -1) in rats was associated with
an attenuation of insulin-stimulated increases in PKB/Akt phosphorylation.
Furthermore, we have previously demonstrated this attenuation in wildtype mice
with muscle glycogen concentrations of 103 µmol • g-1 (Unpublished data).
The maintenance of PKB/Akt activity in the GSL3 transgenic muscle
despite above normal glycogen concentrations could facilitate GLUT4
translocation to the cell surface as well as inhibition of GSK-3. Inhibition of
GSK-3, in turn, might alleviate feedback inhibition of IRS-mediated insulin
signaling. Thus, activation PKB/Akt could enhance insulin-stimulated muscle
glucose uptake by two potential mechanisms in GSL3 transgenic muscle. These
results may also be related to the constitutively active glycogen synthase, which is
over expressed in GSL3 transgenic muscle. The influence of glycogen on
PKB/Akt activity may be dependent upon the ability of glycogen to depress
glycogen synthase activity. This might represent a putative, yet unknown,
association between the activation states of glycogen synthase and PKB/Akt, both
of which are normally inhibited when muscle glycogen has been elevated above
normal.
75
Our observations that insulin-stimulated muscle glucose uptake was
similar yet [14C] glucose incorporation into glycogen was greater in resting
transgenic muscle compared to wildtype correspond with those observed by
Azpiazu et al. (2000). Taken  together, these findings suggest that overexpression
of glycogen synthase may facilitate a repartitioning of intracellular glucose
intermediates towards glycogen synthesis as opposed to the glycolytic,
hexosamine, and oxidative pathways. This repartitioning may prevent
accumulation of G-6-P, glucosamine, and citrate, all of which may act to suppress
insulin-stimulated glucose uptake. Furthermore, overexpression of glycogen
synthase is sufficient to promote glycogen accumulation while preventing muscle
glycogen levels from compromising insulin action on muscle glucose uptake.
In the present study, differences in peak tetanic tension and specific force
in GSL3 transgenic muscle compared to wildtype muscle could not be explained
by muscle wet weight or estimated cross sectional area. Differences in peak
tetanic tension and specific force may result, at least in part, from the 7-fold
greater glycogen content in the GSL3 transgenic muscle. Considering the water
content associated with glycogen storage (Geddes, 1986), the extensive glycogen
macromolecule in GSL3 transgenic muscle may have disrupted myofibrillar
mechanics.
In summary, we have demonstrated that a constitutively active glycogen
synthase prevents glycogen from compromising post-contraction insulin-
stimulated muscle glucose uptake and glucose incorporation into glycogen.
Overexpression of a constitutively active form of glycogen synthase may facilitate
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a repartitioning of intracellular glucose intermediates towards glycogen synthesis
as opposed to the glycolytic, hexosamine, and oxidative pathways following
contractions. Furthermore, our PKB/Akt phosphorylation data support the
possibility that the normal mechanisms responsible for the inverse relationship
between muscle glycogen concentration and glucose uptake may be absent in
GSL3 transgenic muscle. This may represent a putative, yet unknown, association
between the activation states of glycogen synthase and PKB/Akt, both of which
are normally inhibited during conditions where muscle glycogen has been
elevated.
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Table 4.1. Gastrocnemius muscle contractile performance. Peak twitch tension
(Pt), peak tetanic tension (Po), optimal muscle length (Lo), wet
weight, estimated cross-sectional area (CSA), and specific force are
presented.
Wildtype (N=6) Transgenic (N=7)
Pt (N) 1.07 ± 0.03 1.11 ± 0.03
Po (N) 3.30 ± 0.10 2.85 ± 0.18*
Lo (cm) 1.68 ± 0.07 1.63 ± 0.09
Wet weight (g) 0.11 ± 0.01 0.12 ± 0.01
CSA (cm2) 0.16 ± 0.01 0.18 ± 0.02
Specific force (N/cm2) 21.4 ± 1.5 16.1 ± 0.88†
Values are means ± SEM. (*) P < 0.06, vs. WT; (†) P < 0.05, vs. WT.
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Table 4.2. Gastrocnemius muscle fractional velocity at 1.5 mM and 0.5 mM G-
6-P; and -/+ G-6-P activity ratio following hindlimb perfusion with
either low (0.2 mU • ml-1) insulin concentration. Fractional velocities
are expressed in percentages. Groups are non-stimulated wildtype
(N=6), stimulated wildtype (N=5), non-stimulated transgenic (N=5),
and non-stimulated transgenic (N=5).
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Figure 4.1. Gastrocnemius tetanic tension produced during 30 min of in situ
electrical stimulation via the sciatic nerve. Groups are stimulated
wildtype (N=5) and stimulated transgenic (N=5). Group means ±
SEM presented. †P < 0.06, transgenic vs. wildtype.
80
Figure 4.2. Muscle glycogen content in mixed gastrocnemius following 30 min
of in situ electrical stimulation. Groups are non-stimulated wildtype
(N=9) and transgenic (N=9) and stimulated wildtype (N=5) and
transgenic (N=5). Group means ± SEM presented. †P < 0.05, vs.
respective wildtype treatment. *P <0.05, vs. respective non-
stimulated (NON) groups.
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Figure 4.3. Mixed gastrocnemius glycogen synthase activity following hindlimb
perfusion (0.2 mU • ml-1 insulin) following 30 min in situ electric
stimulation protocol. Groups are non-stimulated wildtype (N=6) and
transgenic (N=5) and stimulated wildtype (N=5) and transgenic
(N=5). Group means are presented. †P < 0.05, stimulated (STIM)
transgenic vs. all groups. ‡P < 0.05, non-stimulated (NON)
transgenic vs. all groups.
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Figure 4.4. Insulin-stimulated 2-deoxyglucose uptake in mixed gastrocnemius
muscle following 30 min of in situ electrical stimulation. Groups are
non-stimulated wildtype (N=6) and transgenic (N=6) and stimulated
wildtype (N=6) and transgenic (N=6). Group means ± SEM
presented. *P < 0.05, vs. respective non-stimulated (NON) groups.
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Figure 4.5. Insulin-stimulated [14C] glucose incorporation into glucose from
mixed gastrocnemius following 30 min of in situ electrical
stimulation. Groups are non-stimulated wildtype (N=9) and
transgenic (N=9) and stimulated wildtype (N=5) and transgenic
(N=5). Group means ± SEM presented. †P < 0.05, vs. respective
wildtype treatment. *P < 0.05, vs. respective non-stimulated (NON)
treatment.
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Figure 4.6. Mixed gastrocnemius total PKB/Akt protein as assessed following
hindlimb perfusion. Groups are non-stimulated wildtype (N=6) and
transgenic (N=6) and stimulated wildtype (N=6) and transgenic
(N=6). Values are expressed as percent of insulin-stimulated mouse
standard run on all gels. Group means ± SEM presented.
85
Figure 4.7. Mixed gastrocnemius phosphorylated PKB/Akt (Ser473) as assessed
following hindlimb perfusion (0.2 mU • ml-1). Values are expressed
as percent of insulin-stimulated mouse standard run on all gels.
Groups are non-stimulated wildtype (N=6) and transgenic (N=6) and
stimulated wildtype (N=6) and transgenic (N=6). Group means ±
SEM presented. ‡P < 0.05, vs. non-stimulated (NON) wildtype. *P <
0.05, vs. stimulated (STIM) wildtype.
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CHAPTER V: EXTENDED REVIEW OF THE LITERATURE
Introduction
Glycogen is a large, branched polymer of glucose residues and serves as
the body’s storage form of this sugar. Alpha-1,4-glycosidic bonds link most of the
glucose residues in glycogen. Branches are created by alpha-1,6-glycosidic bonds,
of which there is one in about ten residues. The glycogen macromolecule also
contains the enzymes that catalyze the synthesis and degradation of glycogen and
some of the enzymes regulating these processes. The presence of glycogen greatly
increases the amount of carbohydrate that is immediately available between meals
and during muscular contraction. The two major sites of glycogen storage are
liver and skeletal muscles. The concentration of glycogen is higher in the liver
but, due to its much greater mass, skeletal muscle stores more total glycogen.
Glycogen metabolism in skeletal muscle plays a major role in the control of blood
glucose homeostasis by the pancreatic hormone insulin, the most important
regulator of blood glucose levels. Understanding the process by which insulin
regulates glycogen accumulation in muscle is relevant to both insulin resistance
and restoration of carbohydrate stores following exercise.
Glucose Disposal
Glucose is a relatively polar molecule requiring a transporter for facilitated
diffusion across the plasma membrane. Two isoforms of the facilitative glucose
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transporter family, GLUT1 and GLUT4, are expressed in skeletal muscle (Douen
et al., 1990). GLUT1 resides primarily in the plasma membrane where it likely
plays a role in basal, but not insulin-stimulated glucose transport (Douen et al.,
1990). Conversely, GLUT4 is predominantly located intracellularly, but is
translocated to the plasma membrane by the action of insulin (Douen et al., 1990)
and contractile activity (Douen et al., 1990; Hirshman et al., 1990). The greater
number of GLUT4 transporters incorporated into the plasma membrane during
translocation, the greater the rate of glucose transport (Etgen et al., 1996; Lund et
al., 1993). The hormone insulin is released from pancreatic beta cells in response
to rising blood glucose resulting in an indirect coupling of glucose appearance and
disappearance rates in the circulation. A stable blood glucose concentration
depends on this balance.
Glucose transport is the penetration of glucose through the plasma
membrane while glucose uptake is the clearance of glucose from the extracellular
space and involves the processes of glucose transport and intracellular glucose
disposal. Once a glucose molecule is transported into a cell, it is either
phosphorylated by hexokinase to G-6-P or counter-transported back to the
extracellular compartment. Muscle tissue cannot dephosphorylate glucose because
it lacks glucose-6-phosphatase. Therefore, phosphorylation effectively commits
the G-6-P to metabolism within the cell, as the negatively charged phosphate does
not permit the G-6-P to cross the plasma membrane. Insulin binding to its receptor
results in translocation of GLUT4 to, as well as its insertion into, the plasma
membrane. This process has not been fully elucidated. However, it is known that
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the greater number of GLUT4 transporters that are incorporated into the plasma
membrane in response to insulin, the greater the rate of glucose transport (Etgen
et al., 1996; Lund et al., 1993; Wilson and Cushman, 1994). Additionally, an
increase in GLUT4 protein content is generally associated with increased insulin
responsiveness (Henriksen et al., 1990; Kern et al., 1990). In skeletal muscle, the
majority of G-6-P formed during insulin-stimulated glucose uptake is rapidly
converted to glycogen or oxidized (Ivy and Holloszy, 1981; Lillioja et al., 1986).
Typically, the rate of phosphorylation will exceed the rate of transport,
maintaining a low intracellular free glucose concentration and providing a
concentration gradient essential for net inward glucose transport. However,
hexokinase activity is allosterically inhibited by its product, G-6-P. Therefore, if
G-6-P is not rapidly removed, glucose disposal can become rate limiting and
result in a reduction in the rate of glucose uptake and clearance of glucose from
the circulation.
Glycogenolysis
Glycogen breakdown occurs by orthophosphate cleavage to a
phosphorylated sugar, glucose-1-phosphate (G-1-P) (Cori and Cori, 1947). This
reaction is catalyzed by the enzyme glycogen phosphorylase. Phosphorylase
catalyzes the sequential removal of glycosyl residues from the non-reducing end
of the glycogen molecule. The glycosidic linkage between C-1 of the terminal
residue and C-4 of the adjacent residue is split by orthophosphate. Specifically,
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the bond between the C-1 carbon atom and the glycosidic oxygen atom is cleaved
by orthophosphate, and the alpha configuration at C-1 is retained.
Glycogen is not degraded by phosphorylase alone as the alpha-1,6-
glycosidic bonds at the branch points are not susceptible to cleavage by
phosphorylase. Phosphorylase stops cleaving alpha-1,4-linkages when it reaches a
terminal residue four residues away from an existing branch. A transferase
exposes the alpha-1,6 branch residue to the action of a third degradative enzyme,
an alpha-1,6-glucosidase (debranching enzyme), that hydrolyzes the alpha-1,6-
glycosidic bond liberating a free glucose molecule. Thus, the transferase and the
debranching enzyme convert the branched structure into a linear one, allowing for
further cleavage by phosphorylase. The G-1-P formed in the phosphorolytic
cleavage of glycogen is converted into G-6-P by phoshphoglucomutase.
Glycogen Synthesis
In the synthesis of glycogen, intracellular glucose undergoes several
modifications to generate uridine diphosphate (UDP)-glucose (Leloir et al., 1971).
This reaction takes place in three sequential steps. First, glucose is phosphorylated
by hexokinase to generate G-6-P, which is then converted to G-1-P by
phosphoglucomutase. Finally, UDP-glucose is synthesized from G-1-P and
uridine triphosphate in a reaction catalyzed by UDP-glucose pyrophosphorylase.
The C-1 carbon of the glycosyl unit of UDP-glucose is considered “activated”
because its hydroxyl group is esterified to the diphosphate moeity of UDP.
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New glucose units are added to the non-reducing terminal residues of
glycogen. The UDP-glucose is transferred to the hydroxyl group at a C-4 terminus
of glycogen forming an alpha-1,4-glycosidic linkage. In this elongation reaction,
the growing glycogen macromolecule’s terminal hydroxyl group displaces UDP.
This reaction is catalyzed by glycogen synthase, which can add glucose residues
only if the polysaccharide chain already contains more than four residues. Thus,
glycogen synthesis requires a primer, which is formed by a different synthase.
Glycogen synthase catalyzes only the synthesis of alpha-1,4-linkages. A
branching enzyme is needed to form the alpha-1,6-linkages that make glycogen a
branched polymer. Branching is important because it increases the solubility of
glycogen. Furthermore, branching creates a large number of non-reducing
terminal residues, which are the sites of action of glycogen phosphorylase and
synthase. Thus, branching increases the rate of glycogen synthesis and
degradation.
Branching occurs after a number of glucose residues are joined in alpha-
1,4-linkage by glycogen synthase. The breakage of an alpha-1,4-link and the
formation of an alpha-1,6-link creates branching. A block of residues, typically
seven in number, is transferred to a more interior site of the macromolecule. The
branching enzyme that catalyzes this reaction is quite precise. The block of seven
residues must include the non-reducing terminus and come from a chain of at
least eleven residues long. In addition, new branch points are at least four residues
away from a pre-existing branch.
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The energy yield from the breakdown of glycogen is highly efficient.
About 90% of the residues are phosphorylitically cleaved to G-1-P, which is
converted at no metabolic cost into G-6-P. The other 10% are branch residues,
which are hydrolytically cleaved. One ATP is then used to phosphorylate each of
these glucose molecules to G-6-P. The complete oxidation of G-6-P yields 37
molecules of ATP and storage consumes one ATP per G-6-P.
Glycogenin and Pro- and Macroglycogen
The primer for glycogen synthesis is an autoglucosylating protein called
glycogenin. This protein is capable of catalyzing the addition of glucosyl units to
its Try-194 binding site. In skeletal muscle glycogenin and glycogen synthase are
complexed with the glycogen macromolecule under resting conditions with no
detectable free deglycosylated glycogenin. In rat skeletal muscle, glycogenin
varies with fiber type with type I fibers having the greatest content and activity
(Hansen, 1999). Interestingly, muscle glycogenin content and activity are not
affected by endurance exercise training (Hansen, 1999). Glycogenin may play an
important role in glycogen metabolism. However, the mechanisms remain
unclear. Hansen (1999) has evaluated three possible sites of regulation on the
protein itself including interaction with glycogen synthase, a phosphorylation site,
and regulation by glucose metabolites. Glycogenin and glycogen synthase
disassociate when skeletal muscle is exposed to prolonged electrical stimulation
or epinephrine with reassociation of the glycogen-free glycogenin and glycogen
synthase being time dependent (Smythe et al., 1990). It has been suggested that
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this reassociation may be influenced by neural and hormonal factors, which are
known to regulate glycogen synthesis (Shearer et al., 1999). Regulation of
glycogenin by glucose metabolites or its putative interaction with GLUT4 have
been suggested but not investigated. However, phosphorylation of the glycogenin
protein has been demonstrated in skeletal muscle (Lomako and Whelan, 1988) but
the possible regulatory role is unknown. Transcriptional or translational regulation
of glycogenin may also exist.
There are two forms of glycogen formed from a single glycogenin primer,
proglycogen and macroglycogen (Alonso et al., 1995; Lomako et al., 1991;
Lomako et al., 1993). As more glucosyl units are added to a proglycogen
molecule it expands to a macroglycogen molecule (Alonso et al., 1995). These
two types of glycogen differ in size, carbohydrate and solubility. Macroglycogen
contains more carbohydrate and is larger than proglycogen. Macroglycogen is
soluble in perchloric acid while proglycogen precipitates. In human skeletal
muscle with normal glycogen levels, macroglycogen accounts for ~25% of the
total glycogen concentration (Adamo et al., 1998; Jansson et al., 1981). The
proportion of pro- and macroglycogen varies widely in different muscle fiber
types (Alonso et al., 1995). Because there are no free glycogenin molecules in
skeletal muscle at rest, accumulation of proglycogen would require synthesis of
more glycogenin protein primers while macroglycogen could accumulate simply
by the addition of glycosyl units. Regulation of synthesis and degradation of the
glycogen fractions is not clearly understood. Furthermore, the metabolic
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significance of glycogenin as well as the distinct glycogen pools requires more
research.
Glycogen Synthase
Glycogen synthase is controlled by multisite phosphorylation and by
several allosteric effectors, of which the activator G-6-P is most important. Of the
7 carboxy-terminal phosphorylation sites, Ser640 (site 3a) and Ser644 (site 3b) and
NH2-terminal Ser7 (site 2) and Ser10 (site 2a) are important regulation locales
(Skurat et al., 2000). In general, phosphorylation decreases glycogen synthase
activity, causing an increase in the apparent Km for the substrate UDP-glucose and
an increase in the Ka for G-6-P. The extent of inactivation depends on the sites
phosphorylated and metabolic effector concentrations. G-6-P, for example, is able
to fully activate even highly phosphorylated forms of the enzyme (Villar-Palasi
and Guinovart, 1997). The hormone insulin, for example, activates glycogen
synthase by promoting dephosphorylation of the enzyme, resulting in an increase
in G-6-P sensitivity of glycogen synthase, i.e., a decrease in the concentration of
G-6-P required to activate the enzyme (Villar-Palasi, 1991). The enzymes of
glycogen metabolism are dephosphorylated by glycogen-bound protein
phosphatase-1 (PP-1). In addition, PP-1 is capable of dephosphorylating all of the
sites on glycogen synthase. The existence of differential regulation or two
isoforms of glycogen synthase for pro- and macroglycogen has been speculated
but not demonstrated.
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Regulation of Glycogen Metabolism by Insulin
Insulin regulates the synthesis of glycogen at two steps, first by controlling
the transport and uptake of glucose into the muscle cell (Narahara et al., 1960),
and second, by regulating the phosphorylation and activating states of enzymes
involved in the synthesis and degradation (Villar-Palasi and Larner, 1960). In
recent years, significant advances have been made to understand the mechanisms
of insulin-induced activation of glycogen synthesis. However, the precise steps
involved in this process remain uncertain.
Insulin causes a decrease in the serine phosphorylation of glycogen
synthase leading to its activation (Parker et al., 1983; Roach, 1991; Lawrence,
1994). This decrease could be accomplished either by activating PP-1 which
dephosphoylates glycogen synthase and/or by inhibiting the protein kinases,
which catalyze the phosphorylation of glycogen synthase. For example, insulin
activates PP-1 activity in skeletal muscle (Begum, 1995a; Newgard et al., 2000;
Oliver et al., 1988; Oliver et al., 1990; Srinivasan et al., 1994; Toth et al., 1991).
Since PP-1 can dephosphorylate all the sites of glycogen synthase, its activation
by insulin has been attributed to a decrease in the phosphorylation of glycogen
synthase (Begum, 1995b; Hubbard and Cohen, 1993). However, which form of
PP-1 is involved and the mechanism of activation is unknown (Walker et al.,
2000).
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Glycogen Synthase Kinase-3
Recent research suggests that insulin activates muscle glycogen synthase
in part by decreasing the activity of glycogen synthase kinase-3 (GSK-3) (Cross et
al., 1997; Ueki et al., 1998). This enzyme is constitutively active in the basal state
and is inhibited by Ser21 and Ser9 phosphorylation in response to insulin and other
growth factors in various cell types (Hughes et al., 1992; Welsh and Proud, 1993;
Cross et al., 1994). Following site 5 phosphorylation of glycogen synthase by
casein kinase II, GSK-3 phosphorylates a series of serine residues (sites 4, 3c, 3b,
and 3a) at the carboxy terminus of glycogen synthase and inactivates it (Lawrence
and Roach, 1997; Parker et al., 1983). In vitro, GSK-3 phosphorylates two (3b
and 3c) of the four sites (3b, 3c, 2, and 2a) on glycogen synthase, which also
become dephosphorylated in response to insulin (Moxham et al., 1996). Recently,
PKB/Akt has emerged as the most potential protein kinase catalyzing the
phosphorylation and inactivation of GSK-3 in skeletal muscle (Cross et al., 1995).
The sites of PKB/Akt phosphorylation of GSK-3 are reported as the same sites
phosphorylated in response to insulin in vivo (Cross et al., 1995). GSK-3, in turn,
has been implicated in feedback inhibition of IRS-1-facilitated PI3-kinase activity
(Eldar-Finkelman and Krebs, 1997; Summers et al., 1999). Thus, PKB/Akt may
play a pivotal role in both insulin regulation of glucose transport and glycogen
synthase activity. However, several other insulin-stimulated protein kinases
including epidermal growth factor, c-Jun NH2-terminal kinase, mitogen-
activated/90 kDa ribosomal kinase (p90rsk) and 70 kDa ribosomal S6 kinase (p70rsk)
have been shown to catalyze the phosphorylation and inactivation of GSK-3 in
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vitro (Moxham et al., 1996; Sutherland et al., 1993; Sutherland and Cohen, 1994).
Therefore, the existence of redundant GSK-3 inactivation mechanisms may
facilitate enhanced activity of glycogen synthase. However, a study using specific
inhibitors of p70rsk and p90rsk demonstrated that these kinases might not catalyze the
in vivo phosphorylation and inhibition of GSK-3 activity (Cross et al., 1994).
Skurat et al. (2000) recently demonstrated that GSK-3 inactivation is not essential
for insulin-stimulated glycogen synthase activation in rat fibroblasts. In addition
to indirectly inactivating GSK-3, insulin also increases the dephosphorylation of
glycogen synthase by activating a glycogen-associated form of PP-1 (Newgard et
al., 2000; Walker et al., 2000).
Upon cessation of exercise, a PKB/Akt independent inhibition of GSK-3
has been observed in skeletal muscle in vivo (Markuns et al., 1999). However, this
deactivation does not appear to be responsible for the prolonged activation (i.e., 4
h post-exercise) of glycogen synthase during the insulin-dependent phase of post-
exercise glycogen resynthesis as GSK-3 activity is similar in rested and exercised
muscle (Wojtaszewski et al., 2000). How GSK-3 is inhibited or possibly PP-1
activated, for that matter, by previous exercise is currently unknown but may be
related to increased c-Jun NH2-terminal kinase activity (Aronson et al., 1997;
Moxham et al., 1998; Sherwood et al., 1999).
PI3-Kinase and PKB/Akt
Protein kinase B is the cellular homolog of the retroviral Akt (Bellacosa et
al., 1991; Coffer and Woodgett, 1991; Jones et al., 1991). PKB/Akt is rapidly
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activated through insulin-mediated phosphorylation (Alessi et al., 1996; Cross et
al., 1995). PI3-kinase has been implicated in the activation of PKB/Akt as the
phosphorylation of PKB/Akt is blocked by wortmannin, an inhibitor of PI3-kinase
(Alessi et al., 1996). PI3-kinase activity is stimulated by insulin (Ruderman et al.,
1995) as well as many other stimuli (Toker and Cantley, 1997; Vanhaesebroek et
al., 1997). The SH2 domain of the PI3-kinase p85 subunit interacts with tyrosine
phosphorylated insulin receptor substrates 1 and 2 (IRS-1, IRS-2). This
interaction results in the stimulation of the catalytic activity of the p110 subunit of
PI3-kinase (Cheatham and Kahn, 1995). The PtdIns 3,4-biphosphate and PtdIns
3,4,5-triphosphate lipid products of the PI3-kinase reaction have been shown to
promote association of 3-phosphoinositide-dependent kinase-1 (PDK-1) and
PKB/Akt whereby PDK-1 then activates PKB/Akt via Ser473 and Thr308
phosphorylation (Alessi and Cohen, 1998). Activation of PKB/Akt has been
implicated in insulin-stimulated GLUT4 translocation and glycogen synthase
activation (Cheatham and Kahn, 1995). Turinsky and Damrau-Abney (1999)
recently demonstrated that the increase in insulin-stimulated rat muscle glucose
uptake is associated with an increased activity of PKB/Akt-1 as opposed to
PKB/Akt-2 or PKB/Akt-3. This association was most pronounced in the primarily
slow twitch soleus but was apparent in the plantaris and gastrocnemius muscles as
well.
A few studies have demonstrated that insulin-stimulated PI3-kinase
activity is not increased immediately post-exercise (Goodyear et al., 1995;
Whitehead et al., 2000; Wojtaszewski et al., 1997). However, recent evidence for
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increased insulin-stimulated PI3-kinase activity following exercise exists
(Chibalin et al., 2000; Derave et al., 2000; Howlett et al., 2002; Kawanaka et al.,
2000; Wadley et al., 2001). Chibalin et al. (2000) observed an increase in rat
muscle insulin-stimulated IRS-1- and IRS-2-associated PI3-kinase activities 16 h
following an acute exercise bout. The increase in insulin-stimulated IRS-2-
associated PI3-kinase activity following exercise has recently been confirmed by
Howlett et al. (2002). Wadley et al. (2001) demonstrated an increased expression
of PI3-kinase mRNA 3 h following a single bout of exercise in humans.
Expression of PI3-kinase mRNA was not elevated immediately after exercise or
following endurance exercise training in this study. PI3-kinase activity was not
presented in this study. Studies by Derave et al. (2000) and Kawanaka et al.
(2000) further demonstrated that the increased insulin-stimulated PI3-kinase
activity following exercise is not affected by muscle glycogen content.
During exercise, PKB/Akt is not essential for the regulation of muscle
GLUT4 translocation, glucose transport (Lund et al., 1998) or glycogen synthase
activity (Sakamoto et al., 2002). Recent studies have demonstrated that muscle
PKB/Akt activity is not increased following treadmill running (Nader and Esser,
2001; Markuns et al., 1999) or swimming (Derave et al., 2000) in rats. These
findings are supported by studies which involved electrically induced contractions
in vitro (Brozinick and Birnbaum, 1998; Lund et al., 1998; Whitehead et al.,
2000) and in situ (Sherwood et al., 1999). Using the in vitro isolated rat muscle
preparation, Lund et al. (1998) observed that insulin but not contraction resulted
in an increase in PKB/Akt activity. When insulin and contraction were combined,
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the resultant PKB/Akt activity was not different than following insulin alone.
Furthermore, insulin-stimulated PKB/Akt activity is not significantly higher 16 h
following acute exercise in rats (Chibalin et al., 2000), while in human muscle,
insulin-stimulated PKB/Akt activity was not increased 4 h following an acute
bout of one-legged cycling (Wojtaszewski et al., 2000).
Despite the findings from the above studies, sufficient evidence for a
PKB/Akt increase in response to contractile activity exists (Derave et al., 2000;
Kawanaka et al., 2000; Nader and Esser, 2001; Sakamoto et al., 2002, Thorell et
al., 1999; Turinsky and Damrau-Abney, 1999). Thorell et al. (1999) assessed
PKB/Akt activity in human muscle biopsies following 60 min of moderate-
intensity cycle exercise. PKB/Akt Ser473 phosphorylation was increased by 280%
above resting values immediately upon exercise completion. In addition, when a 2
h euglycemic-hyperinsulinemic clamp was performed following exercise,
PKB/Akt Ser473 phosphorylation was increased 1,000% above resting values.
Nader and Esser (2001) observed an increase in rat tibialis anterior PKB/Akt
phosphorylation immediately after 20 min of in situ electrical stimulation via the
sciatic nerve. This increased activity was evident following high frequency as
well as low frequency stimulation. Interestingly, treadmill running exercise failed
to elicit an increase in PKB/Akt immediately following exercise in this study
(Nader and Esser, 2001). Sakamoto et al. (2002) demonstrated an in situ
contraction-mediated increase in the activities of all three PKB/Akt isoforms.
Maximal activation of the kinase isoforms occurred after 2.5 min of contractions
and had returned to baseline levels by 15 min. Three isoforms of PKB/Akt have
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been identified. The primary insulin-stimulated isoform in rodent muscle is
PKB/Akt-1 (Walker et al., 1998). Turinsky and Damrau-Abney (1999) recently
observed an increased in PKB/Akt-1 activity throughout a 25 min in situ high
frequency electrical stimulation protocol. This group also observed an insulin-
mediated increase in the activity of this isoform. The activities of PKB/Akt-2 and
PKB/Akt-3 were not altered by the stimulation protocol. Two recent studies using
rats have demonstrated that PKB/Akt activity increased following swimming
exercise (Derave et al., 2000; Kawanaka et al., 2000). Derave et al. (2000)
demonstrated that PKB/Akt activity was increased when previously exercised
muscle was exposed to supraphysiologic insulin concentrations in situ. Using an
isolated in vitro muscle preparation, Kawanaka et al. (2000) also observed an
increase in insulin-stimulated PKB/Akt in previously exercised muscle. Both of
these studies, however, demonstrated that elevated muscle glycogen content was
associated with an attenuation of insulin-stimulated increases in PKB/Akt activity.
The ability of exercise to activate skeletal muscle PKB/Akt may by mode-
and isoform-specific. In addition, whether or not exercise enhances insulin-
stimulated PKB/Akt activity may depend on the insulin concentration as well as
muscle glycogen content. Regardless, further research in this area is certainly
warranted.
Exercise and Glycogen Metabolism
During prolonged strenuous exercise, carbohydrate is a required fuel for
sustained muscle contraction. Immediate sources of carbohydrate are muscle
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glycogen and blood glucose. Early in exercise, muscle glycogen is the preferred
source of carbohydrate. However, as exercise continues and the muscle glycogen
levels decline, the rate of glycogenolysis also declines and there is an increased
reliance on blood glucose to support the working muscle’s carbohydrate
requirements (Ahlborg et al., 1967; Bergström et al., 1967; Hermansen et al.,
1967). To accommodate this increased reliance on blood glucose, GLUT4-
containing vesicles are translocated to the plasma membrane (Kristiansen et al.,
1997). Thus, glycolysis and glucose oxidation may remain relatively constant as
long as there is no major decrease in the blood glucose concentration. However,
the decline in muscle glycogen results in perception of fatigue and once depleted,
necessitates termination of exercise or a significant reduction in exercise intensity
(Ahlborg et al., 1967; Bergström et al., 1967; Hermansen et al., 1967). In
addition, it has been found that aerobic endurance performance is directly related
to the initial muscle glycogen stores (Ahlborg et al., 1967; Hermansen et al.,
1967; Hultman, 1967). Thus, following prolonged exercise, replenishment of
muscle glycogen to within a normal range is an essential component of the
recovery process.
During exercise the interaction of blood glucose and muscle glycogen
utilization is complicated by fat metabolism. Alterations in plasma free fatty acid
(FFA) levels influence muscle glycogenolysis during exercise. For example,
inhibition of FFA mobilization by nicotinic acid lowers plasma FFA and increases
muscle glycogen use during exercise (Bergström et al., 1969). In contrast,
increased plasma FFA availability has been shown to reduce the rate of muscle
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glycogen utilization during exercise (Costill et al., 1977; Dyck et al., 1996;
Hickson et al., 1977; Rennie et al., 1976; Vulkovich et al., 1993) via post-
transformational regulation of glycogen phosphorylase activity (Dyck et al.,
1996). Following exercise, elevated free fatty acid concentrations are associated
with impaired muscle insulin action (Schulch and Kipnis, 1965).
Post-Exercise Insulin Action
Following exercise, the synthesis of muscle glycogen occurs as a bi-phasic
response with the first rapid phase being insulin-independent and the second
slower phase being insulin-dependent (Ivy, 1977; Mæhlum et al., 1977; Price et
al., 1994). During the insulin-independent phase the rate of glycogen synthesis is
very rapid, but lasts only 30 to 45 minutes (Price et al., 1994). During the insulin-
dependent phase, synthesis remains negligible unless there is an increase in
glucose availability and plasma insulin concentration (Ivy, 1977; Price et al.,
1994).
Previous muscle contraction results in an increase in insulin stimulation of
glucose transport (Cartee et al., 1989; Garetto et al., 1984; Holloszy and Narahara,
1965; Ren et al., 1994; Richter et al., 1984). This is of benefit as energy
expenditure is coupled to recovery by partitioning substrate toward previously
active muscle. When muscle contraction ceases, the energy requirement of the
muscle declines rapidly and glycolysis is substantially reduced. Glucose transport,
however, remains elevated due to an increased number of glucose transporters on
the plasma membrane (Goodyear et al., 1990). The combination of enhanced
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glucose transport, but low glycolytic flux results in an elevation of G-6-P (Bloch
et al., 1994). The increase in G-6-P stimulates glycogen synthesis by activating
glycogen synthase allosterically, increasing susceptibility to attack by PP-1
following exercise (Villar-Palasi and Guinovart, 1997). Availability of PP-1 is
increased due to its simultaneous release with glycogen synthase from the
glycogen macromolecule during glycogenolysis (Hubbard and Cohen, 1993).
Results from a recent study by Aschenbach et al. (2001) indicate that PP-1
activation is essential for glycogen synthase regulation during exercise. In
addition, contractile activity increases the mitogen-activated kinase pathway
(Hayashi et al., 1999). As mentioned in the previous section, certain components
of this pathway may inactivate GSK-3. As the residual effects of muscle
contraction subside, the membrane bound GLUT4 returns to an intracellular site
(Derave et al., 1999; Etgen et al., 1996) and glucose transport (Hespel and
Richter, 1990) and intracellular G-6-P levels decline (Bloch et al., 1994).
However, glycogen synthesis continues, albeit at a considerably slower rate, due
to increased insulin action in muscle.
When carbohydrate is provided during the recovery process, the rate of
glycogen synthesis is increased further and glycogen supercompensation occurs
(Bergström et al., 1967; Ivy, 1991). Carbohydrate feeding most likely stimulates
glycogen supercompensation by increasing plasma glucose and insulin
concentrations, which in turn enhance the effects of post-exercise insulin action
(e.g., substrate availability, G-6-P and insulin-mediated activation of glycogen
synthase).
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The regulation of the slower, insulin-dependent phase of post-exercise
glycogen recovery is not well understood. However, the activity of glycogen
synthase is increased following exercise due to high levels of G-6-P and low
glycogen concentration, both being potent activators of the enzyme (Bloch et al.,
1994). This enhanced insulin action persists until muscle glycogen levels are
replenished (Price et al., 1994). The mechanisms responsible for the reversal of
exercise-induced, insulin-dependent phase of glycogen synthesis are not clear. As
muscle glycogen stores are restored, this causes a reduction in insulin-stimulated
muscle glucose transport (Cartee and Holloszy, 1990). Increased muscle glycogen
content also lowers the activity of glycogen synthase (Danforth, 1965; Laurent et
al., 2000). Thus, a major pathway of blood glucose disposal is down regulated.
Pro- and Macroglycogen Accumulation Following Exercise
It is not known whether pro- and macroglycogen are catabolized at
different rates during exercise; however, it is known that both are utilized (Asp et
al., 1999). Following exercise, synthesis of both pro- and macroglycogen is
sensitive to carbohydrate availability. Adamo et al. (1998) demonstrated that
during the 48 h following exhaustive exercise net synthesis rates for pro- and
macroglycogen were higher when high carbohydrate was provided compared to a
low carbohydrate trial. The net synthesis rate of proglycogen decreased in the
high carbohydrate group throughout the recovery period and was not different
than low carbohydrate group from 24 to 48 h.  Conversely, the net synthesis rate
of macroglycogen remained higher in the high carbohydrate group compared to
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the low carbohydrate group throughout the 48 h recovery period. These results
suggest that proglycogen is predominantly synthesized during the early phase of
glycogen recovery when blood glucose and insulin concentrations are elevated.
This accumulation would require more glycogenin protein suggesting additional
regulation by insulin, i.e., increased protein synthesis or decreased protein
degradation. However, the slower but consistently elevated macroglycogen
synthesis rate accounts for the majority of the glycogen formed as total glycogen
is elevated to above normal levels. This finding is in agreement with other studies
of macroglycogen accumulation in human (Adamo and Graham, 1998; Asp et al.,
1999; Jansson et al., 1981) and rat muscle (Huang et al., 1997).
In the study by Adamo et al. (1998) the net glycogen synthesis rate during
the low carbohydrate trial was approximately 6 mmol • kg dw-1 • h-1, which is
similar to previously reported results (Ivy et al., 1988). Furthermore, in the high
carbohydrate group, the sum of the pro- and macroglycogen synthesis rates during
the first 4 h after exercise (19 mmol • kg dw-1 • h-1) was similar to the total
glycogen synthesis rate observed by Ivy et al. (1988).
The different time courses of pro- and macroglycogen storage suggest
different regulation of the glycogen fractions. Although a putative differential
glycogen synthase regulation and/or isoform for pro- and macroglycogen
formation has not been demonstrated, the activation state of glycogen synthase is
very different during the two phases of post-exercise glycogen restoration. For
example, during the initial, rapid, insulin-independent phase the elevated G-6-P
concentration allosterically activates glycogen synthase (Bloch et al., 1994). This
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phase is associated primarily with proglycogen accumulation. Following glycogen
restoration to normal levels, i.e., during glycogen supercompensation, when
macroglycogen formation is predominant, glycogen synthase activity is attenuated
(Laurent et al., 2000).
Asp et al. (1999) has recently reported that a greater fraction of muscle
macroglycogen than proglycogen is used during prolonged, muscle damaging
exercise in humans. Following this type of exercise, pro- and macroglycogen
restoration were delayed despite provision of a high carbohydrate diet. This delay
was particularly apparent in type I and type IIA fibers compared to type IIB
fibers. This fiber type difference suggests that the fibers used most during the
marathon accumulate post-exercise glycogen differently than non-recruited fibers
(Sherman et al., 1983). The accumulation of macroglycogen was impaired despite
both a high carbohydrate diet and normal concentrations of proglycogen
precursor. The post-exercise glycogen accumulation findings of Asp et al. (1999)
differ from the high carbohydrate trial of Adamo et al. (1998) suggesting that the
pro- and macroglycogen pools are regulated differently following exercise that
results in muscle damage such as the marathon.
Skeletal Muscle Glycogen Levels and Glucose Uptake
It has been demonstrated that muscle glycogen concentration affects both
membrane glucose transport and intracellular glucose metabolism. Fell et al.
(1982) showed that at the same submaximal insulin concentration the rate of post-
exercise glucose uptake was greater in muscles in which glycogen content was
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lowered by carbohydrate restriction compared to muscles in which glycogen
content was raised with carbohydrate feeding. In a recent in vitro study by Jensen
et al. (1997), epitrochlearis muscle basal and insulin-stimulated glucose uptakes
were inversely related to initial glycogen content. A decline in plasma membrane
permeability during post-exercise recovery appears to be inversely related to the
muscle glycogen content (Cartee et al., 1989). This raises the possibility that
glycogen may have some control over the number of transporters that can be
actively associated with the plasma membrane. Evidence for this possibility is
provided by the study of Etgen et al. (1996). This study compared the effect of
muscle contractions on glucose transport, cell-surface GLUT4 labeling, and
glycogen concentration in soleus and epitrochlearis muscle preparations. Using
the same stimulation protocol for both muscles, it was found that the contraction-
induced increase in glucose transport was significantly higher and muscle
glycogen content significantly lower in the epitrochlearis when compared to the
soleus. Furthermore, the increase in transport in both muscles was highly
associated with the cell-surface GLUT4 concentration (Etgen et al., 1996). Using
the perfused rat hindlimb procedure, Derave et al. (1999) recently observed that
the contraction-induced increase in muscle glucose transport and cell-surface
GLUT4 content were negatively correlated with the initial glycogen
concentration. These results are supported by other perfused rat hindlimb studies,
which suggest an inverse relationship between muscle glycogen levels and
insulin-stimulated glucose uptake (Hespel and Richter, 1990). Alterations in
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muscle G-6-P levels, hexokinase activity and intracellular free glucose may also
influence muscle glucose uptake during glycogen accumulation.
Evidence for Glucose Transport as Rate Limiting for Glycogen
Synthesis
The relative importance of glucose transport and glycogen synthase in
controlling the rate of glycogen synthesis remains unclear. Under basal
conditions, however, most evidence suggests that glucose transport is the
principle rate-determining step for glucose metabolism, as there is little free
glucose in resting skeletal muscle fibers (Ziel et al., 1988). Recently, the
importance of glucose transporters in determining the rate of glycogen synthesis
has been demonstrated leading to widely held view that most of the control is at
the level of the transporter. Utilizing metabolic control analysis, Shulman et al.
(1995) demonstrated that the rate of glucose entry into the muscle cell plays a
dominant role in glycogen accumulation. In addition, studies with transgenic mice
overexpressing the skeletal muscle glucose transporters, GLUT1 and GLUT4,
have provided evidence that increasing glucose transport is sufficient to increase
glycogen synthesis (Hansen et al., 1995; Ren et al., 1993; Tsao et al., 1996).
Basal muscle glycogen content of the transgenic animals was markedly increased,
although the activation-state of glycogen synthase in the transgenic animals was
not different from control muscles (Ren et al., 1993). In addition, transgenic mice
overexpressing GLUT1 exhibit increased glycogen synthesis after exercise (Ren
et al., 2000). Furthermore, mice heterozygous for a disrupted GLUT4 allele,
expressing 50% of the wildtype level of GLUT4, exhibited impaired glycogen
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synthesis during euglycemic-hyperinsulinemic clamps (Rosetti et al., 1997). Take
together, these results suggest that glucose transport is rate limiting for glycogen
synthesis. However, results from animals with genetically modified expression of
glucose transporters do not exclude the possibility that activation of glycogen
synthase by insulin has an important role in the stimulation of glycogen synthesis.
In addition, glucose transport control of glycogen formation may not be valid
under all conditions in vivo and evidence for shared control, i.e., transport and
glycogen synthase, has been provided (Bogardus et al., 1984; Jucker et al., 1999;
Kashiwaya et al., 1994; Kubo and Foley, 1986; Schulz, 1998; Shulman et al.,
1995; Smith and Lawrence; 1984).
Evidence for Glycogen Synthase as Rate Limiting for Glycogen
Synthesis
In skeletal muscle evidence for glycogen synthase control of the rate of
glycogen synthesis has been provided by a number of investigators. This may be
true under certain physiologic conditions. For example, Smith and Lawrence
(1984) demonstrated that following denervation of rat hemidiaphragms, a
decrease in the ability of insulin to activate glycogen synthase preceded the
inhibition of the hormone to stimulate glucose transport. Recent work using
metabolic control analysis has illustrated that the control of glucose uptake is
distributed among glucose transport and phosphorylation, glycogen synthesis and
glycolysis (Jucker et al., 1999; Kashiwaya et al., 1994; Shulman et al., 1995).
Through metabolic control analysis of glycogen synthesis, Schulz (1998)
concluded that the control of glycogen synthesis is distributed among different
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metabolic steps, which exert varying influences depending on the physiologic
conditions, i.e. hormone and substrate concentrations. Jucker et al. (1999) also
assessed metabolic control of in vivo glucose disposal by glucose transport,
glycogen synthase and glycolysis, demonstrating that all three steps affect glucose
disposal. In addition to varied hormonal and substrate levels, fiber type
differences in insulin sensitivity (James et al., 1985) may account for differences
in the distribution of control. For example, it has been shown that the regulation
of glycogen synthase is different in fast versus slow twitch muscle after a glucose
load (Sugden et al., 1997).
Recent Studies Using Transgenic Mice Overexpressing Glycogen
Synthase
Results from metabolic control analysis are further supported by the
findings of Manchester et al. (1996) and Azpiazu et al. (2000). These
investigators have recently utilized a transgenic mouse overexpressing glycogen
synthase to assess control of insulin-stimulated glycogen accumulation from a
novel perspective. Glycogen synthase activity was increased 10-fold in transgenic
muscles. Associated with the elevated levels of synthase were glycogen
concentrations as much as 5-fold higher than found in wildtype muscles
(Manchester et al., 1996). Several lines of evidence from the study of Manchester
et al. (1996) suggest that the increase in glycogen was due to the increase in
glycogen synthase, and not due to increased glucose transport. For example,
UDP-glucose concentrations were lower in transgenic muscle in vivo, which may
be indicative of glycogen synthase control of glycogen intermediate
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concentrations. In addition, levels of GLUT4 were the same or slightly lower in
transgenic compared to wildtype muscle. Azpiazu et al. (2000) extended these
findings by measuring the insulin-stimulated rates of 2-deoxyglucose uptake in
diaphragm, extensor digitorum longus and soleus muscles. In muscles incubated
in vitro, basal and insulin-stimulated rates of glucose uptake in the transgenic and
wildtype muscles were not different. In response to insulin, the increases in
glucose uptake from basal were 8-fold in diaphragm, 2-fold in extensor digitorum
longus and soleus. In muscles incubated in vitro with a maximally effective
concentration of insulin (20 mU • ml-1) or without insulin, the rate of 14C-glucose
incorporation into glycogen was 2- to 2.5-fold higher in transgenic muscle
compared to wildtype muscle (Azpiazu et al., 2000). For example, a 24–fold
insulin-stimulated increase (above basal) in glucose incorporation into glycogen
was observed in the transgenic diaphragm. The increased incorporation in this
muscle could not be accounted for by either the insulin-stimulated increase in
glucose uptake (8-fold) or increase in glycogen synthase activity ratio (4-fold)
alone. This suggests insulin-stimulated increases in both processes may account
for the enhanced glycogen incorporation. With no difference in insulin-stimulated
glucose uptake between the wildtype and transgenic muscle, the enhanced
incorporation into glycogen in transgenic muscle is likely due to a greater
percentage of intracellular G-6-P going to glycogen synthesis as opposed to
glycolysis, the hexoasamine pathway, or oxidation. Thus, overexpression of
glycogen synthase could potentially facilitate a repartitioning of intracellular
glucose intermediates. Azpiazu et al. (2000) concluded that their results were
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evidence for a shared control of insulin-stimulated glycogen synthesis involving
glycogen synthase as well as glucose transport. These results concur with the
recent findings of Jucker et al. (1999). Using metabolic control analysis, this
group determined that during insulin stimulation, the majority of control of
glucose uptake is by glucose transport and glucose phosphorylation. However,
glycogen synthesis and glycolysis were also determined to control glucose uptake,
albeit to a lesser extent.
Insulin-stimulated glucose uptake was not different in wildtype and
transgenic muscle in the study by Azpiasu et al. (2000). In addition, Manchester et
al. (1996) demonstrated that the glycogen content of the transgenic muscles is
several-fold higher than wildtype. Thus, the lack of difference in insulin-
stimulated glucose uptake between the transgenic and wildtype muscle may have
been affected by the higher glycogen content of the transgenic animals. In this
regard, it has been demonstrated that the rate of insulin-stimulated glucose uptake
in muscle is inversely related to glycogen concentration (Derave et al., 2000; Fell
et al., 1982; Jensen et al., 1997; Kawanaka et al., 2000). Recently, Derave et al.
(2000) demonstrated that elevated muscle glycogen levels were associated with
impaired insulin signaling (PKB/Akt activity) and translocation of GLUT4
transporters. Kawanaka et al. (2000) also observed that glycogen-
supercompensated rats exhibit 50% lower PKB/Akt activity and severe insulin
resistance despite an exercise training-induced increase in total GLUT4 protein
(2-fold). Interestingly, insulin receptor tyrosine kinase (Derave et al., 2000) and
PI3-kinase (Derave et al., 2000; Kawanaka et al., 2000) activities were similar in
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muscle with high or low glycogen. These results suggest that, under conditions of
elevated muscle glycogen, insulin-stimulated translocation of GLUT4 is impaired
by decreased PKB/Akt activation. How PKB/Akt is inhibited is currently
unknown.
Azpiazu et al. (2000) only evaluated insulin-stimulated glucose uptake
under conditions of high glycogen in the glycogen synthase transgenic mice.
Therefore, it is likely that the lack of increased insulin-stimulated glucose uptake
in transgenic compared to wildtype muscle observed may have been due to
elevated glycogen levels. It may be possible that increased glycogen synthase
activity can influence glucose uptake in muscle when muscle glycogen
concentrations of transgenic and wildtype have been reduced. However, this has
yet to be demonstrated. To date, no study has assessed the relative importance of
exercise and glycogen synthase activity on skeletal muscle insulin-stimulated
glucose uptake independent of glycogen levels.
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CHAPTER VI: DETAILED METHODS
Experimental Animals and Animal Care
The GSL3 line of transgenic mice used in this study overexpress a
constitutively active glycogen synthase [GS(2,3a)], a rabbit skeletal muscle
glycogen synthase having Ser to Ala mutations at NH2 sites 2 and 3a. Transgenic
pups were identified by using the polymerase chain reaction to detect
chloramphenicol acetyltransferase sequences in tail DNA (donated by Dr. John
Lawrence, University of Virginia, Charlottesville, VA). Transgenic expression of
the constitutively active glycogen synthase is 10 times higher compared to
wildtype muscle, with 5 times greater expression in fast twitch versus slow twitch
muscle (Manchester et al., 1996). Mice were individually housed at The
University of Texas Animal Resource Center on a 12 h light cycle. Standard rat
chow and water were provided ad libitum. Animals were transferred to the
laboratory at least 24 h prior to the first experimental procedures and were kept on
the same light cycle and provided food and water ad libitum throughout the
experiments except where noted below. The University of Texas Animal Care and
Use Committee approved all procedures for this study.
Generation of GSL3 Transgenic Mice (from Manchester et al., 1996).
CDNA encoding GS(2,3a) was inserted into the BstEII site of the
p3300MCKCAT. Just upstream of this BstEII site is the sequence from –3300 to
+7 of the mouse creatine kinase gene, which includes elements that direct
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expression to both skeletal and cardiac muscle. Immediately adjacent on the
downstream side of the BstEII site is a chloramphenicol acetyltransferase reporter
followed by a simian virus 40 intron and polyadenylylation site. After digesting
p3300MCKCAT with BstEII, the vector was blunt-ended and dephosphorylated.
A fragment containing GS(2,3a) cDNA was excised from pCMV-GS(2,3a) by
using BglII and XbaI, then blunt-ligated into p3300MCKCAT. Proper orientation
of the insert was confirmed by nucleotide sequencing. A fragment containing the
3.3-kb creatine kinase gene sequence, GS(2,3a) cDNA, and simian virus 40
sequences  was excised using HindIII followed by a partial digest with KpnI,
inserted between the HindIII and KpnI sites of pSL1180, then excised with
HindIII and EcoRv. The 7.5-kb fragment was purified and injected into the
pronuclei of fertilized mouse eggs [(C57BL6 X CBA)F1 X (C57BL6 X CBA)F1].
Embryos were implanted into pseudopregnant females and transgenic pups were
identified by using the polymerase chain reaction to detect chloramphenicol
acetyltransferase sequences in tail DNA. Three founder lines (GSL3, GSL25, and
GSL30) were established by mating transgene-positive animals to (C57BL6 X
CBA)F1 mice.
Study 1 Experimental Design. GSL3 transgenic and wildtype mice (n=60)
weighing 20-35 g were assigned to either non-exercised or exercised treatment
groups. An additional group of wildtype mice (designated SUPER, n=12) was
assigned to a glycogen supercompensation group. All mice underwent an
intraperitoneal glucose tolerance test (IPGTT) followed approximately 1-2 weeks
later by the hindlimb perfusion procedure. Wildtype and transgenic non-exercised
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groups (designated WT and TG, respectively) were allowed free access to
laboratory chow and water and were otherwise restricted to normal cage activities.
The wildtype and transgenic exercised groups (designated WTX and TGX,
respectively) underwent two days of glycogen depleting (data not shown) exercise
on a motorized treadmill (3 h, 26 m • min-1) with carbohydrate restriction between
runs to limit glycogen restoration. Following the first run, mice were given 1 g of
laboratory chow with lard provided ad libitum. Following the second run mice
had free access to lard but did not receive chow. This glycogen depleting
exercise/diet protocol was performed prior to both the IPGTT and the hindlimb
perfusion procedure allowing glycogen restoration but not supercompensation 24
h following exercise. The wildtype SUPER mice underwent a protocol to raise
muscle glycogen levels to above-normal levels. These mice performed an
exhaustive run (3 h, 26 m • min -1) followed by 24 h of a high carbohydrate
chow/table syrup mix and 15% carbohydrate solution ad libitum. This
supercompensation procedure was performed prior to both the IPGTT and the
hindlimb perfusion. Mice from all groups were fasted (6 h) prior to both the
IPGTT and the hindlimb perfusion.
Study 2 Experimental Design. GSL3 transgenic (n=6) and wildtype mice
(n=6) weighing 20-35 g were assigned to either non-exercised or exercised
treatment groups. All mice in the subsequent four groups were surgically prepared
for in situ electrical stimulation and hindlimb perfusion assessment of 2-
deoxyglucose uptake. Post stimulation [14C] Glucose incorporation into glycogen
was assessed in a different group of wildtype (n = 7) and transgenic (n = 5) mice
121
weighing 20-35 g. All mice were subjected to a 6 h fast prior to the experimental
procedures.
Intraperitoneal Glucose Tolerance Test
Following a 6 h fast, the mice were placed in a restrainer placed on a
heating pad to maximize tail blood flow. The tip (2 mm) of the tail was clipped,
washed with EDTA (24 mg • ml-1 EDTA) and blotted with clean gauze. The mice
were given 1 mg • g-1 body weight of a 10% glucose solution by intraperitoneal
injection. Blood glucose was assessed on a single drop of whole blood prior to
and 30, 60, 120, and 150 min following glucose administration. In addition,
approximately 0.15 ml of blood was taken prior to, 30 and 60 min following
glucose administration. The blood samples were added to tubes containing 24 mg
• ml-1 EDTA.  Following a 10 min centrifugation in a benchtop centrifuge (3,000
g), the plasma was stored at -80ºC until analysis for insulin.
Blood Analysis
Blood glucose was determined with the ONE TOUCH BASIC blood
glucose monitoring system from Johnson & Johnson (Milpitas, CA). This system
requires a small drop of whole blood onto a reading strip, which is then read by
the monitoring unit. Validity of this blood glucose monitoring system was tested
against a YSI blood glucose analyzer (Yellow Springs Instrument Company,
Yellow Springs, OH). The blood glucose is expressed as mM. Plasma insulin was
determined by radioimmunoassay kit (Linco Research, St. Charles, MO) utilizing
the double antibody procedure of Morgan and Lazarow (1963). The 125I-labeled
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insulin was added to tubes containing plasma samples, standards, and quality
controls. Antiserum to rat insulin, was then added. Tubes were incubated
overnight at 4ºC during which time the 125I-labeled and unlabeled insulin
competed for antibody binding. This antibody-antigen complex was then
precipitated by the addition of a carrier and an antibody to the carrier. The bound
and free 125I-labeled insulin was separated by centrifugation for 20 min at 3,000 g.
Standards were used to construct a standard curve and the samples compared to
this curve and expressed as µU • ml -1.
Hindlimb Perfusion
Mice were anesthetized with an intraperitoneal injection of pentobarbital
sodium (6.5 mg • 100 g body weight-1) following a 6 h fast. The surgical
technique was similar to that described previously (Brozinick et al., 1996; Ivy et
al., 1983). All of the major vessels branching from the abdominal aorta and vena
cava except the common iliac artery and iliac vein were ligated and the great
vessels cannulated so that perfusate could flow into the iliac artery, through the
capillary bed of the hindlimbs and out of the abdominal section of the inferior
vena cava. Both hindlimbs were perfused during the equilibrium (10 min) and
tracing (20 min) periods. Anesthetized mice were kept warm by performing the
surgery on a heating pad. The tail was ligated with string and a midline incision
made through the skin and abdominal wall from the xiphoid process to the pubic
symphysis. The skin was retracted and the superficial epigastric arteries leading to
the skin ligated with suture. The inferior vena cava and descending aorta was
exposed by lifting the stomach, spleen, pancreas, and intestinal tract from the
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abdominal cavity, wrapping these organs in parafilm and placing them along side
the animal. The hypogastric arteries on the inside of the abdominal wall were
ligated. Next the testes were pulled up into the abdominal cavity. Suture was then
used to ligate the seminiferous vesicles, testes, and bladder collectively. For
female mice, suture was used to ligate the fallopian tubes, ovaries, and bladder.
These organs were then removed. The descending colon was excised after ligation
just inferior to the transverse colon and just superior to the rectum. Adipose tissue
and fascia remaining in the abdominal cavity anterior to the aorta and vena cava
was removed by gently spreading with gauze dampened in Krebs-Henseleit buffer
(KHB). The iliolumbar arteries and veins and pubic-epigastric trunk were also
ligated.
Once ligation of the major vessels is completed, loose ligatures were
placed around the aorta and vena cava just inferior to the renal vessels and the
vena cava just superior to the iliac bifurcation. Another loose ligature was placed
around the left iliac artery and vein. Next, heparin (100 U) was injected into the
inferior vena cava just inferior to the diaphragm.
Following the heparin injection, the descending aorta and inferior vena
cava were cannulated. First, the ligature around the descending aorta located
proximal to the cannula insertion and just inferior to the renal bifurcation was
ligated. The aorta was cannulated and the catheter inserted until the tip was just
superior to the bifuracation of the iliac arteries. The ligature around the inferior
vena cava at the level of the renal vessels was tied and KHB slowly infused,
causing the vessel to distend. The vena cava was then cannulated and the venous
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catheter inserted past the loose distal ligature and superior to the ligated
iliolumbar vessels and secured into place. The hindlimbs were then flushed by
slow infusion of 8 ml KHB through the arterial catheter to remove most of the
mouse’s blood and prevent clotting. During the infusion of KHB, the mouse was
euthanized with an intracardiac injection of pentobarbital sodium. After the
infusion, the catheters were placed in line with the hindlimb perfusion apparatus.
Hindlimb Perfusion Apparatus
The perfusion apparatus consisted of an arterial reservoir, pump, lung,
water jacket, bubble trap and effluent reservoir. A peristalic pump pulled
perfusate out of the arterial reservoir consisting of a beaker set upon a magnetic
stir plate. The perfusate was pumped first through a “lung” consisting of 3 meters
of gas permeable Silastic tubing (Dow Corning, Midland, MI) contained within a
chamber receiving a flow of 95% O2 and 5% CO2 mixed gas. The perfusate then
passed through a water jacket heated to 37ºC, a bubble trap, and into the aorta of
the mouse. Finally, the venous effluent drips into the effluent reservoir. The flow
rate of the peristalic pump throughout the perfusion period was 1.8 ml • min-1. A
manometer connected to the tubing just prior to the bubble trap measured arterial
pressure.
Perfusate Preparation
All perfusates consisted of 6% bovine serum albumin (BSA) in KHB.
Initially, a 20% BSA solution was made in KHB. This solution was dialyzed for
48 hours against 15 L KHB and filtered through a glass fiber filter (# 61631,
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Gelman) and then a 0.45 µm filter (GN-6, Gelman). The BSA solution was then
diluted to 8-10% with KHB as measured by a refractometer. The appropriate
volume of this solution was added to the perfusate to bring the BSA concentration
to 6%. The pH of the perfusion was adjusted to 7.5 with 10 N NaOH. During the
perfusion the pH of the perfusate falls to 7.4 due to the dissolving of CO2
introduced from the gassing apparatus explained above. This perfusate was
separated into two aliquots for the equilibrium and tracer periods, respectively.
During the equilibrium period, the perfusate also contained 0.2 mM pyruvate as a
cellular energy source. During the tracer period, the perfusate contained 6 mM
[1,2-3H] 2-deoxyglucose (7.5 µCi • mmol -1), 2 mM [U-14C] mannitol (60 µCi •
mmol-1) and the appropriate insulin (Humulin R-100, Eli Lilly, Indianapolis, IN)
concentration. The perfusion insulin concentrations, 0.2 mU • ml-1 or 10 mU • ml-
1
, represent submaximal and maximally effective hormone concentrations,
respectively.
Muscle Contraction Procedure
Following a 6 h fast, mice were anesthetized with pentobarbitol sodium
(6.5 mg • 100 g body weight-1). The skin from the right hindlimb was reflected
and a section of the calcaneous, with the Achilles tendon still attached, clipped
from the foot. The triceps surae muscle group was retracted from the tibia and the
distal tendon (detached from the bony insertion) of the muscle group was attached
to an isometric force transducer. The sciatic nerve was isolated and placed in-line,
via hook electrode, with a Grass Stimulator (Grass Instruments, Quincy, MA).
Both the right hindlimb and the mouse torso were immobilized in a specially
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designed cradle and the muscles of the triceps surae group adjusted to achieve
maximum twitch tension. Peak twitch (Pt) and peak tetanic (Po) tensions were
assessed (Series 300 B Lever System, Aurora Scientific Incorporated, Ontario,
Canada) with supramaximal stimulation strength at the optimal length for the
muscle contracting at 90º to the knee joint.
The goal of this stimulation procedure was to reduce muscle glycogen
prior to the assessment of 2-deoxyglucose uptake. Therefore, a modified version
of the protocol described by Johannsson et al. (1996a & 1996b) and Roy et al.
(1997) was employed. This protocol was chosen because: 1) it is a 30 min
protocol, allowing time for stimulation prep, stimulation, and perfusion prep
while the animal remains sedated but alive; 2) produces 90-100 µmol/g reduction
in gastrocnemius glycogen (Roy et al., 1997); 3) is designed to be performed in
conjunction with a hindlimb perfusion; 4) has demonstrated isometric force
decreases of 65% of initial force after 2 min and 50% of initial force after 10 min
(Johannsson et al., 1996a); 5) because the protocol's surgery prep is very similar
to one recently performed (Lee, S. and R. Farrar, personal communication); and
6) isometric force can be assessed over the entire 30 min protocol and provide an
index of fatigue. The sciatic nerve was stimulated via hook electrode. Peak torque
was assessed with supramaximal stimulation strength at the optimal length for the
muscle. The muscle was stimulated for 30 min using supramaximal (8 V) trains
composed of 1 ms square-wave pulses firing at 100 Hz. Trains of 200 ms were
delivered at a rate of 30 per min (1 per 2 sec). Tension was assessed throughout
the stimulation period and fatigue following 30 min stimulation period expressed
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as percent of Po. Gastrocnemius muscle cross sectional area was estimated by
dividing wet weight by the measured optimal muscle length (cm) multiplied by
the fiber to muscle length ratio for rodent gastrocnemius (0.4) multiplied by
mammalian muscle specific gravity (1.06 g/cm3). Specific force (N/cm2) was then
estimated by dividing muscle tetanic tension (N) by the estimated cross-sectional
area (cm2) (Brooks and Faulkner, 1988). Following the stimulation period, the
mice were prepared for the hindlimb perfusion procedure for measurement of
insulin-stimulated [ 3H] 2-deoxyglucose uptake or determination of [14C] glucose
incorporation into glycogen using a submaximal insulin concentration (0.2 mU •
ml-1). Following the perfusion, stimulated and non-stimulated gastrocnemius
muscles were surgically removed, blotted dry and freeze clamped with
Wollenberg tongs cooled in liquid nitrogen. Tissue was stored at -80ºC until
subsequent analysis.
Measurement of Glucose Uptake
Relative changes in glucose uptake were estimated by determining the rate
of incorporation of [3H] 2-deoxyglucose tracer into muscle tissue. 2-
Deoxyglucose is a non-metabolized glucose analog that has similar rates of
removal from blood into muscle tissue as glucose under a physiologic range of
insulin concentrations. The amount of tracer contained within the extracellular
space was determined by the amount of [14C] mannitol retained in the tissue.
Mannitol is a sugar that is not transported by glucose transporters and therefore
occupies only the extracelluar space.
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2-Deoxyglucose Uptake Assay Procedure
Freeze-clamped mixed (red and white portions) gastrocnemius muscles
from the perfused hindlimbs were sectioned and weighed frozen. A 60-100 mg
piece of muscle was dissolved in 1 ml 1 N KOH by incubating for 15 min at 65ºC,
mixed, and incubated an additional 5 min at 65ºC. An equal volume of 1 N HCl
was added to the digested samples, mixed, and aliquots of the neutralized samples
counted for [3H] and [14C] DPM (Beckman LS 6000SC). Muscle 2-deoxyglucose
uptake was calculated from the specific activity of the original perfusate after
subtracting out the appropriate volume for extracellular space as determined from
radiolabelled mannitol in the muscle sample. The mixed gastrocnemius was used
because it exhibits a high transgene expression but contains similar GLUT4
content in control and GSL3 transgenic animals (Manchester et al., 1996).
[14C]-Glucose Incorporation into Glycogen
[14C]-Glucose incorporation into glycogen was assessed as previously
described (Willems et al., 1991). The perfusion surgery and preparation was
essentially the same as described for 2-deoxyglucose uptake until the final
perfusion period. Briefly, the hindlimbs were perfused with 6 mM glucose (0.15
µCi • ml-1 D-[14C(U)]glucose) with a submaximal insulin concentration (0.2 mU •
ml-1). The [14C]glucose was added to determine the rates of glucose incorporation
into glycogen. Following the perfusion and dissection (described above)
gastrocnemius muscles were weighed frozen, placed in screw-top test tubes
containing 1 ml of 30% KOH saturated with Na2SO4, and digested by incubating
the tubes for 30 min at 100ºC. After the incubation, the tubes were cooled to room
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temperature and the glycogen precipitated overnight at 4ºC after the addition of
1:2 volumes of 95% ethanol. The glycogen was pelleted by centrifugation and
resuspended in distilled H2O. An aliquot of this resuspension was transferred to a
scintillation vial containing 5 ml of scintillation fluid, and radioactivity
determined (Beckman LS 6000SC).
Measurement of Muscle Glycogen
Muscle glycogen concentration was determined by complete enzymatic
degradation with amyloglucosidase (Boehringer Mannheim, Indianapolis, IN) by
a modified method of Passonneau and Lauderdale (1974). A 100 µl aliquot of
neutralized homogenate used for glucose uptake measurements was added to 250
µl of 0.3 M sodium acetate, pH 4.8 and vortexed. Then 250 µl of 0.3 M sodium
acetate, pH 4.8, containing 10 mg • ml-1 amyloglucosidase was added and
vortexed. Following an overnight incubation, 25 µl of 1 N NaOH was added and
vortexed. Duplicate 150 µl aliquots were placed in test tubes and subjected to the
Trinder reaction (Sigma). Tubes containing 0, 50, 100, and 200 mg% glucose and
0.3 M sodium acetate were used as standards. One milliliter of Trinder reagent
was added to each tube, mixed gently and incubated for 18 min at room
temperature and then read on a Beckman DU 6 spectrophotometer at an
absorbance of 505 nm. A linear interpolation against the standard was used to
determine the concentration of glucose units in the original sample. The muscle
glycogen concentration was expressed as µmole glucose • g muscle -1.
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Measurement of Glycogen Synthase Activity
Glycogen synthase was measured by direct incorporation of labeled
substrate ([U-14C] UDP-1-glucose) into glycogen with several concentrations of
G-6-P (0.01, 0.5, 1.5, and 25 mM) as previously described (Sherman et al., 1988).
A 30 to 70 mg piece of muscle was weighed frozen and homogenized at –20ºC in
4 volumes of a buffer containing 25 mM KF, 20 mM EDTA and 60% glycerol
and then diluted with 25 mM KF, 20 mM EDTA and centrifuged at 8,000 g for 15
min at 4ºC. The supernatant was transferred to a test tube and further diluted 2-
fold with buffer containing 100 mM MOPS and 20 mM EDTA (pH 6.9) while
kept on ice. Reaction cocktail was thawed and 0.2 µCi of [U- 14C] UDP-1-glucose
• ml-1 added. The radioactive cocktail was divided into five aliqouts.  One aliquot
contained 150 mM G-6-P. Two 1:9, followed by one 1:1, serial dilutions were
performed from a 150 mM aliquot to yield G-6-P concentrations of 0.75, 1.5, 15
mM. The final assay G-6-P concentrations were 0.01, 0.5, 1.5, and 25 mM.
Relative activities were expressed as the I/(I + D) ratio, the G-6-P-independent
activity divided by the activity with maximal G-6-P concentration. In addition,
fractional velocity of submaximal (0.5 and 1.5 mM G-6-P) to that of maximal (25
mM) G-6-P were measured.
Insulin Signaling Proteins
Muscles were homogenized in ice-cold buffer containing 50 mM HEPES
(pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1.0
mM EDTA, 10 mM Na4P2O7, 10 mM NaF, 2.0 mM Na3VO4, aprotinin (10 µg •
ml-1), leupeptin (10 µg • ml-1), pepstatin (0.5 µg • ml-1), 1% Igepal and 2 mM
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phenylmethylsulfonyl fluoride. Homogentates were incubated with end-over-end
rotation at 4ºC for 60 min and then centrifuged at 200,000 g for 50 min at 4ºC.
IRS-1-associtated PI3-kinase was immunoprecipitated using a 2 µg • µl-1
protein sample as previously described (Christ et al., 2001) using an anti-IRS-1
antibody (2 µg, Upstate #06-248) for 2 h at 4ºC, followed by protein A-Sepharose
(4ºC, overnight; Sigma, St. Louis, MO). The immunoprecipitates were
successively washed and PI3-kinase activities measured immediately on
immunoprecipitates by in vitro phosphorylation of phosphatidylinositol.
Sonicated phosphatidylinositol was added to each sample and the PI3-kinase
reaction started by addition of 10 µl of 50 mM MgCl2250 µM [γ-32P] ATP (0.5
µCi • ml -1, Amersham) in a buffer consisting of 20 mM HEPES (pH 7.4), 0.4 mM
EGTA, and 0.4 mM Na2PO4 and stopped by addition of 6  M HCl. Lipids were
extracted by chloroform-methanol (1:1) and applied to a silica gel TLC plate
(Silica gel 60, Whatman, Hillsboro, OR). The plates were developed (60 min) in
running solvent (CHCl3:MeOH:H2O:NH4OH, 60:47:11.3:2). Radioactivity of
TLC spots for standards and samples was quantified via scintillation counting for
32P (Beckman LS 6000SC).
Three isoforms of PKB/Akt have been identified. The primary insulin-
stimulated isoform in rodent muscle is PKB/Akt 1 (Walker et al., 1998). We have
assessed phosphorylated PKB/Akt as an index for insulin-stimulated activation.
For quantification of phosphorylated PKB/Akt, aliquots of a 200,000 g
supernatant were treated with 2x Laemmli sample buffer containing 100 mM
dithiothreitol and boiled for 5 min. Samples and insulin-stimulated mouse
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gastrocnemius standards (80 µg protein) were subjected to SDS-PAGE (10%
resolving gel) and transferred to nitrocellulose membranes. The membranes were
blocked in 5% nonfat dry milk in TBS containing 0.1% Tween 10 (pH 7.5)
overnight. PKB/Akt is activated by phosphorylation of Thr308 in the core
activation loop and Ser473 in the carboxy terminus of the enzyme (Alessi et al.,
1996). Therefore, the membranes were rinsed in 0.1% Tween 10 and incubated
with sheep antiphospho-PKB/Akt (Ser473) antibody (Upstate Biotechnology Inc.)
for 4 h. The membranes were rinsed in 0.1% Tween 10 and incubated with
horseradish peroxidase-conjugated rabbit anti-sheep IgG (Jackson
ImmunoResearch) for 60 min. Antibody-bound protein was visualized by ECL
(Amersham). The intensity of the bands corresponding to Ser473-phosphorylated
PKB/Akt was assessed using a computer scanner and Adobe Photoshop 9.0
software and expressed as a percentage of insulin-stimulated mouse
gastrocnemius standard.
Total PKB/Akt protein content was assessed on nitrocellulose membranes
used for phosphorylated PKB/Akt. Membranes were stripped of antibodies by
incubation with stripping buffer containing 100 mM 2-mercaptoethanol, 2%
sodium dodecyl sulfate, 62.5 mM Tris HCl (pH 6.7) for 30 min. Membranes were
then washed three times for 15 min in TTBS buffer. Membranes were blocked as
described above overnight washed three more times for 15 min in TTBS and
incubated with sheep anti-Akt/PKBα (1:1000 vol/vol) (Upstate for 4 h with gentle
agitation. Following three more TTBS washes, antibody-bound protein was
visualized using ECL (Amersham) and total PKB/Akt was expressed relative to
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the insulin-stimulated mouse standard. The intensity of the bands corresponding
to total PKB/Akt was assessed using a computer scanner and Adobe Photoshop
9.0 software and expressed as a percentage of insulin-stimulated mouse
gastrocnemius standard.
Western Blotting Analysis for GLUT4 Protein
Muscle homogenates (1:20) in HES buffer were denatured 1:1 in 2x
Laemmli buffer (125 mM Tris, 20% glycerol, 2% SDS, 0.008% bromopherol
blue, pH 6.8). Muscle sample protein content was determined as described by
Bradford (1976). A 75 µg protein aliquot of each sample or the standard was
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on a 12.5% polyacrylamide resolving gel for 55 min at 10 mA (for two
units). A mouse heart homogenate (16 µl) was run on each gel as a standard. A
Miniprotean II dual slab cell (BioRad, Richmond, CA) was used to perform the
electrophoresis. Samples were transferred from the resolving gels onto
polyvinylidene diflouride (PVDF) sheets (BioRad, Richmond, CA). The transfer
procedure was performed for 12 min at 30 mM. The PVDF sheets were stored in
water overnight at 4ºC. The transferred PVDF membranes was blocked for 1 h by
incubation in 5% nonfat dry milk (Carnation, Los Angeles, CA) in TTBS (0.06%
Tween-20, 20 mM Tris, 500 mM NaCl, pH 7.5) at room temperature. Following a
rinse using TTBS, the membranes were incubated in GLUT4 rabbit anti-rat
antibody (diluted 1:500; donated by Dr. Samuel Cushman, NIH, Bethesda, MD).
After two additional 5 min rinses in TTBS, the membranes were incubated with
horseradish peroxidase (HRP)-conjugated donkey anti-rabbit antibody
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(Amersham, Arlington Heights, IL) diluted 1:5000 for one hour. The membranes
were then washed in sacosyl buffer (50 mM Tris Base, 1 M NaCl, O.4% w/v N-
laurylsarcosine, 5 mM EDTA, pH 7.5) three times to decrease non-specific
binding. After the blotting procedure, the membranes were placed in a small
container with 6 ml of mixed detection reagent (equal volume of no. 1 and 2 from
Amersham, Arlington Heights, IL) for 1 min. The membranes were removed and
sealed in plastic wrap for protection. Sealed membranes were placed into x-ray
film cassettes that contain an intensifying screen (Quanta III, Dupont Cronex,
Wilmington, DE). Hyperfilm (Amersham) was loaded onto the cassette and
exposed for 90 sec. GLUT4 bands was visualized by using a computer scanner
and Adobe Photoshop 9.0 software and expressed as a percentage of heart
standard.
Measurement of Hexokinase Activity
Frozen muscle was homogenized (1:20) in HES buffer containing 20 mM
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer, 1 mM EDTA, and
250 mM sucrose (pH 7.4). For hexokinase determination, muscle homogenates
were centrifuged in a benchtop centrifuge at 3,000 g for 15 min. Hexokinase
activity was measured on the supernatant using the spectrophotometric
determination of glucose-6-phosphate as described by Uyeda and Racker (1965).
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CHAPTER VII: SUMMARY OF FINDINGS AND FUTURE
DIRECTIONS
Summary of Findings
By utilizing the GSL3 transgenic mouse, which overexpresses glycogen
synthase, we have investigated the effects of glycogen synthase on post-exercise
muscle glucose metabolism independent of muscle glycogen concentration. In
Study 1, we determined the effects of exercise on whole body glucose tolerance
and insulin-stimulated skeletal muscle glucose uptake and insulin signaling both
pre- and post-exercise independent of muscle glycogen concentration. Study 2
investigated the effects of elevated glycogen synthase activity on insulin-
stimulated muscle glucose uptake and glycogen synthesis immediately following
a lowering of initial glycogen levels by in situ electrical stimulation of muscle. It
was hypothesized that transgenic muscle would exhibit a greater post-exercise
insulin-stimulated muscle glucose uptake independent of muscle glycogen level.
In other words, because of the increased activity of glycogen synthase in the
muscle of these mice, enhanced post-exercise insulin action will be maintained
regardless of glycogen concentration.
In Study 1, we provided evidence that muscle glycogen concentration, per
se, does not affect post-exercise insulin action in vivo or in muscle using an in situ
preparation. Following exercise, GSL3 transgenic muscle exhibits greater insulin
action and insulin-stimulated muscle glucose uptake independent of muscle
glycogen content relative to wildtype muscle. The increase in insulin-stimulated
136
muscle glucose uptake following exercise in GSL3 transgenic muscle could not
be accounted for by increases in GLUT4 protein concentration or hexokinase
activity. Glycogen concentration appears to be inversely-related to post-exercise
muscle insulin signaling and insulin-stimulated glucose uptake in wildtype muscle
when elevated above normal. However, our insulin signaling results support the
possibility that the normal mechanisms responsible for the inverse relationship
between muscle glycogen concentration and glucose uptake may be absent in
GSL3 transgenic muscle.
Study 2 demonstrated that increased glycogen synthase activity prevents
glycogen from compromising post-contraction insulin-stimulated muscle glucose
uptake and glucose incorporation into glycogen. Electrical stimulation of muscle
in situ via the sciatic nerve reduced muscle glycogen concentration by 49% in
wildtype and 27% in GSL3 transgenic. However, GSL3 transgenic muscle
retained a 9.6-fold greater muscle glycogen concentration than wildtype. While
GSL3 transgenic and wildtype muscle demonstrated similar post-contraction
increases in insulin-stimulated glucose uptake, insulin-stimulated incorporation of
[14C] glucose into glycogen was approximately 150% greater in non-stimulated
and electrically stimulated transgenic versus the respective wildtype treatments.
Insulin-stimulated glycogen synthase responsiveness and G-6-P sensitivity, as
well as PKB/Akt Ser473 phosphorylation were greater in transgenic as compared to
wildtype post-contraction. Contractions increased insulin-stimulated PKB/Akt
phosphorylation in wildtype but not in transgenic muscle.
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In summary, glycogen concentration appears to influence post-exercise
muscle insulin signaling and insulin-stimulated glucose uptake in wildtype muscle
when elevated above normal. However, our insulin signaling results support the
possibility that the normal mechanisms responsible for the inverse relationship
between muscle glycogen concentration and glucose uptake is absent in GSL3
transgenic muscle. This may represent a putative, yet unknown, association
between the activation states of glycogen synthase and PKB/Akt, both of which
are normally inhibited when muscle glycogen has been elevated above normal. In
addition, overexpression of glycogen synthase may facilitate a repartitioning of
intracellular glucose intermediates towards glycogen synthesis as opposed to the
glycolytic, hexosamine, and oxidative pathways. Using the GSL3 transgenic
mouse model, we have provided evidence that muscle glycogen concentration,
per se, does not affect post-exercise insulin action in vivo or in muscle using an in
situ preparation.
Future Directions
Little is known about the molecular mechanisms that convert skeletal
muscle contractile activity into biochemical and gene regulatory responses. The
convergence and integration of multiple signals in response to contractile activity
play an important role in controlling metabolism. PKB/Akt appears to play a
pivotal role in both insulin regulation of glucose transport and glycogen synthase
activity. However, a number of other important signaling proteins need to be
assessed using our experimental model. Two prominent signaling proteins, which
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we have implicated as possibly influencing our results, are GSK-3 and IRS-1.
Recent research suggests that insulin activates muscle glycogen synthase in part
by decreasing the activity of GSK-3 (Cross et al., 1997; Ueki et al., 1998). In
skeletal muscle, this GSK-3 inactivation may be mediated by insulin-stimulated
PKB/Akt activity (Cross et al., 1995). GSK-3, in turn, has been implicated in
feedback inhibition of IRS-1 facilitated PI3-kinase activity (Eldar-Finkelman and
Krebs, 1997; Summers et al., 1999). Therefore, by assessing the interaction of
these proteins, we could better determine where the major point of influence by
glycogen is in the insulin-mediated glucose uptake pathway.
Other important questions that need to be addressed concern the
metabolism of the GSL3 transgenic mouse during exercise. Although we did not
observe a difference in running mechanics or time to exhaustion during Study 1,
we do not know if the fuel usage during exercise is similar to that in the wildtype
mice. For instance, with the overexpression of a constitutively active glycogen
synthase, GSL3 transgenic muscle glycogen may simply be recycled into
glycogen as soon as it is hydrolyzed. In this scenario, the GSL3 transgenic mice
may not have been able to use muscle glycogen as a primary fuel source during
exercise. If this indeed proved to be the case, then blood glucose, free fatty acid
and intramuscular triglyceride usage should be measured. In addition, we did not
measure lactate in the muscle or lactic acid in the blood following the exercise
bout. If GSL3 transgenic mice were, in fact, able to utilize glycogen as a fuel
source we would expect lactate production to be greater than in wildtype mice.
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Transgenic overexpression provides a means to selectively alter the
activities of enzymes within a metabolic pathway. One must keep in mind that the
effects observed with long-term overexpression of glycogen synthase are not
necessarily representative of the acute activation of glycogen synthesis by insulin.
In addition, development of compensatory responses to the transgenic expression
must be considered. An example is the increase in phosphorylase observed in
GSL3 muscle by Manchester et al. (1996). Conversely, overexpression of
phosphorylase was accompanied by increased glycogen synthase in cultured
human skeletal muscle cells (Baquè, et al., 1996). Therefore, another future
direction would be to further investigate the role of glycogen concentration on
insulin action under physiological conditions were muscle glycogen has been
raised to above normal levels.
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APPENDIX A: SOLUTIONS
The following is an alphabetical listing of solutions used throughout the
studies presented. The final volume of the prepared solution follows the name of
each solution. Contents of the solutions are listed followed by instructions for
their preparation. Final concentration is the concentration of the listed reagent
after preparation of the solution. Amount needed is the mass or volume of reagent
used. FW or Stock Con. is the formula weight or stock concentration of the
reagent used to prepare the solution.
ACETIC ACID 0.3M (100 ML)
Final Concentration Amount Needed FW or Stock Con.
0.3 M 1.72 ml 17.4 M Stock
ATP 50MM (5ML)
Final Concentration Amount Needed FW or Stock Con.
50mM 0.1378 g FW 551.1
ATP was added to 5ml dH2O stirring on a magnetic and pH to 7.0
32P-ATP SOLUTION (150µL)
Final Concentration Amount Needed
10mM ATP 3µl
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4XHEPES buffer 37.5µl
0.4M MgCl2-6H20 25µl
32P-ATP 24µl
ß-GLYCEROPHOSPHATE 1.0M (45ML)
Final Concentration Amount Needed FW or Stock Con.
1.0M 9.72g FW 216.0
ß-glycerophosphate was added to 35ml dH2O stirring on a magnetic stir plate,
and then brought to volume with dH2O
CALCIUM CHLORIDE 0.5M (45ML)
Final Concentration Amount Needed FW or Stock Con.
0.5M 2.498g FW 110.0
Calcium chloride was added to 35ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O
COOSMASSIE BLUE SOLUTION (25ML)
Final Concentration Amount Needed FW or Stock Con.
0.1% brilliant blue 0.05g FW 826.0
40% methanol 10ml 99.8% methanol stock
10% acetic acid 5ml 99.7% acetic acid stock
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The following agents was added to 20ml dH2O stirring on a magnetic stir plate,
and then brought to volume with dH2O
CUPRIC SULFATE (25ML)
Final Concentration Amount Needed FW or Stock Con.
0.1%  cupric sulfate 0.25g FW 249.6
Cupric sulfate was added to 20ml dH2O stirring on a magnetic stir plate, and then
brought to volume with dH2O
EDTA  80MM (35 ML )
Final Concentration Amount Needed FW or Stock Con.
80mM 1.191g FW 372.2
EDTA was added to 30ml dH2O stirring on a magnetic plate, and then brought to
volume with dH2O and pH at 8.0
DITHIOTHREITOL 1.0M (DTT) (2ML)
Final Concentration Amount Needed FW or Stock Con.
1.0M 0.308g FW 154.25
Dithiothreitol was added to 2ml H2O.
GLUCOSE (250ML)
Final Concentration Amount Needed FW or Stock Con.
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1M 45.05g FW 180.2
D-Glucose was added to 200ml dH2O stirring on a magnetic plate, and then
brought to volume with dH2O
GLYCINE HYDRAZINE BUFFER PH 9.2 (1L)
Final Concentration Amount Needed FW or Stock Con.
0.33 M Glycine 25.02 ml FW 75.07
0.27 M Hydrazine 23.98 ml 54% hydrazine pH 9.2
Reagents were added in the order listed to 800 ml dH2O stirring on a magnetic
stir plate, titrated with 10N HCl and 10 N NaOH and then brought to volume with
dH2O.
GLYCOGEN SYNTHASE HOMOGENATE SUPERNATANT DILUTION
BUFFER (50 ML)
Final Concentration Amount Needed FW or Stock Con.
20 mM EDTA 0.293 g FW 292.2
100 mM MOPS 1.05 g FW 209.3
Reagents were added in order listed to 40 ml dH2O stirring on a magnetic stir
plate, titrated with 5 N NaOH and brought to volume with dH2O. pH 6.9.
GLYCOGEN SYNTHASE HOMOGENIZING BUFFER I (50 ML)
Final Concentration Amount Needed FW or Stock Con.
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50 mM KFl 0.1453 g FW 58.1
20 mM EDTA 0.292 g FW 292.2
60% glycerol 30 ml 99% Stock
Reagents were added in the order listed to 15 ml dH2O stirring on a magnetic stir
plate, titrated with 1 N NaOH and then brought to volume with dH2O. pH 7.0.
GLYCOGEN SYNTHASE HOMOGENIZING BUFFER II (50 ML)
Final Concentration Amount Needed FW or Stock Con.
50 mM KFl 0.1453 g FW 58.1
20 mM EDTA 0.292 g FW 292.2
Reagents were added in the order listed to 15 ml dH2O stirring on a magnetic stir
plate, titrated with 1 N NaOH and then brought to volume with dH2O. pH 7.0.
HEPES 1.0M (45ML)
Final Concentration Amount Needed FW or Stock Con.
1M HEPES 10.725 g FW 238.8
HEPES was added to 35ml dH2O stirring on a magnetic plate, and then brought
to volume with dH2O
4XHEPES PH 7.6 (100ML)
Final Concentration Amount Needed FW or Stock Con.
200mM HEPES 4.77g FW 238.8
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40uM EGTA 0.15g FW 372.2
3mM NaH2PO4 0.048g FW 142.0
HEPES was added to 70ml dH2O stirring on a magnetic plate, pH to 7.6 and then
brought to volume with dH2O
HOMOGENIZATION BUFFER PI3 KINASE (20ML)
Final Concentration Amount Needed FW or Stock Con.
50mM HEPES 1ml 1.0M HEPES (pH 7.6)
150mM NaCl 600µl 5.0N NaCl
20mM Na-pyrophosphate 4ml 100mMNapyrophosphate
20mMB-glycerophosphate 400µl 1.0M glycerophosphate
10mM Na F 400µl 0.5N NaF
2mMNa-OrthoVanadate 400µl 100mMNa-
OrthoVanadate
2mM EDTA 500µl 80mM EDTA
1%IGEPAL 2ml 10% IGEPAL
10% Glycerol 2ml 100% Glycerol
2mM
Phyenylmethylsufonyl
400µl 100mM
Phenylmethylsufonyl
fluoride
1mM MgCl2 50µl 0.4M MgCl2
1mM CaCl2 40µl 0.5M CaCl2
10ug/ml Aprotinin 200µl 1mg/ml
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10ug/ml Leupeptin 40µl 5mg/ml Leupeptin
Add solutions in order while stirring on a stir plate. Once all ingredients have
been added, bring to volume with dH2O
HYDROCHLORIC ACID 1N (1L)
Final Concentration Amount Needed FW or Stock Con.
1N HCL 86ml 11.6 N ACS Reagent
Concentrated hydrocholric acid was slowly added to 800ml dH2O stirring on a
magnetic stir plate and then brought to volume with dH2O.
HYDROCHLORIC ACID 5N (100ML)
Final Concentration Amount Needed FW or Stock Con.
5N HCL 34.5ml 11.6 N ACS Reagent
Concentrated hydrocholric acid was slowly added to 65.5ml dH2O stirring on a
magnetic stir plate and then brought to volume with dH2O
10% IGEPAL (100ML)
Final Concentration Amount Needed FW or Stock Con.
10% 10ml 100% IGEPAL stock
10ml IGEPAL was added to 90ml dH2O stirring on a magnetic stir
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KREBS-HENSELEIT BUFFER (3L)
Final Concentration Amount Needed FW or Stock Con.
1X Krebs-Henseleit 300ml 10X KHB Stock 1
1x Krebs-Henseleit 300ml 10X KHB Stock 2
Krebs-Henseleit Stock 1and 2 was added to 1L dH2O stirring on a magnetic stir
plate and the solution was gassed for 45 min with 95%O2, 5% CO2.  Then the
solution was brought to volume.
KREBS-HENSELEIT DIALYSIS BUFFER (15L)
Final Concentration Amount Needed FW or Stock Con.
116 mM NaCl 101.53 g FW 58.44
4.6 mM KCl 5.143 g FW 74.56
2.5 mM CaCl2•2H2O 5.512 g FW 147.0
1.16 mM KH2PO4 2.367 g FW 136.1
1.16 mM MgSO4•7H2O 4.289 g FW 246.48
Reagents were added in order listed to 12.5 L dH2O stirring on a magnetic stir
plate. Then 2.5 L of well-gassed NaHCO3 (sodium bicarbonate buffer) was
added.
KREBS-HENSELEIT STOCK 1 10X KHB (2L)
Final Concentration Amount Needed FW or Stock Con.
1.16M NaCl 135.58g FW 58.44
46mM KCl 6.858g FW 74.56
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253.0 mM NaHCO3 42.50g FW 84.01
11.6 mM KH2PO4 3.156g FW 136.1
Reagents were added in the order listed to 1600ml dH2O stirring on a magnetic
plate, and then brought to volume with dH2O
KREBS-HENSLEIT BUFFER STOCK 2 10 X KHB (2L)
Final Concentration Amount Needed FW or Stock Con.
25Mm CaCl2. 2H2O 7.350g FW 147.0
11.6mM MgSO4.7H2O 5.718g FW 246.48
Reagents were added in the order listed to 1600ml dH2O stirring on a magnetic
stir plate and the brought to volume with dH20.
LITHIUM CHLORIDE 2.0M (50ML)
Final Concentration Amount Needed FW or Stock Con.
2.0M 4.239g FW 42.39
Lithium chloride was added to 35ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O
MAGNESIUM CHLORIDE 0.4M (45ML)
Final Concentration Amount Needed FW or Stock Con.
0.4M 3.659g FW 202.3
149
Magnesium chloride was added to 35ml dH2O stirring on a magnetic stir plate,
and then brought to volume with dH2O
MANNITOL (250ML)
Final Concentration Amount Needed FW or Stock Con.
500mM 22.78g FW 182.2
Mannitol was added to 200ml dH2O stirring on a magnetic stir plate, and the
brought to volume with dH2O.
PBS (500ML)
Final Concentration Amount Needed FW or Stock Con.
136mM NaCL 4g FW 58.44
2mM KCl 0.1g FW 74.5
1mM KH2PO4 0.12g FW 136.0
9mM Na2HPO4 7g FW 142
Reagents were added to 400ml dH2O stirring on a magnetic stir plate, and the
brought to volume with dH2O, then pH at 7.4.
PERCHLORIC ACID 6% (100ML)
Final Concentration Amount Needed FW or Stock Con.
6% PCA 8.57ml 70% PCA reagent
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Concentrated perchloric acid was slowly added to 80ml dH2O stirring on a
magnetic stir plate, then brought to volume with dH2O.
PHENOLMETHYLSULFONYLFLUORIDE 100MM (40ML)
Final Concentration Amount Needed FW or Stock Con.
100mM 0.6968 g FW 174.19
Phenolmethylsulfonylfluoride was added to 30ml 100% ethanol stirring on a
magnetic stir plate, and then brought to volume with ethanol.
POTASSIUM BICARBONATE 30% (100ML)
Final Concentration Amount Needed FW or Stock Con.
30% KHCO3 30g FW 100.1
Potassium bicarbonate as added to 70ml dH2O stirring on a magnetic stir plate,
gently heated and then brought to volume with dH2O. This is saturated solution at
room temperature.
POTASSIUM HYDROXIDE 1N (1L)
Final Concentration Amount Needed FW or Stock Con.
1N KOH 56.1g FW 56.11
Potassium hydroxide pellets were added to 800ml dH2O stirring on a magnetic
stir plate, and then brought to volume with dH2O.
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PTA (500ML)
Final Concentration Amount Needed FW or Stock Con.
Tween 20 0.1g Stock
SDS 0.2g FW 288.4
NaN3 0.04g FW 65.0
Reagents were added to 400ml dH2O stirring on a magnetic stir plate, and the
brought to volume with dH2O, then pH at 7.4 and filtered sterilized.
PYRUVATE (250ML)
Final Concentration Amount Needed FW or Stock Con.
750mM Na-pyruvate 20.63g FW 110
Sodium pyruvate was added to 200ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O.
SODIUM ACETATE (1L)
Final Concentration Amount Needed FW or Stock Con.
0.3M Sodium Acetate 40.83g FW 136.1
Sodium acetate was added to 800 ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O
SODIUM ACETEATE 0.3M PH 4.8 BUFFER
Final Concentration Amount Needed FW or Stock Con.
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0.3 sodium Acetate 50ml 0.3M Na Acetate Stock
0.3M Acetic Acid 100ml 0.3M Acetic Acid Stock
Acetic acid was added to sodium acetate stirring on a magnetic stir plate until pH
was reduced to 4.8.
SODIUM BICARBONATE BUFFER (2.5 L)
Final Concentration Amount Needed FW or Stock Con.
151.7 M NaHCO3 31.87 g FW 84.01
Sodium bicarbonate was added to 2 L dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O. It was then gassed for 45 min with 95%
O2/5% CO2.
SODIUM CARBONATE (1L)
Final Concentration Amount Needed FW or Stock Con.
Sodium carbonate 20g F.W 106
0.1 N NaOH 10ml 10N NaOH Stock
Sodium carbonate and 10 ml 10 N NaOH was added to 900 ml dH2O stirring on a
magnetic stir of plate, and then brought to volume with dH2O.
SODIUM CHLORIDE 5.0N (40ML)
Final Concentration Amount Needed FW or Stock Con.
5.0N 11.688g FW 56.44
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Sodium chloride was added to 35ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O.
SODIUM FLOURIDE 0.5M (45ML)
Final Concentration Amount Needed FW or Stock Con.
0.5M 0.9448g FW 41.99
Sodium chloride was added to 35ml dH2O stirring on a magnetic stir plate, and
then brought to volume with dH2O
SODIUM POTASSIUM TARTRATE (25ML)
Final Concentration Amount Needed FW or Stock Con.
2% Na potassium tartrate 0.5g FW 282.23
Sodium potassium tartrate was added to 20ml dH2O stirring on a magnetic stir
plate, and then brought to volume with dH2O
SODIUM PYROPHOSPHATE 100MM (45ML)
Final Concentration Amount Needed FW or Stock Con.
100mM 2.0075g FW 446.1
Sodium pyrophosphate was added to 35ml dH2O stirring on a magnetic stir plate,
and then brought to volume with dH2O
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SODIUM ORTHOVANADATE 100MM (30ML)
Final Concentration Amount Needed FW or Stock Con.
100mM 0.5517g FW 183.9
Sodium orthovanadate was added to 20ml dH2O stirring on a magnetic stir plate,
and then brought to volume with dH2O
TLC ACTIVATION BUFFER (3L)
Final Concentration Amount Needed FW or Stock Con.
2mM EDTA 2.98g FW 372.2
90mM Potassium oxalate 52g FW 184.2
Reagents were added to 2.4L dH2O stirring on a magnetic stir plate, and brought
to volume with methanol.
TLC RUNNING BUFFER (1.1L)
Final Concentration Amount Needed FW or Stock Con.
50% CHCL3 600ml Stock 100% CHCl3
25% Methanol 470ml Stock 100% Methanol
6% NH4OH 20ml Stock 100% NH4OH
Reagents were added to beaker stirring on a magnetic stir plate, and the brought to
volume with dH2O
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TRIS HCL PH 7.5 1M BUFFER (45ML)
Final Concentration Amount Needed FW or Stock Con.
1M Tris pH 7.5 5.45 g FW 121.1
Tris HCl was added to 30ml dH2O stirring on a magnetic stir plate, titrated with
concentrated HCl and then brought to volume with dH2O.
TRIS HCL PH 7.5 100MM BUFFER (100ML)
Final Concentration Amount Needed FW or Stock Con.
100mM Tris 10ml 1M Tris pH 8.1 Stock
Concentrated Tris HCL buffer was added to 80ml dH2O stirring on a magnetic
stir plate, then brought to volume with dH2O
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APPENDIX B: STUDY 1 RAW DATA
Mouse treadmill run times expressed in minutes (*Indicates abbreviated run
times due to sore feet/claws).
Pre IPGTT Pre IPGTT  Pre Perfusion  Pre Perfusion
Group/mouse #1 #2 #1 #2
WTX 180 180 178 170
WTX 165 170 180 160*
WTX 180 180 180 180
WTX 180 180 180 180
WTX 180 180 180 180
WTX 180 150* 180 180
WTX 180 140* 180 180
WTX 180 180 180 160
WTX 180 180 180 180
WTX 180 180 180 170
WTX 180 180 180 180
WTX 180 180 180 180
Pre IPGTT Pre IPGTT  Pre Perfusion  Pre Perfusion
Group/mouse #1 #2 #1 #2
TGX 180 180 180 170
TGX 180 180 180 180
TGX 180 180 180 180
TGX 170 170 180 180
TGX 180 180 180 180
TGX 180 180 180 180
TGX 160* 140* 180 160*
TGX 180 180 160* 160*
TGX 180 180 180 180
TGX 180 180 180 180
TGX 180 170 180 180
TGX 170 180 180 180
TGX 180 180 180 170
Pre IPGTT  Pre Perfusion
Group/mouse #1 #1
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SUPER 180 180
SUPER 180 180
SUPER 180 180
SUPER 180 180
SUPER 180 180
SUPER 180 160
SUPER 180 180
SUPER 180 180
Mixed gastrocnemius muscle glycogen expressed in µmol • g wet weight-1.
WT TG WTX TGX SUPER
13.02 244.58 18.8 149.07 149.6
32.18 190.92 24.49 211.21 119.16
37.45 137.19 45.81 183.67 82.86
20.47 184.47 39.33 227.56 125.49
14.82 297.02 22.78 190.59 90.04
41.83 204.68 15.05 267.96 90.43
19.81 139.15 25.34 145.74 99.5
20.76 206.88 38.92 311.75 101.88
51.66 186.87 44.75 294.37 101.34
16.38 117.36 31.13 231.31 84.01
33.95 180.42 28.54 232.95 85.77
22.64 170.54 33.95 233.39 116.02
48.51 249.23 32.33 311.75
200.46 117.38
167.48
28.73 193.56 30.86 218.41 103.84 mean
3.621 12.739 2.658 15.623 5.842 SEM
Blood glucose response to an intraperitoneal injection of 10% glucose
solution (1 mg • g body weight-1). Values are expressed as mM.
group pre 30min 60min 120min 150min
WT 7.11 16.00 16.56 11.22 9.94
WT 6.94 10.56 10.67 9.11 7.72
WT 6.11 15.78 17.89 13.83 9.33
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WT 7.28 14.28 12.72 8.72 7.94
WT 7.83 15.33 15.22 12.56 10.72
WT 6.78 13.78 12.11 11.06 9.11
WT 7.94 13.83 16.33 15.44 10.94
WT 3.94 8.61 7.67 6.78 7.11
WT 7.11 12.11 11.33 9.89 9.11
WT 5.17 16.06 12.94 7.06 8.22
mean 6.62 13.63 13.34 10.57 9.02
SEM 0.39 0.79 0.99 0.89 0.40
group pre 30min 60min 120min 150min
TG 7.94 15.44 17.22 10.17 8.89
TG 7.78 18.83 19.83 17.22 12.83
TG 5.61 13.50 11.06 9.50 9.17
TG 6.78 16.56 15.50 14.11 11.72
TG 6.06 14.50 12.00 9.67 8.17
TG 7.06 13.67 13.39 9.72 9.89
TG 6.33 16.00 14.17 10.22 9.17
TG 6.11 20.50 18.00 12.17 10.28
TG 5.61 14.28 14.83 11.06 8.39
TG 6.83 18.50 19.67 15.61 15.56
TG 4.61 9.50 6.83 5.11 6.17
TG 6.67 16.28 14.83 12.78 11.22
mean 6.45 15.63 14.78 11.44 10.12
SEM 0.27 0.84 1.08 0.93 0.71
group pre 30min 60min 120min 150min
WTX 2.94 9.94 8.44 6.67 5.56
WTX 3.67 14.22 12.89 9.56 9.22
WTX 3.22 10.56 9.50 8.28 7.89
WTX 2.78 10.06 7.44 4.50 5.00
WTX 2.89 10.89 10.06 7.67 7.11
WTX 2.94 15.72 16.50 8.72 8.06
WTX 3.78 8.89 9.00 6.89 6.39
WTX 3.94 8.61 7.67 6.78 7.11
WTX 4.83 21.00 18.94 14.61 10.89
WTX 2.50 12.67 10.94 7.00 6.33
WTX 2.94 14.83 11.67 7.94 6.11
WTX 3.72 19.83 16.11 10.56 7.33
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mean 3.35 13.10 11.60 8.26 7.25
SEM 0.18 1.15 1.05 0.70 0.45
group pre 30min 60min 120min 150min
TGX 3.72 14.11 13.44 7.89 6.94
TGX 3.39 12.94 12.44 10.61 9.22
TGX 2.72 14.78 12.17 6.44 6.61
TGX 2.72 16.11 14.94 7.67 6.17
TGX 2.94 14.72 13.44 9.78 7.39
TGX 4.78 19.28 19.78 11.89 11.61
TGX 3.72 12.28 10.56 7.33 6.72
TGX 3.22 12.89 11.22 7.28 7.56
TGX 3.56 15.78 15.06 10.50 8.00
TGX 3.83 15.83 15.61 11.17 7.83
TGX 3.94 16.50 13.33 9.00 5.67
TGX 5.61 19.50 18.11 11.83 9.11
TGX 3.67 20.78 19.78 18.28 13.22
mean 3.68 15.81 14.61 9.97 8.16
SEM 0.22 0.74 0.84 0.86 0.60
group pre 30min 60min 120min 150min
SUPER 7.00 11.94 10.39 11.00 8.11
SUPER 6.94 13.67 13.11 12.61 8.28
SUPER 5.28 12.56 13.78 13.44 9.22
SUPER 6.00 11.72 14.11 12.22 10.89
SUPER 6.44 12.22 11.11 9.00 8.11
SUPER 5.83 10.78 10.33 9.28 8.28
SUPER 6.17 10.50 11.00 9.89 9.22
SUPER 5.67 13.72 13.17 11.22 10.89
mean 6.17 12.14 12.13 11.08 9.13
SEM 0.21 0.42 0.56 0.57 0.64
Plasma insulin response to intraperitoneal injection of 10% glucose solution
(1 mg • g body weight-1). Values are expressed as µU • ml-1.
group pre 30 min 60 min
WT 16.18 25.39 26.89
WT 8.43 35.23 20.68
WT 9.20 29.59 18.78
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WT 8.98 29.22 17.09
WT 30.00 45.90 33.63
WT 16.67 27.83 no sx.
WT 23.96 39.68 39.40
WT 14.32 29.34 19.45
WT 29.43 18.98 22.13
WT 18.96 no sx. 15.03
mean 17.61 31.24 23.68
SEM 2.535 2.658 2.709
group pre 30 min 60 min
TG 22.33 no sx. 21.74
TG 9.77 27.39 8.06
TG 18.22 19.30 15.96
TG 8.73 26.66 9.96
TG 26.78 46.81 48.94
TG 11.35 24.06 11.65
TG 13.94 53.62 32.72
TG 7.12 17.22 20.00
TG 18.38 26.12 31.27
TG 32.92 34.26 28.93
TG 7.14 15.73 10.36
TG 12.27 23.34 24.98
mean 15.74 28.59 22.05
SEM 2.370 3.607 3.488
group pre 30 min 60 min
WTX 3.83 3.95 5.46
WTX 4.38 4.73 8.94
WTX 3.01 0.70 5.52
WTX 2.60 0.44 4.27
WTX 0.70 0.70 2.13
WTX 0.70 0.70 0.83
WTX 1.18 9.00 3.98
WTX 0.70 12.65 6.72
WTX 9.39 13.24 10.69
WTX 2.10 2.92 0.78
WTX 0.17 4.00 1.24
WTX 0.69 7.95 0.70
mean 2.45 5.08 4.27
SEM 0.746 1.331 0.964
group pre 30 min 60 min
TGX 0.70 13.80 3.24
TGX 6.54 12.17 5.60
TGX 0.87 16.16 4.48
TGX 0.70 11.41 7.41
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TGX 1.09 12.09 4.81
TGX 3.57 7.44 4.73
TGX 0.94 16.24 5.95
TGX 0.70 21.07 7.84
TGX 11.75 10.36 2.76
TGX 0.22 4.49 7.20
TGX 0.47 4.49 4.87
TGX 2.53 6.65 6.42
TGX 0.70 20.80 0.70
mean 2.37 12.09 5.08
SEM 0.921 1.526 0.560
group pre 30 min 60 min
SUPER 0.90 3.78 1.80
SUPER 1.01 2.16 1.80
SUPER 2.16 2.16 2.16
SUPER 11.52 12.96 11.16
SUPER 1.44 1.80 2.16
SUPER 1.44 8.10 12.96
SUPER 7.34 10.08 15.12
SUPER 6.48 12.96 12.96
SUPER 7.78 10.01 12.96
SUPER 2.16 11.16 2.16
mean 4.22 7.52 7.52
SEM 1.184 1.452 1.860
Low (0.2 mU • ml-1) insulin 2-deoxyglucose uptake results expressed in µmol •
g wet weight-1 • h-1.
WT TG WTX TGX SUPER
7.94 4.34 11.31 12.73 4.33
6.99 4.85 9.52 7.86 2.79
7.24 5.46 4.69 8.03 5.37
6.87 4.12 7.77 6.34 2.82
7.53 2.85 7.04 8.41 4.66
7.56 5.3 7.49 8.25 4.43
6.12 8.2
10.05
8.65
7.36 4.72 7.97 8.72 4.07 mean
0.163 0.404 0.921 0.593 0.426 SEM
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High (10 mU • ml-1) insulin 2-deoxyglucose uptake results expressed in µmol •
g wet weight-1 • h-1.
WT TG WTX TGX SUPER
7.88 4.46 7.27 10.08 7.8
8.26 5.69 12.75 11.22 8.03
7.37 3.94 10.84 13.49 6.48
12.52 6.32 6.74 9.61 7.94
12.01 7.38 11.57 12.19 8.26
6.78 7.88 12.01 13.72 8.19
8.9 9.01 12.82
9.10 6.38 10.57 11.72 7.78 mean
0.856 0.695 0.958 0.701 0.269 SEM
Low (0.2 mU • ml-1) insulin glycogen synthase activity expressed in nmol • g
wet weight-1 • min-1.
WT
25mM 1.5mM 0.5mM .01mM
288.57 35.33 12.20 8.10
263.38 43.05 10.14 3.02
135.88 117.96 20.17 10.00
236.89 36.32 11.66 5.14
231.18 58.17 13.54 6.57 mean
33.473 20.005 2.252 1.548 SEM
TG
25mM 1.5mM 0.5mM .01mM
699.71 99.76 35.79 19.71
864.58 150.19 55.75 24.77
798.87 195.50 55.76 16.38
576.22 70.88 17.64 8.58
734.85 129.08 41.24 17.36 mean
62.800 27.544 9.165 3.397 SEM
WTX
25mM 1.5mM 0.5mM .01mM
236.91 62.46 20.59 10.94
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186.55 34.81 13.78 4.80
95.26 19.53 7.67 6.40
161.30 22.84 8.27 3.64
170.01 34.91 12.58 6.45 mean
29.457 9.752 3.004 1.602 SEM
TGX
25mM 1.5mM 0.5mM .01mM
219.21 28.17 10.89 10.20
707.29 173.25 38.15 14.66
630.77 119.83 38.88 8.48
795.55 107.12 26.92 7.02
661.07 125.78 36.17 9.75
698.67 131.50 35.03 9.98 mean
35.921 14.452 2.763 1.657 SEM
SUPER
25mM 1.5mM 0.5mM .01mM
142.41 55.42 42.76 22.47
49.75 9.44 9.91 7.97
50.94 11.34 6.75 2.12
33.61 2.92 2.63 0.98
239.67 41.67 12.71 3.42
103.276 24.158 14.95 7.39 mean
39.110 10.286 6.528 3.608 SEM
Low (0.2 mU • ml-1) insulin glycogen synthase activity (I/I+D) ratio and
fractional velocity (0.5 mM and 1.5 mM G-6-P expresssed as percent of
maximal activity at 25 mM G-6-P).
WT
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.028 4.23 12.24
0.011 3.85 16.35
0.074 14.84 86.81
0.022 4.92 15.33
0.03 6.96 32.68 mean
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0.014 2.637 18.064 SEM
TG
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.028 5.11 14.26
0.029 6.45 17.37
0.021 6.98 24.47
0.015 3.06 12.30
0.02 5.40 17.10 mean
0.003 0.873 2.670 SEM
WTX
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.046 8.69 26.36
0.026 7.39 18.66
0.067 8.05 20.50
0.023 5.13 14.16
0.04 7.31 19.92 mean
0.010 0.776 2.527 SEM
TGX
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.047 4.97 12.85
0.021 5.39 24.49
0.013 6.16 19.00
0.009 3.38 13.46
0.015 5.47 19.03
0.01 5.10 19.00 mean
0.002 0.599 2.252 SEM
SUPER
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.158 30.03 38.92
0.160 19.92 18.97
0.042 13.25 22.26
0.029 7.83 8.69
0.014 5.30 17.39
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0.06 11.57 16.83 mean
0.033 3.238 2.897 SEM
High (10 mU • ml-1) insulin glycogen synthase activity expressed in nmol • g
wet weight-1 • min-1.
WT
25mM 1.5mM 0.5mM .01mM
376.77 78.68 28.07 11.53
217.62 56.55 12.73 3.73
153.69 26.03 14.87 11.78
143.29 17.37 11.65 5.23
222.84 44.66 16.83 8.07 mean
53.876 14.114 3.806 2.094 SEM
TG
25mM 1.5mM 0.5mM .01mM
1020.63 154.91 44.26 6.81
1224.64 438.22 113.26 26.51
1960.47 622.93 177.73 60.96
2212.08 471.87 107.84 25.28
1604.46 421.98 110.77 29.89 mean
285.929 97.664 27.267 11.294 SEM
WTX
25mM 1.5mM 0.5mM .01mM
343.46 47.83 16.78 2.33
440.68 106.48 44.30 30.75
599.74 61.99 26.39 7.82
147.14 60.17 19.46 4.60
382.76 69.12 26.73 11.38 mean
94.647 12.845 6.196 6.556 SEM
TGX
25mM 1.5mM 0.5mM .01mM
1706.20 502.29 126.99 23.18
1378.59 504.70 144.27 28.23
1536.86 383.36 96.35 21.74
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1548.52 299.74 80.07 21.36
1545.81 311.2 80.55 17.03
1543.20 400.26 105.65 22.31 mean
51.837 44.519 12.880 1.802 SEM
SUPER
25mM 1.5mM 0.5mM .01mM
231.04 35.69 13.77 8.88
86.01 24.72 19.71 16.94
73.34 14.93 15.32 10.28
304.00 42.01 11.85 7.64
139.80 15.76 3.36 2.00
166.84 26.62 12.80 9.15 mean
44.126 5.373 2.693 2.402 SEM
High (10 mU • ml-1) insulin glycogen synthase activity (I/I+D) ratio and
fractional velocity (0.5 mM and 1.5 mM G-6-P expresssed as percent of
maximal activity at 25 mM G-6-P).
WT
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.031 7.45 20.88
0.017 5.85 25.99
0.077 9.68 16.94
0.036 8.13 12.12
0.04 7.78 18.98 mean
0.013 0.793 2.943 SEM
TG
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.007 4.34 15.18
0.022 9.25 35.78
0.031 9.07 31.77
0.011 4.88 21.33
0.02 6.88 26.02 mean
0.005 1.319 4.726 SEM
WTX
I/(I+D) fract. velo. fract. velo.
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ratio 0.5 1.5
0.007 4.89 13.93
0.070 10.05 24.16
0.013 4.40 10.34
0.031 13.23 40.89
0.03 8.14 22.33 mean
0.014 2.123 6.846 SEM
TGX
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.014 7.44 29.44
0.020 10.47 36.61
0.014 6.27 24.94
0.014 5.17 19.36
0.011 5.21 20.13
0.01 6.78 25.26 mean
0.002 1.255 3.980 SEM
SUPER
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.038 5.96 15.45
0.197 22.92 28.74
0.140 20.89 20.36
0.025 3.90 13.82
0.014 2.40 11.27
0.09 12.53 18.55 mean
0.045 5.438 3.899 SEM
Low (0.2 mU • ml-1) insulin IRS-1-associated PI3-kinase results expressed as
percent of insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX
1.38 2.66 2.82 4.98
0.69 1.56 0.97 1.78
1.52 1.39 1.84 1.35
0.59 1.57 0.94 2.15
0.73 1.52 2.03 2.06
1.20
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0.98 1.74 1.72 2.25 mean
0.194 0.232 0.353 0.567 SEM
High (10 mU • ml-1) insulin IRS-1-associated PI3-kinase results expressed as
percent of insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX SUPER
2.13 2.99 4.37 6.69 1.58
2.35 0.91 7.44 0.82 0.75
1.70 3.77 7.26 1.95 1.91
3.19 2.20 2.18 3.86 1.44
2.51 2.35 3.14 2.47 1.09
5.78 2.52
2.38 3.00 4.88 3.05 1.35 mean
0.245 0.677 1.068 0.831 0.200 SEM
Low (0.2 mU • ml-1) insulin total PKB/Akt results expressed as percent of
insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX SUPER
48.62 56.82 42.33 68.02 67.45
65.12 62.70 45.00 47.21 69.21
38.90 62.68 50.81 52.85 62.88
35.83 61.68 48.08 68.89 68.45
37.23 68.41 69.08 65.21 72.37
42.85 69.89 65.83 39.24 43.79
50.13 38.76 36.93
36.34 37.57
44.09
44.76 61.76 49.53 51.11 64.02 mean
4.487 2.543 4.255 4.400 4.237 SEM
High (10 mU • ml-1) insulin total PKB/Akt results expressed as percent of
insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX SUPER
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59.42 63.21 70.05 108.02 63.31
61.47 65.24 117.78 115.69 83.83
75.62 65.99 54.14 52.48 88.38
65.31 38.05 48.00 67.48 87.91
51.27 66.00 48.43 38.05 91.08
67.91 38.57 36.81
49.88 48.95 58.19
42.48 45.67
62.62 57.34 58.95 68.10 82.90 mean
3.979 4.241 8.993 12.04 5.032 SEM
Low (2 mU • ml-1) insulin phosphorylated PKB/Akt (Ser 473) results
expressed as percent of insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX SUPER
48.62 70.75 62.41 84.42 32.80
33.28 36.37 42.84 56.98 15.00
60.20 46.83 63.63 68.26 31.73
41.41 32.53 78.50 108.43 29.27
21.98 53.78 52.14 100.75 28.93
23.28 38.82 91.10 81.16 38.09
66.93 65.85 63.15
47.81 55.23
48.69
31.13 49.43 63.04 74.12 29.30 mean
6.090 5.680 5.661 6.966 3.163 SEM
High (10 mU • ml-1) insulin phosphorylated PKB/Akt (Ser 473) results
expressed as percent of insulin-stimulated mouse gastrocnemius standard.
WT TG WTX TGX SUPER
76.83 54.58 140.77 85.99 18.94
52.00 43.93 99.41 62.34 44.83
42.13 70.73 69.10 57.93 42.53
78.00 60.66 67.08 104.46 22.61
55.15 81.88 67.90 90.72 11.55
115.15 25.86 43.43
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87.54 79.17 58.68
25.57 78.92
60.82 67.51 78.53 71.94 28.09 mean
7.109 9.835 11.509 8.288 6.618 SEM
Total protein content in mixed gastrocnemius muscle expressed as mg
protein • g muscle wet weight-1.
WT 239.86 TG 232.27
WT 245.45 TG 180.45
WT 153.63 TG 274.34
WT 259.52 TG 193.05
WT 267.65 TG 276.08
WT 208.46 TG 150.87
WT 239.86 TG 240.71
WT 226.89 TG 253.05
WT 259.52 TG 206.08
WT 267.65 TG 180.87
WTX 240.03 TG 200.21
WTX 254.34 TG 203.66
WTX 227.81 TGX 285.88
WTX 163.93 TGX 175.53
WTX 180.65 TGX 189.60
WTX 101.62 TGX 244.18
WTX 199.85 TGX 196.68
WTX 202.55 TGX 185.16
WTX 293.88 TGX 220.23
WTX 178.44 TGX 189.11
WTX 187.22 TGX 201.02
WTX 233.95 TGX 187.74
WTX 190.36 TGX 230.60
SUPER 265.72 TGX 165.11
SUPER 184.49 TGX 224.36
SUPER 118.28 mean 210.63
SUPER 165.42 SEM 4.765
SUPER 194.28
SUPER 259.34
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SUPER 225.51
SUPER 209.63
SUPER 173.71
SUPER 175.01
SUPER 212.93
mean 210.10
SEM 2.111
GLUT4 protein content in mixed gastrocnemius muscle expressed as percent
of heart standard.
WT 36.06 TG 31.26
WT 85.23 TG 46.33
WT 54.57 TG 74.56
WT 40.06 TG 53.05
WT 47.04 TG 76.08
WT 54.26 TG 50.87
WT 69.93 TG 60.71
WT 70.91 TG 78.62
WT 72.85 TG 52.02
WT 49.70 TG 77.91
mean 58.06 TG 89.35
SEM 5.043 TG 78.66
mean 64.12
WTX 93.99 SEM 5.04
WTX 58.23
WTX 74.08 TGX 85.88
WTX 32.87 TGX 75.53
WTX 46.01 TGX 89.60
WTX 79.56 TGX 44.18
WTX 63.39 TGX 96.68
WTX 82.19 TGX 85.16
WTX 64.22 TGX 87.74
WTX 40.22 TGX 70.60
mean 63.48 TGX 65.11
SEM 6.203 TGX 54.36
mean 75.48
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SUPER 76.45 SEM 5.331
SUPER 86.44
SUPER 67.35 TG mean 69.28
SUPER 79.76 TG SEM 3.784
SUPER 81.9
SUPER 77.85
SUPER 83.56
mean 79.04
SEM 2.333
WT mean 65.51
WT SEM 3.364
Hexokinase activity in mixed gastrocnemius muscle expressed as µmol • g •
min-1.
WT 3.77 TG 4.47
WT 2.14 TG 3.21
WT 2.25 TG 3.55
WT 5.06 TG 2.86
WT 2.24 TG 4.49
WT 3.51 TG 3.06
WT 2.80 TG 3.20
WT 3.06 TG 3.35
WT 3.18 TG 3.85
mean 3.11 TG 3.74
SEM 0.310 TG 4.47
TG 3.76
WTX 2.95 TG 3.16
WTX 2.03 TG 3.83
WTX 2.23 TG 2.62
WTX 3.93 mean 3.57
WTX 3.18 SEM 0.151
WTX 1.36
WTX 2.91 TGX 3.15
WTX 2.90 TGX 3.59
WTX 2.64 TGX 4.22
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WTX 2.08 TGX 3.00
WTX 2.87 TGX 2.28
WTX 3.18 TGX 3.02
WTX 2.12 TGX 3.20
WTX 3.34 TGX 3.60
WTX 2.06 TGX 3.26
WTX 1.94 TGX 2.71
mean 2.61 TGX 1.96
SEM 0.166 TGX 3.13
TGX 3.60
SUPER 4.12 TGX 2.60
SUPER 4.45 TGX 4.27
SUPER 0.86 TGX 2.73
SUPER 3.68 mean 3.14
SUPER 1.61 SEM 0.157
SUPER 1.60
SUPER 3.74
SUPER 1.83
mean 2.53
SEM 0.195
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APPENDIX C: STUDY 2 RAW DATA
Study 2: Isolated, in situ whole gastrocnemius peak twitch tension (Pt
expressed in mN), wet weight (ww), muscle length (ml), and peak tetanic
tension (Po expressed in mN).
group Pt ww(mg) ml(mm)      Po
WT 1030 100 18 3580
WT 1185 130.4 18 3553
WT 1080 135.2 17 3444
WT 1043 100 18 3185
WT 1030 104 16 3061
WT 753 99.5 14 3003
TG 1148 121 15 2901
TG 987 90 16 2246
TG 1092 101 16 2462
TG 1228 155 19 3172
TG 1030 98.7 15 2475
TG 1123 141 20 3320
TG 1148 161 14 3395
Study 2: Isolated, in situ whole gastrocnemius tension assessed during
electrical stimulation over 30 min. Values are expressed as mN.
group 5min 10min 15min 20min 25min 30min avg
WT 1413 1388 1358 1358 1364 1283 1360.67
WT 1524 1530 1604 1617 1635 1581 1581.83
WT 1655 1623 1679 1629 1635 1623 1640.67
WT 1462 1506 1580 1598 1753 1666 1594.17
WT 1771 1543 1728 1841 1851 1691 1737.50
WT 1523 1675 1498 1576 1602 1534 1568.00
mean 1580.47
SEM 50.643
TG 1938 1925 1932 1876 1882 1851 1900.67
TG 1555 1617 1586 1592 1574 1567 1581.83
TG 1728 1629 1685 1612 1650 1650 1659.00
TG 1555 1475 1456 1401 1419 1432 1456.33
TG 1808 1790 1833 1833 1839 1827 1821.67
TG 1635 1771 1545 1450 1620 1580 1600.17
TG 2179 2358 2160 1777 1851 2000 2054.17
mean 1724.83
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SEM 78.857
Study 2: Isolated, in situ whole gastrocnemius tension assessed during
electrical stimulation over 30 min and expressed as a percentage of peak
tetanic tension.
group 5min 10min 15min 20min 25min 30min avg
WT 39.5 38.8 37.9 37.9 38.1 35.8 38.0
WT 42.9 43.1 45.1 45.5 46.0 44.5 44.5
WT 48.1 47.1 48.8 47.3 47.5 47.1 47.6
WT 45.9 47.3 49.6 50.2 55.0 52.3 50.1
WT 57.9 50.4 56.5 60.1 60.5 55.2 56.8
WT 50.72 55.78 49.88 52.48 53.35 51.08 52.21
mean 48.20
SEM 2.650
TG 66.8 66.4 66.6 64.7 64.9 63.8 65.5
TG 69.2 72.0 70.6 70.9 70.1 69.8 70.4
TG 70.2 66.2 68.4 65.5 67.0 67.0 67.4
TG 49.0 46.5 45.9 44.2 44.7 45.1 45.9
TG 73.1 72.3 74.1 74.1 74.3 73.8 73.6
TG 49.2 53.3 46.5 43.7 48.8 47.6 48.2
TG 64.2 69.5 63.6 52.3 54.5 58.9 60.5
mean 61.6
SEM 4.076
Study 2: In situ electrical stimulation data from isolated whole
gastrocnemius. Muscle peak tetanic tension (Po), optimal length (Lo), specific
gravity, fiber/muscle length ratio, estimated cross-sectional area (CSA), and
specific force are presented.
Sp. Gravity fiber/muscle Sp. Force
group Po(N) MLo(cm) MW(g) (g/cm3) length ratio CSA(cm2) (N/cm2)
WT 3.580 1.8 0.100 1.06 0.4 0.13103 27.32
WT 3.553 1.8 0.130 1.06 0.4 0.17086 20.79
WT 3.444 1.7 0.135 1.06 0.4 0.18757 18.36
WT 3.185 1.8 0.100 1.06 0.4 0.13103 24.31
WT 3.061 1.6 0.104 1.06 0.4 0.15330 19.97
WT 3.003 1.4 0.100 1.06 0.4 0.16762 17.92
3.30 1.68 0.11 1.06 0.40 0.16 21.44 mean
0.104 0.065 0.007 0.000 0.000 0.009 1.498 SEM
TG 2.901 1.4 0.121 1.06 0.4 0.2038 14.23
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TG 2.246 1.6 0.090 1.06 0.4 0.1327 16.93
TG 2.462 1.6 0.101 1.06 0.4 0.1489 16.54
TG 3.172 1.9 0.155 1.06 0.4 0.1924 16.49
TG 2.475 1.5 0.099 1.06 0.4 0.1552 15.95
TG 3.320 2.0 0.141 1.06 0.4 0.1663 19.97
TG 3.395 1.4 0.161 1.06 0.4 0.2712 12.52
2.85 1.63 0.12 1.06 0.40 0.18 16.09 mean
0.175 0.089 0.011 0.000 0.000 0.018 0.877 SEM
Study 2: In situ electrical stimulation data from isolated whole
gastrocnemius. Muscle peak tetanic tension (Po) and percent of Po
throughout 30 min stimulation period.
Percent of
Po
group Po(N) 5 min 10 min 15 min 20 min 25 min 30 min Avg.
WT 3.580 39.47 38.77 37.93 37.93 38.10 35.84 38.01
WT 3.553 42.89 43.06 45.14 45.51 46.02 44.50 44.52
WT 3.444 48.05 47.13 48.75 47.30 47.47 47.13 47.64
WT 3.185 45.90 47.28 49.61 50.17 55.04 52.31 50.05
WT 3.061 57.86 50.41 56.45 60.14 60.47 55.24 56.76
WT 3.003 50.72 55.78 49.88 52.48 53.35 51.08 52.21
3.30 47.48 47.07 47.96 48.92 50.07 47.68 48.20 mean
0.104 2.622 2.394 2.501 3.029 3.215 2.834 2.650 SEM
TG 2.901 66.80 66.36 66.60 64.67 64.87 63.81 65.52
TG 2.246 69.23 71.99 70.61 70.88 70.08 69.77 70.43
TG 2.462 70.19 66.17 68.44 65.48 67.02 67.02 67.38
TG 3.172 49.02 46.50 45.90 44.17 44.74 45.15 45.91
TG 2.475 73.05 72.32 74.06 74.06 74.30 73.82 73.60
TG 3.320 49.25 53.34 46.54 43.67 48.80 47.59 48.20
TG 3.395 64.18 69.46 63.62 52.34 54.52 58.91 60.51
2.85 63.10 63.73 62.25 59.32 60.62 60.87 61.65 mean
0.175 3.754 3.756 4.317 4.732 4.268 4.142 4.076 SEM
Study 2: 2-Deoxyglucose uptake from mixed gastrocnemius muscle during
hindlimb perfusion with 0.2 µU • ml-1 insulin. Values are expressed as µmol •
g-1 • h-1.
WT non-stim WT stim TG non-stim TG stim
2.84 7.13 2.44 8.60
2.02 7.27 3.41 7.89
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3.31 5.16 4.33 9.15
4.15 7.27 4.18 7.29
5.78 7.36 3.74 7.34
5.31 7.79 3.66 7.04
3.90 7.00 3.63 7.89 mean
0.594 0.379 0.275 0.340 SEM
Study 2 (Incorporation study): Mixed gastrocnemius muscle glycogen
content determined by a modified method of Lo et al. (1970) expressed as
µmol • g wet weight-1.
WT non-stim WT stim TG non-stim TG stim
32.12 17.61 282.57 222.05
25.65 6.08 233.36 213.04
32.33 25.18 193.64 120.27
37.66 23.63 239.16 138.09
34.73 29.84 212.64 150.69
29.20 12.18
23.01 9.38
47.51 18.53
47.37 16.64
34.40 17.67 232.18 168.83 mean
2.871 2.569 14.959 20.517 SEM
Study 2 (Incorporation study): [14C] Glucose incorporation in mixed
gastrocnemius muscle during hindlimb perfusion with 0.2 µU • ml-1 insulin.
Values are expressed as µmol • g-1 • h-1.
WT non-stim WT stim TG non-stim TG stim
0.07 0.17 1.28 2.61
0.85 0.97 1.80 3.62
0.67 0.87 0.58 2.82
0.61 1.22 1.34 2.42
0.48 1.29 2.89 3.95
0.87 1.75
1.07 1.79
0.41 1.34
0.62 1.43
0.63 1.20 1.58 3.08 mean
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0.098 0.165 0.382 0.298 SEM
Study 2: Low (0.2 mU • ml-1) insulin glycogen synthase activity expressed as
nmol • g wet weight-1 • min-1.
WT
STIM.
25 mM 1.5 mM 0.5 mM 0.1 mM
67.40 28.45 22.75 34.63
82.81 26.93 27.98 20.67
198.69 49.06 29.32 23.90
68.57 63.84 51.55 34.90
38.18 32.76 22.37 16.69
165.47 15.76 2.84 1.37
103.52 36.13 26.14 22.03 mean
25.897 7.083 6.397 5.116 SEM
WT
NON-STIM.
25 mM 1.5 mM 0.5 mM 0.1 mM
49.15 17.69 18.34 13.58
54.61 31.5 22.89 20.87
44.17 25.06 23.83 22.45
71.26 58.31 50.61 45.62
101.66 25.19 6.56 1.48
64.17 31.55 24.45 20.80 mean
10.423 7.038 7.227 6.596 SEM
TG
STIM.
25 mM 1.5 mM 0.5 mM 0.1 mM
1547.77 254.26 84.62 36.38
1835.94 337.25 100.78 41.46
1518.2 225.04 87.04 63.45
2144.08 350.26 85.11 22.05
2584.51 666.22 152.96 29.46
1926.10 366.61 102.10 38.56 mean
199.833 78.600 13.057 7.029 SEM
TG
NON-STIM.
25 mM 1.5 mM 0.5 mM 0.1 mM
493.5 126.98 63.08 33.62
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993.24 160.21 53.55 25.06
802.12 172.88 89.07 68.93
1158.24 138.31 55.55 8.55
713.59 129.27 34.27 8.01
832.14 145.53 59.10 28.83 mean
114.439 9.012 8.871 11.158 SEM
Study 2: Low (0.2 mU • ml-1) insulin glycogen synthase activity (I/I+D) ratio
and fractional velocity (0.5 mM and 1.5 mM G-6-P expresssed as percent of
maximal activity at 25 mM G-6-P).
WT
STIM.
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.51 33.75 42.21
0.25 33.79 32.52
0.12 14.76 24.69
0.51 75.18 93.10
0.44 58.59 85.80
0.01 1.72 9.52
0.31 36.30 47.98 mean
0.087 11.078 13.857 SEM
WT
NON-STIM.
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.28 37.31 35.99
0.38 41.92 57.68
0.51 53.95 56.74
0.64 71.02 81.83
0.01 6.45 24.78
0.36 35.19 43.09 mean
0.097 11.128 11.569 SEM
TG
STIM.
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.02 5.47 16.43
0.02 5.49 18.37
0.04 5.73 14.82
180
0.01 3.97 16.34
0.01 5.92 25.78
0.02 5.32 18.35 mean
0.006 0.347 1.941 SEM
TG
NON-STIM.
I/(I+D) fract. velo. fract. velo.
ratio 0.5 1.5
0.07 12.78 25.73
0.03 5.39 16.13
0.09 11.10 21.55
0.01 4.80 11.94
0.01 4.80 18.12
0.04 6.56 15.83 mean
0.014 1.859 3.447 SEM
Study 2: Low (0.2 mU • ml-1) insulin total and phosphorylated PKB/Akt
expressed as percent of insulin-stimulated mouse gastrocnemius standard.
Total Akt Phophorylated
WT 51.48 39.46
Non-stimulated 86.24 25.14
77.00 43.98
89.18 32.60
93.51 46.84
93.24 18.98
81.77 34.50 mean
6.543 4.472 SEM
Total Akt Phophorylated
WT 84.67 70.44
Stimulated 87.43 107.37
84.08 131.36
74.50 46.25
91.03 77.35
82.00 44.85
83.95 79.60 mean
2.280 13.970 SEM
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Total Akt Phophorylated
TG 88.39 104.71
Non-stimulated 92.38 105.57
92.63 142.75
61.93 115.00
60.43 62.32
49.99 114.88
74.29 107.54 mean
7.740 10.660 SEM
Total Akt Phophorylated
TG 84.60 91.20
Stimulated 94.26 93.71
90.69 128.15
88.80 135.37
85.31 108.98
88.33 169.71
88.66 121.19 mean
1.450 12.120 SEM
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